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Abstract 
Natural products and molecules derived from natural products have historically been one 
of the primary sources of new pharmaceuticals including antibiotics, antimalarials and anticancer 
drugs. However, many natural products cannot be isolated in sufficient quantities for 
commercialization due to insufficient natural resources, elevated costs of extractions and/or 
environmental factors; thus, pharmaceutical companies attempt to synthetically generate these 
compounds on scales large enough in order to serve the public.  
Tricyclic guanidine alkaloids are a class of natural products that exhibit a wide range of 
interesting biological properties including anti-HIV, antibacterial and anti-tumor activity but face 
practical isolation challenges. Unfortunately, current methods for the synthesis of these 
molecules suffer from an inability to provide access to stereochemically different cores and fail 
to facilitate the synthesis of analogs in a straightforward manner. To address these limitations, 
the research outlined in this thesis focused on the development of annulation strategies that can 
be utilized for the synthesis of polycyclic guanidines of any given stereochemical configuration 
and that are amenable to rapid analog construction. 
In all, this dissertation describes the synthesis of tricyclic guanidine natural products and 
structurally related alkaloids from bicyclic ureas and sulfamides that were prepared in a concise 
and stereocontrolled manner via Pd-catalyzed carboamination reactions. Chapters 2 and 3 of this 
dissertation detail the development of Pd-catalyzed carboamination reactions that are believed to 
proceed via syn-aminopalladation. This chemistry was utilized to accomplish the first total 
synthesis of (+)-merobatzelladine B. Additionally, an asymmetric variant of this methodology 
allows for the construction of bicyclic ureas via the desymmetrization of meso-pyrrolidinyl 
ureas, in good yields, diastereo- and enantioselectivities. The utility of the desymmetrization 
methodology was demonstrated by transforming one of the bicyclic urea products into 9-epi-
batzelladine K. In an effort to synthesize the natural stereoisomer of batzelladine K, Pd-catalyzed 
carboamination reactions that are believed to proceed via anti-aminopalladation were explored. 
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The optimization of this chemistry, along with the scope and limitations of the methodology, is 
described in chapter 4.  Lastly, the final chapter of this dissertation details the application of the 
carboamination methodology developed in chapters 2-4 towards the total synthesis of the 
tetraponerine alkaloids. 
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Chapter 1  
Annulation Strategies for the Total Synthesis of Tricyclic Guanidine Alkaloids 
1.1 Introduction: Biological Properties and Structural Diversity 
Tricyclic guanidine natural products (Figure 1.1) comprise a class of marine alkaloids that 
exhibit remarkable biological properties, including antiviral, antimicrobial, and antifungal 
activity.1–5 Several members of the batzelladine family, a subset of this class of natural products, 
are known to inhibit protein-protein interactions associated with the replication of HIV-1 in cells, 
and thus have gained significant attention due to their therapeutic potential for the AIDS virus.6 
Batzelladines A and B are known to inhibit the binding of HIV glycoprotein gp-120 to CD4 on 
human T-cells.7 Other batzelladine alkaloids, such as batzelladine F, induce dissociation of the 
protein tyrosine kinase p56lck complex from CD4.8 Additionally, several members of the 
crambescidin family, including crambescidin 800, show nanomolar toxicity against a number of 
human cancer cell lines.9 The wide-ranging biological activity of these compounds can in part be 
attributed to the cationic nature of the guanidinium functional group that can participate in a 
large number of non-covalent molecular interactions.10 
In all, the structurally unique tricyclic guanidinium ring system (hydro-5,6,6a-
triazaacenapthalene) that defines this class of natural products can be found in over 30 different 
alkaloids. While each of these natural products share this common structural motif, the 
substituents that decorate the tricyclic core of these molecules leads to significant structural 
diversity and wide-ranging biological properties. For instance, a large number of these molecules 
including batzelladine F and ptilomycalin A feature pendant esters that tether the tricyclic core to 
a diverse array of different functional groups, including other tricyclic guanidine subunits.1,11 
Interestingly, differences in the ester side chains dramatically alter the biological properties of 
the natural products. For example, batzelladine A inhibits the binding of HIV glycoprotein gp120 
to CD4 receptors as mentioned above, where as batzelladine D has no known biological activity.7 
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Furthermore, several tricyclic guanidine alkaloids do not feature an ester side chain, yet exhibit 
interesting biological properties such as the antibacterial and antimalarial activity of 
merobatzelladines A and B.12 The other area of structural diversity within this family of alkaloids 
is the C1 and C8 alkyl chains, which vary in terms of length, units of unsaturation, and oxidation. 
Remote oxidation of the alkyl branches is characteristic of the crambescidin alkaloids, including 
ptilomycalin A and crambescidin 359, which feature two spirocyclic hemiaminals in addition to 
the tricyclic guanidine framework. 
Figure 1.1 Tricyclic guanidine natural products. 
 
In addition to structural diversity, the batzelladine and crambescidin alkaloids feature 
different stereochemical configurations of the tricyclic core. As highlighted in Figure 1.1, both 
the trans- and cis-configurations of the pyrrolidine subunit are prevalent in this class of natural 
products. Batzelladine F highlights this stereochemical diversity as it contains two distinct 
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tricyclic guanidine subunits, with each featuring one of the pyrrolidine configurations.11,13 The 
stereochemical diversity is generally limited to the configuration of the pyrrolidine unit, as all of 
the alkaloids in this class feature a trans relationship between the C4 (and/or C6) proton and the 
C1 (and/or C8) alkyl chain, except, merobatzelladines A and B.12,14 Both natural products feature 
a cis relationship between the C6 proton and the C8 alkyl chain as highlighted in Figure 1.1. 
1.2 Biomimetic Syntheses  
The architecturally complex structures of tricyclic guanidine natural products, in addition to 
their remarkable biological properties, make this class of alkaloids ideal targets for total 
synthesis. Shortly after the isolation of ptilomycalin A,1 the parent member of this family, Snider 
and Murphy identified a potential biosynthetic pathway for the formation of these natural 
products. As shown in Scheme 1.1, Snider proposed that the methyl ester of ptilomycalin A (1-1) 
could be constructed in a single step from addition of guanidine to bis-Michael acceptor 1-2.15 
This proposal was predicated on the idea that a double Michael addition would afford the 
pyrrolidine ring, and subsequent imine and hemiaminal formation would generate the final four 
rings. Ultimately, Snider was able to validate this hypothesis by converting bis-enone 1-2 to the 
methyl ester of ptilomycalin A (1-1) in just four steps. A related biomimetic strategy was 
simultaneously explored by Murphy, and culminated in the total synthesis of crambescidin 359, a 
molecule that features the same pentacyclic core of ptilomycalin A but absent the ester side 
chain.16  
Scheme 1.1 Total synthesis of crambescidin alkaloids via biomimetic annulation strategy. 
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Additionally, Snider utilized a similar synthetic sequence to complete the racemic total 
synthesis of batzelladine E (Scheme 1.2). Intermolecular axial delivery of a hydride to 
hemiaminal 1-3, effected the stereoselective synthesis of the natural product.17 This report 
marked the first synthesis of a member of the batzelladine family and remains the only synthesis 
of batzelladine E to date. Recently, Bhutani applied this biomimetic strategy to synthesize 
racemic batzelladine K,18 and 50 derivatives in an effort to evaluate these compounds for 
potential biological applications.19  
Scheme 1.2 Biomimetic synthesis of batzelladine alkaloids by Snider and Bhutani. 
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synthesis of ptilomycalin A in 1995.21 Specifically, the tethered Biginelli condensation of 1-5 and 
β-ketoester 1-6 generated bicyclic urea 1-7 in good yield and 7.5:1 diastereoselectivity in favor 
of the cis-pyrrolidine (Scheme 1.3). Acid-mediated spirocyclization of 1-7 afforded tricyclic urea 
1-8 with high stereoselectivity. However, the ester C7 stereocenter was epimeric to that of the 
natural product, and thus required base induced epimerization prior to completion of the 
synthesis. The final two rings of the pentacyclic alkaloid were fashioned in a similar manner to 
the biomimetic strategy developed by Snider and Murphy as described in Scheme 1.1. Despite 
being the first synthesis of any member in the tricyclic guanidine class of natural products, this 
synthetic route generated ptilomycalin A on a gram scale, permitting further biological studies to 
be conducted. Shortly thereafter, the group reported a second generation approach towards this 
family of alkaloids, which was more convergent and culminated in the total syntheses of 
crambescidins 657 and 800, neofolitispates 2 and ptilomycalin A.22 Further evolution of this 
annulation strategy provided crambescidins 359 and 431.23  
Scheme 1.3 Overman’s total synthesis of ptilomycalin A and other crambescidin alkaloids via 
tethered Biginelli condensation reactions. 
 
 Given the stereochemical diversity displayed within this family of natural products, the 
Overman group sought to develop reactions conditions that would selectively afford products of 
the Biginelli condensation reaction with a trans-pyrrolidine. Simply switching to a guanidine 
substrate 1-9 (Scheme 1.4) from ureido aminal 1-5 (Scheme 1.3) led to a reversal in selectivity, 
specifically providing the trans-isomer 1-10 with 7:1 diastereoselectivity.24 The success in 
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effecting this change in selectivity was highlighted in the total syntheses of isocrambescidins 657 
and 800.25 
Scheme 1.4 Tethered Biginelli condensation annulation to access trans-core of isocrambescidins 
by Overman. 
 
  In addition to their work directed towards members of the crambescidin family, the Overman 
group successfully completed the first enantioselective synthesis of a batzelladine alkaloid 
(batzelladine D).26 The tethered Biginelli annulation reaction of 1-11 and β-ketoester 1-12 
afforded bicyclic core 1-13 with ~6:1 diastereoselectivity in favor of the trans-isomer (Scheme 
1.5). Following annulation of the third ring via an intramolecular SN2 reaction, hydrogenation of 
the alkene in 1-14, which was installed via the Biginelli reaction, afforded a mixture of products 
(1-15 and 1-16). The unselective nature of this step is a major limitation of the Biginelli 
annulation chemistry for the synthesis of batzelladine alkaloids. In spite of this limitation, this 
chemistry was further utilized to complete the first total synthesis of batzelladine F, and establish 
the constitution and relative stereochemistry of the natural product.11,27,28 Notably, the syn-isomer 
displayed in one of the two tricyclic guanidine subunits was accessed by employing the 
intramolecular Biginelli annulation reaction to close the third and final ring, as opposed to the 
second ring in all of the chemistry described above. Lastly, the total synthesis of 
dehydrobatzelladine C was accomplished by utilizing the Biginelli chemistry to access a key 
intermediate.29 Advantageously, this synthesis did not require the problematic unselective olefin 
hydrogenation due to the oxidized core of the molecule. 
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Scheme 1.5 Batzelladine alkaloid synthesis via tethered Biginelli condensation reactions by 
Overman. 
  
 The Nagasawa group reported the first total synthesis of (–)-crambescidin 359 through an 
iterative sequence of 1,3-dipolar cycloaddition reactions (Scheme 1.6).30 The key sequence 
served to install the entirety of the alkaloid’s carbon framework. Interestingly, both cycloaddition 
reactions proceeded with complete regio- and stereocontrol. However, the cycloaddition 
sequence stereoselectively generated trans-pyrrolidine 1-17, whereas the pyrrolidine in 
crambescidin 359 has a cis configuration. To address this unfavorable stereochemical outcome, 
the authors used a two-step epimerization reaction sequence, which generated the desired cis-
pyrrolidine (1-18) as a separable mixture of diastereomers (7:1 crude dr). Having successfully 
stereoselectively constructed the pyrrolidine ring and the carbon framework of the natural 
product, annulation of the remaining four rings was accomplished in a single step from bis-
ketone 1-19, in a similar fashion to the biomimetic work developed by Snider and Murphy 
highlighted above (Scheme 1.1). 
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Scheme 1.6 Nagasawa’s total synthesis of (–)-crambescidin 359 via 1,3-dipolar cycloadditions. 
 
 The Nagasawa group expanded upon their initial work by completing the total synthesis of 
both (+)-batzelladine A and (–)-batzelladine D (Scheme 1.7).31–33 These syntheses took advantage 
of the selective formation of the trans-2,5-disubstituted pyrrolidine (1-20) generated following 
the iterative sequence of 1,3 dipolar cycloadditions. Importantly, the ester side chains displayed 
in the natural products were easily incorporated, as conjugated alkenes served as viable 
substrates for the cycloaddition reactions. Furthermore, the cycloaddition reaction sequence 
stereoselectively introduced alcohol functionality, which facilitated annulation of the six-
membered rings via sequential Mitsunobu reactions. Notably, the Nagasawa group employed the 
same general cycloaddition/Mitsunobu synthetic strategy to complete the first total synthesis of 
(+)-batzelladine K.34 
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Scheme 1.7 Cycloaddition/ Mitsunobu annulation sequence for batzelladine alkaloids by 
Nagasawa. 
 
 In 2006, the Gin group reported the asymmetric synthesis of batzelladines A and D, which 
highlighted their recently developed [4 + 2] annulation reactions between vinyl carbodiimides 
and chiral N-alkyl imines (Scheme 1.8).35 This strategy provided an expedient route towards the 
construction of the bicyclic core common to several members of the batzelladine family. 
Specifically regarding the total synthesis of (–)-batzelladine D, vinyl carbodiimide 1-21 was 
coupled with enantiopure 3,4-dihydropyrrole 1-22 to afford the desired dihydropyrimidine 1-23 
in good yield and as a single diastereomer. The configuration of the pyrrolidine subunit was 
determined to be trans after detailed NMR experiments. The stereochemical outcome of this 
reaction was rationalized based on steric factors although the exact mechanism of the [4 + 2] 
annulation is unclear. In addition to the [4 + 2] annulation methodology developed to construct 
the bicyclic core of batzelladines A and D, the Gin group introduced a new annulation strategy 
for closing the third ring of these natural products. Annulation of the final ring in batzelladine D 
was accomplished via an intramolecular halo-amination of olefin 1-24. The tricyclic product was 
generated with complete stereocontrol as the final stereocenter in batzelladine D was established.  
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Scheme 1.8 Gin’s asymmetric total syntheses of batzelladines A and D. 
  
 In 2010, Gin expanded upon the [4 + 2] annulation chemistry developed in his group to 
accomplish the total synthesis of (–)-crambidine (Scheme 1.9).36 In an effort to access the more 
highly oxidized core displayed in the natural product, thioimidiate 1-25 was used as the coupling 
partner in the key annulation reaction. Closure of the final ring of the alkaloid was again 
accomplished via addition across a multiple bond, specifically the Au-catalyzed hydroamination 
of alkyne 1-26.  
Scheme 1.9 Crambidine synthesis via [4 + 2] annulation and hydroamination by Gin. 
 
 The methyl ester of batzelladine C was first synthesized in 2009, leading to the unambiguous 
assignment of the relative and absolute stereochemistry of the natural product.37 The unknown 
C8 stereocenter was installed via a three-component coupling of alkylidenepyrrolidine 1-27, 
hexanal, and TMS-isothiocyanate (Scheme 1.10). While the diastereoselectivity of the reaction 
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was modest (2:1), this permitted the synthesis of both possible stereoisomers of the methyl ester 
of batzelladine C. Annulation of the final ring was accomplished via an intramolecular iodo-
cyclization based on the work developed by Gin described above (Scheme 1.8).  
Scheme 1.10 Elliott’s synthesis of batzelladine C methyl ester via a three-component annulation. 
  
 In 2007, Evans utilized a stereoselective intramolecular radical cyclization to afford a key 
intermediate in the synthesis of (–)-batzelladine D (Scheme 1.11).38 Homolytic cleavage of alkyl 
iodide 1-28 when treated with tributyltin hydride and triethylborane initiated the key 
diastereoselective cyclization. Annulation of the third and final ring of batzelladine D was 
accomplished via intramolecular guanylation of methyl isourea 1-29. 
Scheme 1.11 Evan’s total synthesis of batzelladine D via stereoselective radical cyclization. 
 
 In all, the groups of Overman, Nagasawa, Gin and Evans have successfully synthesized 14 
different crambescidin and batzelladine natural products. Importantly, a number of these 
syntheses established the relative and absolute stereochemical configuration of the synthetic 
target, in addition to other alkaloids in the family based on analogous assignments. Lastly, 
several of these natural products and synthetic analogs were prepared on scales large enough to 
permit further biological testing including structure-activity relationship studies.39 
1.4 Limitations of Current Synthetic Methods 
 Overall, the synthetic challenge posed by the structural and stereochemical complexity of 
tricyclic guanidine natural products has inspired the development of a number of new 
methodologies and led to several extraordinary total syntheses as highlighted above. However, 
general methods that provide access to stereochemically different cores are exceedingly rare20 
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and versatile strategies for the construction of tricyclic guanidines remain highly desirable. 
Specifically, biomimetic pathways for the synthesis of members of the batzelladine family are 
currently limited to racemic routes and are limited to alkaloids featuring a cis-pyrrolidine.17,18 
Furthermore, no methods have been successfully demonstrated to afford tricyclic guanidine 
products with a cis relationship between the C6 proton and C8 alkyl chain as observed in 
merobatzelladines A and B. Moreover, given the rich biological history of this class of alkaloids, 
approaches that facilitate the synthesis of analogs in a straightforward manner are of tremendous 
interest, yet strikingly uncommon. To address these limitations, the research described in the 
dissertation is centered on the development of annulation strategies for the synthesis of 
polycyclic guanidines of any given stereochemical configuration and that are amenable to rapid 
analog construction.  
1.5 Pd-Catalyzed Carboamination Reactions 
 Over the past decade, the Wolfe group has successfully developed a series of Pd-catalyzed 
annulation reactions that afford nitrogen-containing heterocycles from simple starting materials 
(Scheme 1.12).40–42 Alkene substrates bearing a pendant amine are cross-coupled with an aryl or 
alkenyl halide in the presence of a palladium catalyst and base to afford various heterocyclic 
products including pyrazolidines,43 piperazines,44,45 and benzodiazepines.46 These reactions effect 
the formation of two new bonds and up to two new stereocenters. These annulation reactions 
have been proven to be efficient for heterocyclic scaffolds of varying ring sizes, and generally 
proceed with high levels of stereocontrol.  Importantly, a large number of analogs of a particular 
heterocycle can be easily generated from a single substrate due to the commercial availability of 
the electrophilic coupling partners.  
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Scheme 1.12 General scheme of Pd-catalyzed carboamination reactions and representative 
nitrogen-containing heterocyclic products. 
 
 In most cases, the Pd-catalyzed annulation reactions are believed to proceed via the catalytic 
cycle shown below in Scheme 1.13.47,48 Oxidative addition of the aryl (or alkenyl) halide to the 
Pd(0) catalyst affords complex 1-30. Deprotonation of the substrate with base and coordination 
of the amine to the Pd-metal center affords the key Pd(aryl)amido species 1-31. Migratory 
insertion of the alkene into the Pd-N bond results in syn-aminopalladation and reductive 
elimination generates the desired heterocyclic product and regenerates the Pd(0) catalyst. 
Scheme 1.13 Proposed catalytic cycle for Pd-catalyzed carboamination reactions that proceed 
via syn-aminopalladation. 
 
NH
nRn
PG = Ar, Boc
n = 1,2,3
N
nRn
R
R X
R = aryl, alkenyl
X = Cl, Br, I
Pd cat.
Base R1R
1
N
N
Ph
Bn
Bn
Ph
Piperazines
73%, >20:1 dr
N
N
Bn
PMP
Ph
Benzodiazepines
88%, >20:1 dr
N
NBoc
Boc
Pr
CF3
Pyrazolidines
81%, >20:1 dr
PG PG
reductive 
elimination
oxidative 
addition
deprotonation/
coordination
syn-aminopalladation
R = alkenyl or aryl
X = Cl, Br, or I
NH
PG
N
PdPG
Ln
R
N
PdPG Ln R
N
nRn
R
R1
PG
R1
R1
R1
R-X
NaX
NaOtBu
LnPd0
LnPd X
R
1-30
1-31
	   14	  
 The high stereoselectivity generally observed in these transformations can be attributed to the 
highly organized nature of the transition state for the stereocenter-forming syn-aminopalladation 
event (Scheme 1.14). For instance, the selectivity observed for the formation of cis-2,5 
disubstituted pyrrolidines likely arises from transition state 1-32, where the substituent on the 
backbone of the substrate occupies a pseudo-axial position in order to minimize A(1,3)-strain with 
the N-protecting group.40 Additionally, carboamination reactions that facilitate the formation of 
6-membered rings, including the synthesis of piperazines and morpholines, are believed to 
proceed via boat-like transition states such as 1-33.45,49  
Scheme 1.14 Stereochemical rationale for 5- and 6-membered ring-forming carboaminations. 
 
 Recently, a series of Pd-catalyzed carboamination reactions have been shown to go through 
an alternative mechanistic pathway, one in which the aminopalladation step results in anti-
addition of the two components across the alkene, rather than syn-addition.50 As shown in 
Scheme 1.15, 5-membered cyclic sulfamides and ureas have been synthesized via the cross-
coupling of substrates 1-34 and 1-35 with phenyl triflate. Deuterium labeling studies indicated 
that these products were formed as a result of anti-addition across the olefin. These results are in 
stark contrast to most of the difunctionalization reactions that have been developed in the Wolfe 
lab over the past decade.40–42 Importantly, this chemistry has the potential to greatly expand the 
number of products that can be synthetized via Pd-catalyzed carboamination reactions. For 
example, substrates containing 1,2-disubstituted alkenes such as 1-36 can be converted into 
products (1-37) that could not be constructed using carboamination reactions that proceed via 
syn-aminopalladation.  
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Scheme 1.15 Pd-catalyzed carboamination reactions that proceed via anti-addition. 
 
 A plausible catalytic cycle for the aforementioned transformation is shown in Scheme 1.16.50 
This mechanism is initiated via oxidative addition of an aryl triflate to the Pd(0) catalyst. The 
non-coordinating nature of the triflate anion may lead to cationic complex 1-38, which can then 
coordinate to the olefin of the substrate. As opposed to the migratory insertion observed 
previously in Wolfe group chemistry, the aminopalladation step for these transformations is 
believed to occur via outer-sphere nucleophilic attack of the amino-group onto the olefin, 
resulting in anti-addition across the alkene. Reductive elimination from intermediate 1-39 affords 
the desired heterocyclic product and regenerates the Pd(0) catalyst.  
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Scheme 1.16 Proposed catalytic cycle for Pd-catalyzed carboamination reactions that proceed 
via anti-aminopalladation. 
 
Overall, Pd-catalyzed carboamination reactions have proven to be of tremendous utility for 
the construction of nitrogen-containing heterocycles. As such, we envisioned that 
carboamination reactions could serve as the foundation for a novel annulation strategy towards 
the synthesis of tricyclic guanidine natural products. This approach was particularly attractive as 
it was anticipated that tricyclic guanidines with different stereochemical configurations could be 
synthesized from a single precursor (Scheme 1.17). This aspect of the research was particularly 
important for two reasons: 1) this class of alkaloids displays a wide range of stereochemical 
diversity and 2) existing methodology for the construction of these alkaloids is generally limited 
to the synthesis of a single stereoisomer. Additionally, this strategy was attractive for its potential 
to rapidly generate analogs from a late stage intermediate without any changes to the general 
synthetic strategy. Specifically, a library of analogs could be easily prepared from a single 
precursor by simply changing the electrophilic coupling partner employed during the 
carboamination reaction.  To this end, our goal was to develop of a series of novel 
carboamination reactions that could be utilized for the construction of polycyclic guanidines of 
any given stereochemical configuration and which would facilitate the rapid synthesis of 
analogs. 
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Scheme 1.17 Synthesis of bicyclic products via Pd-catalyzed carboaminations. 
 
As depicted in Scheme 1.17, our general strategy was to construct stereochemically-different 
bicyclic products via the cross-coupling of alkenyl halides and 2-allyl pyrrolidinyl substrates 1-
40. Chapters 2 and 3 detail our development of Pd-catalyzed carboamination reactions that 
proceed via syn-aminopalladation and afford bicyclic ureas 1-41 with high levels of 
diastereoselectivity. The utility of this chemistry was demonstrated in the asymmetric synthesis 
of merobatzelladine B and 9-epi-batzelladine K. Additionally, chapter 4 details the optimization 
and scope of carboamination reactions that proceed via anti-aminopalladation and afford bicyclic 
sulfamides 1-42 with good stereocontrol. The chemistry described in chapter 4 highlights that the 
diastereoselectivity of carboamination reactions can be reversed by simply employing reaction 
conditions that favor an anti-aminopalladation mechanism. Furthermore, these carboamination 
products could serve as key intermediates in the synthesis of members of the batzelladine family, 
including batzelladine K, which were previously inaccessible via the methodology developed in 
chapters 2 and 3. In all, the research detailed in this dissertation demonstrates that the 
stereochemical outcome of carboamination reactions can be controlled through judicious choice 
of substrate, catalyst, and reaction conditions. We report herein our findings on the use of Pd-
catalyzed carboamination reactions as an annulation strategy for the stereoselective synthesis of 
tricyclic guanidine natural products, their analogs, and related polycyclic alkaloids.  
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Chapter 2  
Asymmetric Total Synthesis of (+)-Merobatzelladine B 
2.1 Introduction 
In 2009, Matsunaga et al. reported the isolation of merobatzelladines A and B from the 
marine sponge monanchora sp. (Figure 2.1).12,14 These compounds are members of a new sub-
class of the batzelladine alkaloids that possess the signature tricyclic guanidine core common to 
all batzelladines, but display a unique stereochemical feature that differs from other members in 
this family. The C8 alkyl substituents in merobatzelladines A and B are positioned in a syn-
relationship with the C6 hydrogen atoms, whereas other related natural products, such as 
batzelladines A, E, or F, contain an anti-relationship between these groups. Merobatzelladines A 
and B exhibit moderate antimicrobial activity against Vibrio anguillarum, and also show 
inhibitory activity against the K1 strain of Plasmodium falciparum (IC50 = 0.48 µg/mL and 0.97 
µg/mL, respectively). Given the rich biological activity of the related batzelladine alkaloids, it is 
possible that merobatzelladines A and B may exhibit additional useful properties that have yet to 
be reported.   
Figure 2.1 Polycyclic guanidine natural products. 
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Given the importance of polycyclic guanidine alkaloids, several different approaches have 
been employed for the synthesis of these compounds. As detailed in chapter 1, the most widely 
utilized routes typically generate the fused ring system through condensation reactions,10,11,20,51,52 
cycloaddition reactions,35,37 radical cyclizations,38 and substitution reactions.31 Although these 
routes have proven highly useful, none provide a means for generation of a C–C bond adjacent to 
the ring (such as the C8’–C4H9 bond in merobatzelladine B) during the ring-closing event. In 
addition, none of these routes has been employed for the generation of molecules with the syn-
relationship between the C8 alkyl group and the C6 H-atom such as that displayed in 
merobatzelladines A and B. This chapter describes the first total synthesis of merobatzelladine B, 
which provides the natural product as a single stereoisomer in high optical purity, and represents 
a new strategy for the construction of polycyclic guanidine alkaloids. 
2.2 Synthetic Plan and Model Studies 
Our approach to the synthesis of merobatzelladine B was centered around the use of Pd-
catalyzed alkene carboamination reactions for the formation of two of the three rings in the 
natural product.41,42 As shown in Scheme 2.1, we envisioned that a Pd-catalyzed carboamination 
between vinyl bromide and an appropriately functionalized γ-aminoalkene derivative 2-1 would 
generate cis-disubstituted pyrrolidine 2-2 with high stereocontrol. A second carboamination 
reaction between allylpyrrolidine derivative 2-3 and 1-bromo-1-butene would afford bicyclic 
product 2-4, which could then be transformed to the polycyclic guanidine natural product 
through functional group interconversion and ring-closure via an intramolecular SN2 reaction.  
Scheme 2.1 Iterative carboamination strategy for tricyclic guanidine synthesis. 
 
Our prior studies on Pd-catalyzed alkene carboamination reactions have illustrated that the 
conversion of N-Boc-γ-aminoalkenes to 2,5-disubstituted pyrrolidines typically proceeds in good 
yield with > 20:1 diastereoselectivity favoring the cis-isomer.41,53,54 As such, the transformation 
of 2-1 to 2-2 appeared quite feasible; however, the likelihood of success in the planned Pd-
catalyzed carboamination between 2-3 and an alkenyl halide was less clear. The generation of 
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six-membered rings via Pd-catalyzed carboamination is considerably more difficult than 
formation of five-membered rings,44,45,49 and this has not previously been accomplished with an 
unsaturated urea substrate.55,56 To test the feasibility of this key transformation, we examined the 
Pd-catalyzed carboamination of 2-allyl-pyrrolidine-derived urea 2-5 with simple aryl and alkenyl 
halides. After optimization of conditions, we found that a catalyst composed of Pd2(dba)3/PCy3 
provided satisfactory results in these reactions (Scheme 2.2). The bicyclic urea products 2-6a and 
2-6b were obtained in good yield and high diastereoselectivity, which may arise via cyclization 
through boat-like transition state 2-7.45,47–49 The alternative boat-like transition state 2-8, which 
leads to the minor diastereomer, appears to suffer from significant steric interactions between the 
alkene and the pyrrolidinyl ring. Moreover, cyclization through a chair-like transition state 
appears to be less accessible due to poor overlap between the alkene pi-system and the Pd–N 
bond.45,49  
Scheme 2.2 Model studies: synthesis of bicyclic ureas by Pd-catalyzed carboamination. 
 
2.3 Total Synthesis of (+)-Merobatzelladine B 
Having illustrated the feasibility of our approach to the generation of fused bicyclic ureas, we 
undertook the synthesis of merobatzelladine B by constructing an appropriately functionalized γ-
aminoalkene derivative for the pyrrolidine-forming carboamination. As shown in Scheme 2.2, 
the amine-bearing stereocenter was generated via a highly efficient asymmetric Mannich 
reaction of sulfinyl imine 2-9.57,58 The stereocontrolled reduction of ketone 2-10 proved quite 
challenging,59 and after examining many different reducing agents we found that the combination 
of NaBH4 and CeCl3 led to formation of 2-11 with 3:1 diastereoselectivity. However, the two 
diastereomers were separable by column chromatography, and 2-11 was isolated as a single 
stereoisomer in 63% yield. Protection of the alcohol as a benzyl ether followed by exchange of 
the sulfinyl group for a Boc-group provided 2-12 in 91% yield over three steps and 99% ee. 
With intermediate 2-12 in hand, the key sequence of carboamination reactions was undertaken. 
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provided pyrrolidine 2-13 in 68% yield and with excellent stereocontrol (>20:1 dr). Treatment of 
2-13 with TFA led to cleavage of the Boc group and protodesilylation of the alkene. The 
resulting pyrrolidine was coupled with p-methoxybenzylisocyanate to generate pyrrolidinyl urea 
2-14 in 72% yield over the two-step sequence. The Pd/PCy3-catalyzed carboamination of 2-14 
with Z-1-bromo-1-butene proceeded smoothly to yield bicyclic urea 2-15 in 91% yield and >20:1 
dr. 
Scheme 2.3 Total synthesis of (+)-merobatzelladine B. 
 
Bicyclic urea 2-15 was converted to guanidinium salt 2-16 in 89% yield by treatment with 
POCl3 followed by addition of ammonia. This transformation was conducted under rigorously 
anhydrous conditions to avoid HCl-mediated side reactions. The tetrafluoroborate counterion 
was introduced during the workup procedure by washing a dichloromethane solution of the crude 
guanidine product with aqueous NaBF4. This anion exchange was essential to avoid 
complications during the subsequent ring-closing step. The use of the analogous guanidinium 
chloride salt in the ring-closing reaction led to the formation of a chlorinated side product 
resulting from the substitution of chloride for hydroxide. A diastereomeric side product resulting 
from double inversion at C1 was also formed. Use of the BF4 salt prevented the formation of 
these side products.  
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Guanidinium salt 2-16 was then transformed to the natural product in a three-step sequence 
involving initial hydrogenation with Pd/C to effect reduction of the alkene and cleavage of the 
benzyl ether protecting group. Ring-closure was achieved via intramolecular Mitsunobu 
reaction,31 and deprotection of the N-PMB group provided merobatzelladine B in 41% yield over 
the three step sequence from 2-16. The synthetic alkaloid was obtained in enantiopure form 
{[α]23D + 40.1 (c 0.7, MeOH); [lit.]: [α]23D + 27 (c 0.15 MeOH)]}, and NMR spectra were 
identical to the data previously reported for the natural product.12 
2.4 Conclusions 
In summary, we have developed the first asymmetric total synthesis of (+)-merobatzelladine 
B, which confirms the structural and stereochemical assignments of the natural product. Our 
route afforded the desired alkaloid in 15 steps and 6.7% overall yield from commercially 
available pent-4-enal. The results described above represent a fundamentally new strategy for the 
stereocontrolled synthesis of polycyclic guanidine natural products. This new approach allows 
for formation of a carbon-carbon bond during the ring-closing event, and is the first route shown 
to provide access to alkaloids with a syn-relationship between the C6 hydrogen atom and the C8 
alkyl group. This strategy could potentially be employed to access other guanidine alkaloids that 
contain this stereochemical feature, and could also be used for the generation of novel analogs of 
the batzelladine alkaloids. In addition, this work also illustrates the feasibility of forming 5,6-
fused bicyclic urea ring systems via Pd-catalyzed carboamination, which could be of value for 
preparation of other interesting biologically active heterocycles. 
 
The work described in this chapter was published in Angewandte Chemie International 
Edition.60 
2.5 Experimental  
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium and tri-(2-furyl)phosphine were purchased from Strem 
Chemical Co. and used without further purification. Tricyclohexylphosphonium tetrafluoroborate 
was purchased from Acros Chemical Co. and used without further purification. All reagents were 
obtained from commercial sources and were used as obtained unless otherwise noted. POCl3 was 
purified by distillation under N2 prior to use. tert-Butyl 2-allylpyrrolidine-1-carboxylate,61 and 
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(E)-1-bromodec-1-ene62 were prepared according to published procedures. Toluene, THF, 
methylene chloride and diethyl ether were purified using a GlassContour solvent purification 
system. Structural and stereochemical assignments were made on the basis of 2-D COSY and 
NOESY experiments. Ratios of diastereomers were determined by either 1H NMR or capillary 
GC analysis of crude reaction mixtures.  Yields refer to isolated yields of compounds estimated 
to be ≥95% pure as determined by 1H NMR. 
 
Experimental Procedures and Compound Characterization Data 
 
(Z)-1-bromobut-1-ene. This compound was prepared via a modification of a published 
procedure by Ellman.63 A flame-dried flask equipped with a stirbar was cooled under vacuum, 
backfilled with N2 and charged with (E)-2-pentenoic acid (10 ml, 100 mmol) and methylene 
chloride (100 mL). The resulting solution was cooled to 0 ºC and bromine (11 mL, 220 mmol) 
was slowly added over 15 min. The solution was gradually warmed to rt, at which time the N2 
line was replaced with a vent needle, and then stirred overnight. The solvent and excess bromine 
were carefully removed by stirring under a stream of N2 in the back of a ventilation hood. The 
crude material was dissolved in DMF (100 mL) and Et3N (15 mL, 110 mmol) was slowly added 
to the reaction flask (open to air) over the course of 5 min. Within minutes a precipitate formed 
and the reaction was stirred for a total of ca. 15 min. The DMF solution was transferred to a 
distillation flask to remove most of the precipitate. The precipitate was washed with DMF (2 x 
15 mL) and each wash was added to the distillation flask. The resulting solution was subjected to 
atmospheric pressure distillation and the fraction collected from 60–115 oC was transferred to a 
separatory funnel. The solution was washed with saturated aqueous NH4Cl (10 mL) and dried 
over anhydrous sodium sulfate to afford 7.6 g (56%) of the title compound as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 6.13–6.06 (m, 2 H), 2.24–2.17 (m, 2 H), 1.02 (t, J = 7.6 Hz, 3 H). 
Spectroscopic properties were identical to those previously reported. 
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(±)-2-Allyl-N-(4-methoxyphenyl)pyrrolidine-1-carboxamide (2-5). A round bottomed flask 
equipped with a stirbar was charged with tert-butyl 2-allylpyrrolidine-1-carboxylate (465 mg, 2.2 
mmol) and methylene chloride (2.2 mL). The resulting solution was cooled to 0 ºC and 
trifluoroacetic acid (2.2 mL, 28.7 mmol) was added. The solution was gradually warmed to rt 
and stirred until the starting material had been consumed as judged by TLC analysis (ca. 30 min). 
The reaction mixture was diluted with water, basified with NH4OH to pH > 12, and transferred to 
a separatory funnel. The layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was dissolved in methylene chloride (11 mL) and 
4-methoxyphenyl isocyanate (285 µL, 2.2 mmol) was added. The reaction mixture was stirred at 
rt until starting material had been completely consumed as judged by TLC analysis (ca. 1 h). The 
crude reaction mixture was concentrated in vacuo, and purified by flash chromatography on 
silica gel to afford 300 mg (53%) of the title compound as a colorless oil. 1H NMR (500 MHz, 
CDCl3) δ 7.29 (d, J = 9.5 Hz, 2 H), 6.83 (d, J = 9.0 Hz, 2 H), 6.07 (s, 1 H), 5.82 (ddt, J = 17.0, 
10.0, 7.5 Hz, 1 H), 5.13-5.07 (m, 2 H), 4.07–4.04 (m, 1 H), 3.78 (s, 3 H), 3.45–3.42 (m, 2 H), 
2.60–2.55 (m, 1 H), 2.22–2.16 (m, 1 H), 2.04–1.93 (m, 3 H), 1.83–1.79 (m, 1 H); 13C NMR (125 
MHz, CDCl3) δ 155.6, 154.3, 135.2, 132.2, 121.7, 117.4, 114.1, 57.2, 55.5, 46.3, 38.7, 29.5, 
23.8; IR (film) 3306, 1639 cm-1. MS (ESI) 261.1599 (261.1598 calcd for C15H20N2O2, M + H+). 
 
 
(±)-(3R*,4aR*)-2-(4-Methoxyphenyl)-3-(4-methylbenzyl)hexahydropyrrolo[1,2-c]pyrimidin-
1(2H)-one (2-6a). A flame-dried Schlenk tube was cooled under a stream of N2 and charged with 
Pd2(dba)3 (6.4 mg, 0.007 mmol), PCy3HBF4 (10.3 mg, 0.028 mmol) and NaOtBu (50 mg, 0.52 
mmol). The flask was purged with N2, then a solution of 2-5 (83 mg, 0.35 mmol) in toluene (3.5 
mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. 4-Bromotoluene 
(89 µL, 0.52 mmol) was added and the flask was heated to 110 ºC and stirred overnight (ca. 14 
h). The mixture was cooled to room temperature and saturated aqueous NH4Cl (3 mL) and ethyl 
acetate (3 mL) were added. The organic layer was filtered through a plug of silica gel and the 
N
NO
H
H
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silica gel was washed with ethyl acetate (10 mL). The filtrate was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. Analysis of the crude material by 1H NMR revealed 
the product had been formed as a 14:1 mixture of diastereomers. The crude material was purified 
by flash chromatography on silica gel to afford 78 mg (70%) of the title compound as a pale 
yellow oil with 14:1 dr. Data are for the major isomer.  1H NMR (500 MHz, CDCl3) δ 7.19 (d, J 
= 9.0 Hz, 2 H), 7.06 (d, J = 8.0 Hz, 2 H), 6.92–6.90 (m, 4 H), 3.96 (dt, J = 11.5, 4.5 Hz, 1 H), 
3.82 (s, 3 H), 3.82–3.76 (m, 1 H), 3.60 (dt, J = 11.5, 7.5 Hz, 1 H), 3.55–3.51 (m, 1 H), 3.02 (dd, J 
= 13.8, 3.8 Hz, 1 H), 2.64 (dd, J = 13.5, 11.0 Hz, 1 H), 2.30 (s, 3 H), 2.13 (dt, J = 12.0, 5.5 Hz, 1 
H), 2.05–1.95 (m, 2 H), 1.88–1.82 (m, 1 H), 1.54 (dt, J = 12.5, 2.5 Hz, 1 H) 1.50–1.44 (m, 1 H); 
13C NMR (125 MHz, CDCl3) δ 157.5, 154.4, 135.9, 135.5, 134.8, 130.1, 129.2, 128.8, 114.2, 
60.4, 55.4, 52.5, 46.1, 38.1, 33.8, 29.5, 23.4, 20.9; IR (film) 1640 cm-1. MS (ESI) 351.2071 
(351.2071 calcd for C22H26N2O2, M + H+). 
 
 
(±)-(E,3R*,4aR*)-2-(4-Methoxyphenyl)-3-(undec-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (2-6b). A flame-dried Schlenk tube was cooled under a stream of N2 and 
charged with Pd2(dba)3 (6.4 mg, 0.007 mmol), PCy3HBF4 (10.3 mg, 0.028 mmol) and NaOtBu 
(67 mg, 0.70 mmol). The flask was purged with N2, then a solution of 2-5 (83 mg, 0.35 mmol) in 
toluene (3.5 mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. A 
solution of (E)-1-bromodec-1-ene (153 mg, 0.70 mmol) in toluene (1 mL) was added and the 
flask was heated to 110 ºC and stirred overnight (ca. 14 h). The mixture was cooled to room 
temperature and saturated aqueous NH4Cl (3 mL) and ethyl acetate (3 mL) were added. The 
organic layer was filtered through a plug of silica gel and the silica gel was washed with ethyl 
acetate (10 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. Analysis of the crude material by 1H NMR revealed the product had been formed as a 
18:1 mixture of diastereomers.  The crude material was purified by flash chromatography on 
silica gel to afford 98 mg (77%) of the title compound as a pale yellow oil with 18:1 dr. Data are 
for the major isomer. 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 9.0 Hz, 2 H), 6.86 (d, J = 9.0 
N
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H
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Hz, 2 H), 5.42 (dt, J = 15.5, 7.5 Hz, 1 H), 5.16 (dt, J = 15.0, 7.0 Hz, 1 H), 3.79 (s, 3 H), 3.76–
3.73 (m, 1 H), 3.68–3.62 (m, 1 H), 3.58 (dt, J = 11.5, 7.5 Hz, 1 H), 3.50–3.46 (m, 1 H), 2.39 (dt, 
J = 13.5, 5.0 Hz, 1 H), 2.24 (ddt, J = 13.0, 2.0, 1.5 Hz, 1 H), 2.20-2.11 (m, 2 H), 2.00–1.91 (m, 3 
H), 1.85–1.78 (m, 1 H), 1.62 (dt, J = 12.3, 5.0 Hz, 1 H), 1.49 (ddt, J = 12.0, 10.0, 7.5 Hz, 1 H), 
1.30–1.23 (m, 12 H), 0.87 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 157.5, 154.4, 
135.7, 134.2, 129.3, 125.4, 114.1, 58.7, 55.4, 52.5, 46.0, 35.9, 33.9, 32.5, 31.8, 30.3, 29.4, 29.2, 
29.1, 23.4, 22.6, 14.1 (one carbon signal is absent due to incidental equivalence); IR (film) 1640 
cm-1. MS (ESI) 399.3009 (399.3006 calcd for C25H38N2O2, M + H+). 
 
 
(+)-(SS)-2-Methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide (2-9). This compound was 
prepared according to a published procedure by Ellman.64 A flame-dried flask was cooled under 
a stream of N2 and charged with pent-4-enal (1.38 mL, 14 mmol) and THF (40 mL). Titanium 
ethoxide (4.2 mL, 20 mmol) was added and the reaction mixture was stirred at rt for 5 min. (S)-
tert-butanesulfinamide (1.21 g, 10 mmol) was added in one portion and the mixture was stirred 
overnight (ca. 14 h) at rt. The reaction mixture was poured into brine (40 mL) and stirred for 10 
min.  Ethyl acetate (20 mL) was added, the mixture was filtered through celite and the celite was 
washed with ethyl acetate (100 mL). The mixture was transferred to a separatory funnel, brine 
(20 mL) was added, and the layers were separated. The aqueous phase was extracted with ethyl 
acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel to afford 1.62 g (87%) of the title compound as a colorless oil: [α]23D +244.8 (c 5.5, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 8.08 (t, J = 4.5 Hz, 1 H), 5.84 (ddt, J = 17.0, 10.0, 4.5 
Hz, 1 H), 5.08 (dd, J = 17.0, 1.5 Hz, 1 H), 5.02 (dd, J = 10.0, 1.5 Hz, 1 H), 2.63 (td, J = 7.5, 4.0 
Hz, 2 H), 2.40 (q, J = 7.0 Hz, 2 H), 1.19 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 168.8, 136.7, 
115.8, 56.5, 35.2, 29.3, 22.3; IR (film) 1621 cm-1. MS (ESI) 188.1101 (188.1104 calcd for 
C9H17NOS, M + H+). 
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(+)-(SS,5S)-2-Methyl-N-(7-oxododec-1-en-5-yl)propane-2-sulfinamide (2-10). This compound 
was prepared via a modification of a published procedure by Davis.57 A flame-dried flask was 
cooled under a stream of N2, charged with diethyl ether (80 mL), and cooled to –78 ºC. Solid 
KHMDS (5.6 g, 28.0 mmol) was added and the reaction mixture was stirred for 5 min at –78 ºC. 
Heptan-2-one (3.43 mL, 24.0 mmol) was slowly added to the reaction flask and the mixture was 
stirred at –78 ºC for 1 h. A solution of 2-9 (1.50 g, 8.0 mmol) in diethyl ether (10 mL) was added 
to the reaction flask and stirred at –78 ºC for 2 h. The reaction was quenched with saturated 
aqueous NH4Cl (10 mL) at –78 ºC and gradually warmed to rt. The mixture was transferred to a 
separatory funnel and the layers were separated. The organic layer was washed with water (1 x 
10 mL) and then the combined aqueous layers were extracted with diethyl ether (2 x 20 mL).  
The combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to 
afford 1.95 g (81%) of the title compound as a pale yellow oil: [α]23D +47.8 (c 3.2, CH2Cl2). 1H 
NMR (400 MHz, CDCl3) δ 5.77 (ddt, J = 16.8, 10.0, 6.8 Hz, 1 H), 5.04–4.96 (m, 2 H), 4.07 (d, J 
= 9.2 Hz, 1 H), 3.53 (oct, J = 4.8 Hz, 1 H), 2.90 (dd, J = 17.6, 5.6 Hz, 1 H), 2.77 (dd, J = 17.6, 
4.4 Hz, 1 H), 2.39 (t, J = 7.6 Hz, 2 H), 2.24–2.02 (m, 2 H), 1.78–1.67 (m, 1 H), 1.60–1.50 (m, 3 
H), 1.38–1.18 (m, 4 H), 1.22 (s, 9 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 
210.8, 137.7, 115.2, 55.8, 53.2, 48.0, 43.8, 34.7, 31.2, 30.4, 23.1, 22.6, 22.4, 13.9; IR (film) 
3216, 1708 cm-1. MS (ESI) 302.2155 (302.2148 calcd for C16H31NO2S, M + H+). 
 
 
(+)-(SS,5S,7S)-N-(7-Hydroxydodec-1-en-5-yl)-2-methylpropane-2-sulfinamide (2-11). A 
flame-dried flask was cooled under a stream of N2 and charged with 2-10 (322 mg, 1.1 mmol) 
and THF (11 mL). The reaction flask was cooled to 0 ºC, CeCl37H2O (831 mg, 2.2 mmol) was 
added, and the mixture was stirred for 5 min. NaBH4 (600 mg, 15.9 mmol) was added in a single 
portion and the resulting solution was stirred until the starting material had been consumed as 
O
C4H9
OS
t-Bu
HN
HNOH
C4H9
S O
t-Bu
	   28	  
judged by ESI+ MS analysis (ca. 2 h). The reaction mixture was slowly quenched with water (3 
mL) and the mixture was transferred to a separatory funnel. The layers were separated and the 
aqueous layer was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Analysis of the crude 
material by 1H NMR revealed the product had been formed as a 3:1 mixture of diastereomers. 
The crude material was purified by flash chromatography on silica gel to afford 204 mg (63%) of 
the title compound as a colorless oil with >20:1 dr: [α]23D +55.1 (c 2.1, CH2Cl2). 1H NMR (500 
MHz, CDCl3) δ 5.79 (ddt, J = 17.3, 10.3, 6.8 Hz, 1 H), 5.03–4.95 (m, 2 H), 3.79 (m, 1 H), 3.65 
(d, J = 8.0 Hz, 1 H), 3.52–3.45 (m, 1 H), 3.36 (d, J = 4.5 Hz, 1 H), 2.21–2.04 (m, 2 H), 1.80 
(ddd, J = 14.5, 10.5, 4.0 Hz, 1 H), 1.64–1.21 (m, 11 H), 1.23 (s, 9 H), 0.87 (t, J = 7.0 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 138.0, 115.0, 67.8, 55.8, 53.9, 42.6, 37.8, 36.3, 31.9, 30.3, 25.5, 
22.7, 22.6, 14.0; IR (film) 3243 cm-1. MS (ESI) 304.2314 (304.2305 calcd for C16H33NO2S, M + 
H+). 
 
 
(+)-(SS,5S,7S)-N-[7-(Benzyloxy)dodec-1-en-5-yl]-2-methylpropane-2-sulfinamide (2-S1). A 
flame-dried flask was cooled under a stream of N2 and charged with 2-11 (345 mg, 1.1 mmol) 
and THF (11 mL). The reaction was cooled to 0 ºC and NaH (65 mg, 1.6 mmol, 60% suspension 
in mineral oil) was added. The reaction flask was stirred for 5 min at 0 ºC and then benzyl 
bromide (190 µL, 1.6 mmol) was added and the resulting mixture was stirred overnight at rt. The 
reaction was quenched with water (10 mL) and the mixture was transferred to a separatory 
funnel. The layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 10 
mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to 
afford 428 mg (96%) of the title compound as a colorless oil. The enantiopurity was determined 
to be 99% ee by chiral HPLC analysis (Regis Tech. (R,R) WHELK-O1, 0.46 cm x 25 cm, 5% 
iPrOH/hexanes, 1.0 mL/min, l = 254 nm, RT = 8.57 and 11.82 min). [α]23D +63.4 (c 2.1, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.37–7.24 (m, 5 H) 5.79 (ddt, J = 17.5, 11.5, 6.5 Hz, 1 H), 5.04–
4.96 (m, 2 H), 4.60 (d, J = 11.0 Hz, 1 H), 4.45 (d, J = 11.0 Hz, 1 H), 4.13 (d, J = 6.0 Hz, 1 H), 
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3.76–3.69 (m, 1 H), 3.54-3.47 (m, 1 H), 2.18–2.03 (m, 2 H), 1.84 (ddd, J = 15.0, 9.5, 3.0 Hz, 1 
H), 1.76–1.51 (m, 5 H), 1.35–1.24 (m, 6 H), 1.07 (s, 9 H), 0.89 (t, J = 6.8 Hz, 3 H); 13C NMR 
(125 MHz, CDCl3) δ 138.5, 138.2, 128.3, 128.1, 127.6, 114.9, 76.9, 71.0, 55.4, 53.9, 39.1, 35.4, 
33.0, 32.0, 30.0, 24.8, 22.7, 22.6, 14.0; IR (film) 3257 cm-1. MS (ESI) 394.2777 (394.2774 calcd 
for C23H39NO2S, M + H+). 
 
 
(+)-(5S,7S)-tert-Butyl 7-(benzyloxy)dodec-1-en-5-ylcarbamate (2-12). A flame-dried flask was 
cooled under a stream of N2 and charged with (2-S1) (426 mg, 1.1 mmol) and methanol (5.5 
mL). A solution of anhydrous hydrochloric acid (1.1 mL, 4.4 mmol, 4 M in dioxane) was added 
and the mixture was stirred at rt for 1 h, at which time TLC analysis indicated that the starting 
material had been completely consumed. The reaction mixture was diluted with water (5 mL) 
and CH2Cl2 (5 mL), basified with NH4OH to pH > 12, and transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude product was dissolved in THF (11 mL), solid di-tert-butyldicarbonate (264 mg, 
1.2 mmol) was added and the reaction mixture was stirred at rt for 3 h. 1 M NaOH (5 mL) was 
added and the resulting biphasic mixture was stirred overnight at rt. The mixture was transferred 
to a separatory funnel, the layers were separated and the aqueous layer was extracted with ethyl 
acetate (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo.  The crude material was purified by flash chromatography on 
silica gel to afford 401 mg (95%) of the title compound as a colorless oil: [α]23D +31.8 (c 1.5, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.41–7.32 (m, 4 H), 7.30–7.26 (m, 1 H), 5.81 (ddt, J = 
17.0, 10.0, 7.5 Hz, 1 H), 5.01 (dd, J = 17.3, 1.8 Hz, 1 H), 4.95 (d, J = 10.0 Hz, 1 H), 4.79 (d, J = 
14.0 Hz, 1 H), 4.55 (d, J = 11.0 Hz, 1 H), 4.45 (d, J = 11.0 Hz, 1 H), 3.84–3.76 (m, 1 H), 3.60–
3.52 (m, 1 H), 2.18–2.02 (m, 2 H), 1.74–1.47 (m, 6 H), 1.44 (s, 9 H), 1.37–1.24 (m, 6 H), 0.90 (t, 
J = 7.3 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 155.5, 138.6, 138.3, 128.3, 128.1, 127.5, 114.6, 
78.6, 76.3, 71.3, 47.9, 39.2, 34.8, 33.8, 32.0, 30.4, 28.4, 24.7, 22.6, 14.0; IR (film) 3347, 1702 
cm-1. MS (ESI) 390.3004 (390.3003 calcd for C24H39NO3, M + H+). 
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(+)-(E,2S,2’S,5R)-tert-Butyl 2-[2’-(benzyloxy)heptyl]-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-
carboxylate (2-13). A flame-dried Schlenk flask was cooled under a stream of N2 and charged 
with Pd2(dba)3 (18.3 mg, 0.02 mmol), tri-(2-furyl)phosphine (18.6 mg, 0.08 mmol) and NaOtBu 
(200 mg, 2.08 mmol). The flask was purged with N2, then a solution of 2-12 (406 mg, 1.04 
mmol) in distilled xylenes (5.2 mL) was added via syringe and the resulting mixture was stirred 
at rt for 5 min. (E)-(2-bromovinyl)trimethylsilane (319 µL, 2.08 mmol) was added and the flask 
was heated to 140 ºC and stirred overnight (ca. 14 h). The mixture was cooled to room 
temperature and saturated aqueous NH4Cl (5 mL) and ethyl acetate (5 mL) were added. The 
mixture was filtered through a plug of silica gel and the silica gel was washed with ethyl acetate 
(20 mL). The mixture was transferred to a separatory funnel, water was added (10 mL), the 
layers were separated, and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo.  The crude material was purified by flash chromatography on silica gel to afford 347 mg 
(68%) of the title compound as a pale brown oil. This compound was found to exist as a mixture 
of rotamers as judged by 1H and 13C NMR analysis; data are for the mixture.  [α]23D +14.5 (c 0.7, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.38–7.26 (m, 5 H), 6.00–5.91 (m, 1 H), 5.69 (d, J = 
18.5 Hz, 1 H), 4.57–4.42 (m, 2 H), 3.99–3.60 (m, 2 H), 3.58–3.24 (m, 1 H), 2.59–2.52 (m, 1 H), 
2.37–2.18 (m, 1 H), 2.02–1.81 (m, 3 H), 1.78–1.63 (m, 2 H), 1.59–1.23 (m, 9 H), 1.46 (s, 9 H), 
0.90 (t, J = 7.3 Hz, 3 H), 0.04 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 154.5, 143.1, 138.9, 
133.1, 128.3, 127.8, 127.5, 127.4, 79.0, 78.1, 70.7, 57.5, 57.1, 41.7, 40.8, 34.0, 32.0, 30.2, 28.6, 
28.4, 24.8, 22.6, 14.1, 0.0, –1.0, –1.2, –1.4; IR (film) 1693 cm-1. MS (ESI) 488.3553 (488.3554 
calcd for C29H49NO3Si, M + H+). 
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(+)-(2R,2’S,5S)-2-Allyl-5-[2’-(benzyloxy)heptyl]-N-(4-methoxybenzyl)pyrrolidine-1-
carboxamide (2-14). A round bottomed flask equipped with a stirbar was charged with 2-13 
(397 mg, 0.81 mmol) and methylene chloride (1.6 mL). The resulting solution was cooled to 0 ºC 
and trifluoroacetic acid (1.6 mL, 20.9 mmol) was added. The solution was gradually warmed to 
rt and stirred until the starting material had been consumed as judged by TLC analysis (ca. 15 
min). The reaction mixture was diluted with water, basified with NH4OH to pH > 12, and 
transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was dissolved in methylene 
chloride (8 mL) and 4-methoxybenzyl isocyanate (159 µL, 0.97 mmol) was added. The reaction 
mixture was stirred at rt until starting material had been completely consumed as judged by TLC 
analysis (ca. 1 h). The crude reaction mixture was concentrated in vacuo, and purified by flash 
chromatography on silica gel to afford 282 mg (72%) of the title compound as a colorless oil: 
[α]23D +52.7 (c 4.3, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.31–7.24 (m, 3 H), 7.22–7.18 (m, 2 
H), 6.97 (d, J = 9.0 Hz, 2 H), 6.73 (d, J = 9.0 Hz, 2 H), 5.96–5.88 (m, 1 H), 5.78 (ddt, J = 17.8, 
10.3, 7.5 Hz, 1 H), 5.07 (dd, J = 17.5, 2.0 Hz, 1 H), 5.03 (dd, J = 11.5, 2.0 Hz, 1 H), 4.49 (d, J = 
11.5 Hz, 1 H), 4.20 (d, J = 11.5 Hz, 1 H), 4.13 (dd, J = 14.5, 5.5 Hz, 1 H),  4.10–4.05 (m, 1 H), 
4.02 (dd, J = 14.5, 5.5 Hz, 1 H), 3.94–3.88 (m, 1 H), 3.76 (s, 3 H), 3.68–3.62 (m, 1 H), 2.64–2.57 
(m, 1 H), 2.27–2.20 (m, 1 H), 2.05–1.89 (m, 2 H), 1.76–1.55 (m, 5 H), 1.56–1.42 (m, 1 H), 1.34–
1.22 (m, 6 H), 0.89 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 158.3, 158.3, 138.2, 
135.3, 132.5, 128.7, 128.3, 127.4, 126.8, 116.8, 113.5, 75.8, 67.4, 57.9, 55.1, 54.9, 43.6, 40.5, 
40.3, 32.2, 31.8, 31.8, 28.7, 24.6, 22.5, 13.9; IR (film) 3361, 1642 cm-1. MS (ESI) 479.3271 
(479.3268 calcd for C30H42N2O3, M + H+). 
 
 
(+)-(Z,2’S,3R,4aR,7S)-7-[2’-(Benzyloxy)heptyl]-2-(4-methoxybenzyl)-3-(pent-2-en-1-
yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (2-15). A flame-dried Schlenk tube was 
cooled under a stream of N2 and charged with Pd2(dba)3 (8.0 mg, 0.009 mmol), PCy3HBF4 (12.9 
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mg, 0.04 mmol) and NaOtBu (56 mg, 0.58 mmol). The flask was purged with N2, then a solution 
of 2-14 (138 mg, 0.29 mmol) in toluene (1.5 mL) was added via syringe and the resulting 
mixture was stirred at rt for 5 min. A solution of (Z)-1-bromobut-1-ene (78.3 mg, 0.58 mmol) in 
toluene (1 mL) was added and the flask was heated to 110 ºC and stirred overnight (ca. 14 h). 
The mixture was cooled to room temperature and saturated aqueous NH4Cl (2 mL) and ethyl 
acetate (2 mL) were added. The mixture was filtered through a plug of silica gel and the silica 
gel was washed with ethyl acetate (10 mL). The mixture was transferred to a separatory funnel, 
water was added (5 mL), the layers were separated, and the aqueous layer was extracted with 
ethyl acetate (3 x 5 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo.  The crude material was purified by flash 
chromatography on silica gel to afford 139 mg (91%) of the title compound as a pale yellow oil: 
[α]23D +35.3 (c 2.7, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.37–7.29 (m, 3 H), 7.28–7.23 (m, 2 
H), 7.17 (d, J = 8.4 Hz, 2 H), 6.83 (d, J = 8.4 Hz, 2 H), 5.51–5.42 (m, 1 H), 5.22–5.12 (m, 2 H), 
4.55 (d, J = 11.4 Hz, 1 H), 4.49 (d, J = 11.4 Hz, 1 H), 4.02 (d, J = 15.2 Hz, 1 H), 4.01–3.94 (m, 1 
H), 3.77 (s, 3 H), 3.60–3.48 (m, 2 H), 3.24–3.16 (m, 1 H), 2.46–2.38 (m, 1 H), 2.26 (dd, J = 13.2, 
3.6 Hz, 1 H), 2.19–2.10 (m, 1 H), 2.05–1.81 (m, 6 H), 1.65–1.20 (m, 11 H), 0.94 (t, J = 7.4 Hz, 3 
H) 0.89 (t, J = 6.8 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 158.5, 154.6, 139.0, 134.4, 131.3, 
128.7, 128.2, 127.7, 127.3, 124.4, 113.7, 78.9, 70.9, 56.8, 55.1, 53.6, 52.2, 47.3, 39.0, 34.1, 32.0, 
31.3, 31.0, 30.9, 29.7, 24.7, 22.6, 20.8, 14.0, 14.0; IR (film) 1631 cm-1. MS (ESI) 533.3737 
(533.3738 calcd for C34H48N2O3, M + H+). 
 
 
(+)-(Z,2’S,3R,4aR,7S)-7-[2’-(Benzyloxy)heptyl]-2-(4-methoxybenzyl)-3-(pent-2-en-1-
yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-iminium tetrafluoroborate (2-16). A flame-
dried flask was cooled under a stream of N2 and charged with 2-15 (86 mg, 0.16 mmol) and 
toluene (1.6 mL). Freshly distilled POCl3 (1.6 mL, 17.2 mmol) was added, and the reaction 
mixture was refluxed overnight (ca. 14 h). The reaction mixture was cooled to rt and 
concentrated in vacuo.  The crude product was dissolved in acetonitrile (1.6 mL) and a solution 
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of ammonia (6.4 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting 
material had been consumed as judged by ESI+ MS analysis (ca. 15 min). The reaction mixture 
was concentrated and dissolved in methylene chloride (5 mL). Water (5 mL) was added and the 
mixture was transferred to a separatory funnel. The layers were separated and the organic layer 
was washed with saturated aqueous NaBF4 (3 x 10 mL). The combined aqueous layers were 
extracted with methylene chloride (3 x 10 mL). The combined organics layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The crude material was purified 
by flash chromatography on silica gel to afford 88 mg (89%) of the title compound as a pale 
brown oil: [α]23D +59.9 (c 3.6, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.30–7.21 (m, 5 H), 7.10 
(d, J = 8.5 Hz, 2 H), 6.90 (d, J = 8.5 Hz, 2 H), 5.99 (s, 2 H), 5.62–5.51 (m, 1 H), 5.20–5.12 (m, 1 
H), 4.63 (d, J = 17.0 Hz, 1 H), 4.58 (d, J = 17.5 Hz, 1 H), 4.57 (d, J = 11.0 Hz, 1 H), 4.45 (d, J = 
11.0 Hz, 1 H), 4.09–4.06 (m, 1 H), 3.80 (s, 3 H), 3.68–3.62 (m, 1 H), 3.61–3.52 (m, 2 H), 2.56–
2.44 (m, 1 H), 2.36–2.20 (m, 2 H), 2.19–2.08 (m, 2 H), 2.02–1.93 (m, 4 H), 1.78–1.56 (m, 4 H), 
1.43–1.20 (m, 7 H), 0.95 (t, J = 7.5 Hz, 3 H) 0.87 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 159.5, 151.5, 137.7, 136.2, 128.4, 128.2, 127.8, 127.4, 125.8, 122.3, 114.7, 77.2, 71.4, 
57.6, 55.9, 55.3, 55.3, 52.6, 51.2, 38.3, 32.5, 32.0, 31.8, 31.2, 29.8, 29.5, 24.9, 22.5, 20.9, 13.9; 
IR (film) 3366, 3252, 1592 cm-1. MS (ESI) 532.3908 (532.3898 calcd for C34H49N3O2, M + H+). 
 
 
 
(+)-Merobatzelladine B. A glass vial equipped with a magnetic stirbar was charged with 2-16 
(43 mg, 0.07 mmol), Pd/C (43 mg), and methanol (3 mL). The glass vial was placed in a 
stainless steel bomb equipped with a regulator. The vessel was pressurized to 45 psig with H2 
and stirred overnight (ca. 14 h) at rt under a hydrogen atmosphere (45 psig). Complete 
consumption of starting material was confirmed with ESI+ analysis. The mixture was filtered 
through a plug of celite and washed with methanol (20 mL). The crude product was transferred 
to a round-bottomed flask and concentrated in vacuo. The Mitsunobu reaction was carried out 
based on a published procedure by Nagasawa.32 The crude product was dissolved in toluene (3.5 
mL) and PPh3 (22 mg, 0.08 mmol) was added. The reaction flask was cooled to 0 ºC and DIAD 
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(16.3 µL, 0.083 mmol) was added. The reaction mixture was stirred at 0 ºC until the starting 
material had been consumed as judged by ESI+ MS analysis (ca. 1 h). The reaction was 
quenched with a drop of water and concentrated in vacuo. The material was purified by flash 
chromatography on silica (EtOAc, 2:98 MeOH:CH2Cl2, 10:90 MeOH:CH2Cl2) to provide N-p-
methoxybenzyl merobatzealladine B in ca. 70% purity (the remaining impurities were not 
identified). The PMB deprotection was carried out using the procedure of Gin, with slight 
modifications.35 This material was dissolved in methylene chloride (2 mL) and trifluoroacetic 
acid (6 mL, 78 mmol) was added. The reaction mixture was refluxed overnight (ca. 15 h). The 
crude material was concentrated in vacuo and then purified by flash chromatography on silica gel 
to afford 11.9 mg (41%) of the title compound as a pale brown oil. Spectroscopic properties are 
identical to those reported for the natural product.12 [α]23D +40.1 (c 0.7, MeOH) [lit.Error! 
ookmark not defined. [α]25D +27 (c 0.15, MeOH)].  1H NMR (700 MHz, CD3OD) δ 3.78–3.71 
(m, 2 H), 3.52–3.48 (m, 1 H), 3.42 (dtd, J = 11.6, 6.3, 3.2 Hz, 1 H), 2.28–2.21 (m, 3 H), 2.17 
(ddd, J = 13.3, 4.6, 1.8 Hz, 1 H), 1.62–1.22 (m, 20 H), 0.93–0.88 (m, 6 H); 13C NMR (175 MHz, 
CD3OD) δ 150.6, 57.5, 53.5, 51.6, 50.2, 36.2, 35.9, 34.8, 32.8, 32.7, 31.9, 31.2, 30.8, 26.8, 25.9, 
23.6, 23.6, 14.3, 14.3; IR (film) 3188, 3107, 1679 cm-1. MS (ESI) 306.2909 (306.2904 calcd for 
C19H36N3, M+). 
 
 
 
Assignment of Stereochemistry of 2-6a and 2-6b 
The relative stereochemistry of compound 2-6a was assigned on the basis of observed 1H NMR 
nOe experiments. Significant nOe relationships are shown below. 
 
The relative stereochemistry of compound 2-6b was assigned on the basis of observed 1H NMR 
nOe experiments. Significant nOe relationships are shown below. 
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Chapter 3    
Desymmetrization of meso-2,5-Diallylpyrrolidinyl Ureas via Asymmetric Pd-
Catalyzed Carboamination: Stereocontrolled Synthesis of Bicyclic Ureas 	  
3.1 Introduction 
Catalytic asymmetric desymmetrization reactions are powerful and efficient tools for the 
synthesis of chiral molecules.65–67 These transformations convert simple achiral substrates into 
complex enantioenriched products through the differentiation of two enantiotopic groups, and 
can generate complex structures bearing multiple stereocenters in a highly controlled fashion. As 
such, the development of asymmetric desymmetrization reactions that allow for the construction 
of important structural motifs is of considerable utility. 
As mentioned in chapters 1 and 2, tricyclic guanidines are an interesting class of compounds 
that could potentially be accessed via catalytic asymmetric desymmetrization reactions (Figure 
3.1). These scaffolds are displayed in a wide variety of biologically active natural products,2–6 
including the batzelladine alkaloids7,68–70 (e.g. batzelladine K), the merobatzelladine alkaloids 
(e.g., merobatzelladine B),12,14 and the crambescidin alkaloids (e.g., crambescidin 359).9,71,72 
Many synthetic routes to these compounds involve the generation of a fused-bicyclic urea or 
guanidine derivative (e.g., 3-1), which is then transformed to the tricyclic guanidine in 
subsequent steps.20,31,35,38,60 As such, development of a concise asymmetric synthesis of 3-1 could 
provide access to a broad array of interesting alkaloids. 
Figure 3.1 Bioactive guanidine alkaloids prepared from bicyclic urea and guanidine precursors. 
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Chapter 2 described our asymmetric synthesis of the tricyclic guanidine natural product (+)-
merobatzelladine B, which featured a new strategy for the construction of bicyclic ureas and 
polycyclic guanidines via Pd-catalyzed carboamination reactions of enantiomerically enriched 2-
allylpyrrolidine-1-carboxamide derivatives 3-2 (Scheme 3.1).60 These reactions provided bicyclic 
urea products 3-3 in good yield with excellent diastereoselectivity, but control of absolute 
stereochemistry required the chiral-auxiliary mediated introduction of the C2 stereocenter during 
the fairly lengthy asymmetric synthesis of 3-2 (7–9 steps). 
Scheme 3.1 Synthesis of bicyclic ureas through Pd-catalyzed asymmetric desymmetrization. 
  
A potentially more attractive route to enantiomerically enriched bicyclic ureas and related bi- 
and tricyclic guanidines would involve the asymmetric Pd-catalyzed desymmetrization of meso-
2,5-diallylpyrrolidnyl urea 3-4. This approach would allow for facile introduction of different R-
substituents, and the alkene present in product 3-5 provides a convenient handle for further 
elaboration to tricyclic guanidine products or more highly substituted urea derivatives. In 
addition, the meso-substrate 3-4 can be prepared in only four steps. Our preliminary studies in 
this area are described in this chapter. These transformations represent the first examples of 
asymmetric desymmetrizations of bis-alkene substrates in intermolecular Pd-catalyzed alkene 
carboamination reactions, and also the first examples of six-membered ring formation in an 
asymmetric Pd-catalyzed alkene carboamination.73–78 
3.2 Optimization and Scope of Desymmetrization Transformations 
meso-Pyrrolidinyl urea substrates 3-4 were readily prepared in just four steps following the 
synthetic route detailed in Scheme 3.2. The three-component coupling of 4-pentenal, tert-butyl 
carbamate and allyl trimethylsilane afforded racemic N-Boc-γ-aminoalkene 3-6 in a single step. 
cis-2,5-disubstituted pyrrolidine 3-7 was generated as a single diastereomer from a Pd-catalyzed 
carboamination cross-coupling reaction between substrate 3-6 and 2-bromovinyl trimethylsilane. 
The high stereoselectivity observed for this transformation is based on transition state 1-32 as 
depicted in Scheme 1.14. Pyrrolidine 3-7 was converted to various meso-substrates 3-4 upon 
treatment with TFA and an N-aryl isocyanate. This relatively short synthetic sequence permitted 
chiral 
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the preparation of these compounds on a multi-gram scale, and makes this route an attractive 
approach for future total synthesis endeavors.  
Scheme 3.2 Synthesis of meso-pyrrolidinyl urea substrates. 
 
In initial experiments we elected to employ a catalyst composed of Pd2(dba)3/(S)-Siphos-PE 
for desymmetrization reactions of 3-4, as we previously illustrated this complex provides good 
results in related asymmetric carboamination reactions of simple N-allyl urea derivatives.79–85 We 
decided to first optimize the structure of the urea N-aryl group, as prior studies in our lab 
suggested this group may have a significant influence on the level of asymmetric induction.79 
Thus, we explored the coupling of Z-1-bromobutene with ureas 3-4 bearing different N-aryl 
substituents. As shown in Table 3.1, the use of electron-poor p-cyanophenyl or p-nitrophenyl N-
aryl groups resulted in the formation of products 3-5 with the highest levels of both 
diastereoselectivity and enantioselectivity. However, these electron-poor substrates were 
transformed in modest chemical yield due to competing cleavage of the urea moiety (entries 5–
6). Use of the electron-rich p-methoxyphenyl group led to improved yields but with lower levels 
of stereocontrol. After some exploration we found that a substrate bearing a p-chlorophenyl 
group was transformed to the desired product with both good chemical yield and 
stereoselectivity (entry 3). The reaction of the analogous p-bromophenyl derivative proceeded in 
low yield because of competing oligomerization of the substrate (entry 4). 
Table 3.1 N-aryl group effects. 
 
Entry Ar Product Yield(%)[b] dr[c] er 
1 4-MeOC6H4 3-5a 65 7:1 86:14 
2 3,4-MeOC6H4 3-5b 41 7:1 82:18 
N
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Ar
HH
N
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HHNH
Boc
H
TMS
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2) Ar-NCO
BF3.OEt2
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allyl–TMS
CH2Cl2
Pd2(dba)3 (2 mol %)
P-(2-furyl)3 (8 mol %)
NaOtBu
Xylenes or Mesitylene
135 – 155 oCTMS
Br56% 77%, >20:1 dr
55 – 64%
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3-7 3-4[multi-gram scale]
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+ EtBr
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3 4-ClC6H4 3-5c 76 12:1 (20:1)[d] 95:5 
4 4-BrC6H4 3-5d 12[e] 18:1 94:6 
5 4-CNC6H4 3-5e 40[e] 17:1 95:5 
6 4-NO2C6H4 3-5f 22[f] 20:1 96:4 
[a] Conditions: 1.0 equiv substrate, 1.5 equiv (Z)-1-bromobutene, 1.5 equiv NaOtBu, 2 mol % Pd2(dba)3, 8 mol % 
(S)-Siphos-PE, Toluene (0.2 M), 100 °C, 2h. [b] Isolated yield (average of two or more runs). [c] Diastereomeric 
ratio of the pure isolated material. Diastereomeric ratios of the isolated materials were identical to those of the crude 
products except for entry 3. [d] The diastereomeric ratio of the crude material was 12:1. The product was isolated in 
76% yield with 20:1 dr. [e] This material contained a small amount of the corresponding aniline derivative. [f] The 
reaction was conducted at 120 °C for 16 h. The isolated material contained ca. 8% of unreacted substrate. 
As shown in Table 3.2, the asymmetric desymmetrization reactions of 3-4c are effective with 
a number of different alkenyl and aryl bromide electrophiles. The main side products generated 
in these reactions were cis-2,5-diallylpyrrolidine (resulting from competing urea cleavage) and 
an unsaturated bicyclic urea that is generated by competing β-hydride elimination of an 
intermediate alkylpalladium complex. In the reaction of 3-4c with E-1-bromohexene a 
regioisomeric side product bearing a 2-hex-1-enyl group was also generated.86  
Table 3.2 Desymmetrization Reaction Scope. 
 
Entry R Product Yield(%)[b] dr[c] er 
1 Z-butene 3-5c 76 >20:1[d] 95:5 
2 E-hexene 3-5g 50[f] >20:1[d] 95:5 
3 Z-hexene 3-5h 61 >20:1[d] 94:6 
4 2-methyl 
propene 
3-5i 48 10:1 94:6 
5 2-propene 3-5j 55 20:1[d] 88:12 
6 4-MeC6H4 3-5k 84 8:1 92:8 
7 4-MeOC6H4 3-5l 70 7:1 92:8 
8 Ph 3-5m 83 6:1 90:10 
9 4-F3CC6H4 3-5n 74 5:1 85:15 
10 4-F3CC6H4 3-5n 55[g] 11:1[e] 90:10 
11 4-F3COC6H4 3-5o 68 7:1 87:13 
12 4-F3COC6H4 3-5o 51[g] 18:1[d] 92:8 
13 3-MeOC6H4 3-5p 72 5:1 87:13 
Pd2(dba)3 
(S)-Siphos-PE
NaOtBu N
NO
R
H
H
Ar
N
NHO
Ar
HH H
Toluene, 100 oC
2 h
+
Ar = 4-Cl-C6H4
R Br
3-4c 3-5
O
O P N
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14 2-naphthyl 3-5q 75 7:1 88:12 
15 2-MeC6H4 3-5r 81 5:1 71:29 
[a] Conditions: 1.0 equiv substrate, 1.5 equiv R–Br, 1.5 equiv NaOtBu, 2 mol % Pd2(dba)3, 8 mol % (S)-Siphos-PE, 
Toluene (0.2 M), 100 °C, 2h. [b] Isolated yield (average of two or more runs). [c] Diastereomeric ratio of the pure 
isolated material. Diastereomeric ratios of the isolated materials were identical to those of the crude products unless 
otherwise noted. [d [The diastereomeric ratio of the crude material was 10–12:1. [e] The diastereomeric ratio of the 
crude material was 6:1 [f] This material contained 15% of the analogous 2-hex-1-enyl regioisomer. [g] The reaction 
was conducted using NaOMe as base instead of NaOtBu. 
The best enantioselectivities were obtained when either alkenyl bromides, electron-rich aryl 
bromides, or electron-neutral aryl bromides were employed as substrates. Diastereoselectivities 
were generally higher with the alkenyl electrophiles than with aryl electrophiles. Use of sterically 
hindered aryl bromides (entries 14–15) or electron-poor aryl bromides (entries 9, 11, and 13) led 
to lower diastereo- and enantioselectivities. Selectivities improved when NaOMe was used in 
place of NaOtBu in reactions of electron-poor aryl bromides (entries 10 and 12), although yields 
decreased in these cases.  
3.3 Deprotection and Synthesis of Tricyclic Guanidine Derivative  
To further demonstrate the utility of the asymmetric desymmetrization reactions, we 
examined the deprotection of 3-5c and the conversion of 3-5c to tricyclic guanidine derivatives. 
As shown in Scheme 3.3, cleavage of the N-p-chlorophenyl group can be accomplished via Pd-
catalyzed amination with acetamide,87 followed by oxidation of the resulting N-aryl amide (3-8) 
with ceric ammonium nitrate. This sequence afforded 3-9 in 65% yield over two steps. 
Scheme 3.3 Deprotection of desymmetrization product. 
 
The conversion of 3-5c to tricyclic guanidine 3-10 was carried out as shown in Scheme 3.4. 
Treatment of 3-5c with POCl3 followed by NH3 provided bicyclic guanidine 3-11 in 78% yield. 
Wacker oxidation of 3-11 afforded hemiaminal 3-12, which was then transformed to tricyclic 
product 3-10 in 70% yield with 5:1 dr via reductive amination with NaBH3CN.17 Preliminary 
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efforts to cleave the N-aryl group from 3-10 were unsuccessful. Overall, the synthesis of 3-10, 
which is structurally related to the batzelladine and merobatzelladine alkaloids, was 
accomplished in 5 steps and 41% yield from meso-2,5-diallylpyrrolidinyl urea 3-4c. In addition, 
this is the first example of a Wacker oxidation/ring-closure sequence to generate a tricyclic 
guanidine. 
Scheme 3.4 Synthesis of tricyclic guanidine derivative. 
 
3.4 Synthesis of 9-epi-Batzelladine K 
Finally, 3-5c was converted to tricyclic guanidine 3-13, which is an unnatural stereoisomer of 
batzelladine K,18,19,34,70 as shown in Scheme 3.5. To avoid problems with base-mediated 
epimerization of the C4 stereocenter, the Pd-catalyzed amination with acetamide was carried out 
prior to Wacker oxidation of the alkene. This two-step sequence provided 3-14 in 65% yield. 
Reduction of the alkene followed by CAN deprotection generated urea 3-15, which was 
converted to guanidine aminal 3-16 by O-methylation and treatment with ammonia.22 The 
reduction of 3-16 proceeded with modest diastereoselectivity (3:1 dr), but upon purification 9-
epi-batzelladine K was isolated as a single stereoisomer in 48% yield over three steps from 3-15. 
Scheme 3.5 Synthesis of 9-epi-batzelladine K. 
 
N
NO
H
H Et
H
Ar Ar = 4-ClC6H4
1) POCl3
2) NH3
78%
N
N
H
H Et
H
Ar
N
H
Me
+ Cl
–
N
NH2N
H
H Et
H
Ar
Cl– NaBH3CN50 °C
70%
5:1 dr
(2 steps)
N
N
H
H Et
H
Ar
N
H
+
MeHO
Cl–
3-5c 3-11 3-12
PdCl2, CuCl 
THF, H2O
3-10
H
N
NO
H
H Et
H
Ar
1) Pd2dba3
(Me)4tBuXphos
acetamide, K3PO4
tBuOH, 110 oC
Ar = 4-ClC6H4
2) PdCl2, CuCl 
DMF, H2O
N
NO
H
H Et
H
Ar3-5c
O
65% Ar =4-C6H4NHC(O)Me
1) H2, Pd/C
2) CAN, rt→50 oC
N
N
H
O
H
H Et
HO
1) MeOTf
    DTBP
2) NH3, MeOH, 60 °C
N
N
H
H
H Et
H
N
H
Me
+
MeO
NaBH3CN
50 °C
48%
(over three steps)
3:1 dr crude
one pure  steroisomer 
isolated
Cl–
N
N
H
H
H Et
H
N
H
Me
+ Cl
–
9-epi-Batzelladine K (3-13)
3-14
3-15
3-16
51%
9
4
49
9
4
H
	   42	  
3.5 Conclusions 
In conclusion we have developed a concise route to enantiomerically enriched bicyclic ureas 
via Pd-catalyzed desymmetrizing carboamination reactions of meso-diallylpyrrolidinyl ureas. 
These transformations effect formation of both a C–N and a C–C bond, and provide products 
bearing three stereocenters with good levels of diastereoselectivity and enantioselectivity. These 
reactions illustrate the potential utility of asymmetric Pd-catalyzed alkene carboamination for 
desymmetrization processes and provide synthetically valuable products in a straightforward 
manner.  
 
The work described in this chapter was published in Angewandte Chemie International Edition.88 
 
3.6 Experimental 
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware 
unless otherwise noted. Tris(dibenzylidene)acetone dipalladium, tri(2-furyl)phosphine, and (S)-
Siphos-PE were purchased from Strem Chemical Co. and used without purification. 
Tricyclohexylphosphonium tetrafluoroborate was purchased from Acros Chemical Co. and used 
without further purification. 2-Di-tert-butylphosphino-3,4,5,6-tetramethyl-2’,4’,6’-triisopropyl-
1,1’-biphenyl was purchased from Sigma-Aldrich and used without further purification. All other 
reagents were obtained from commercial sources and were used as obtained unless otherwise 
noted. NaOtBu and CuCl were stored in the glove box and removed prior to use. BF3OEt2 and 
POCl3 were purified by distillation under N2 prior to use. (Z)-1-bromobutene63 was prepared 
according to a slight modification of a literature procedure; the preparation was conducted at rt 
instead of using microwave heating as described in chapter 2. (Z)-1-bromohexene,62 and (E)-1-
bromohexene62 were prepared according to published procedures. Toluene, THF, diethyl ether 
and dichloromethane were purified using a GlassContour solvent purification system. Yields 
refer to isolated yields of compounds estimated to be ≥95% pure as determined by 1H NMR 
analysis unless otherwise noted. The yields reported in the experimental section describe the 
result of a single experiment, whereas yields reported in Chapter 3 are average yields of two or 
more experiments. Thus, the yields reported in the experimental section may differ from those 
shown in Chapter 3. Structural and stereochemical assignments were made on the basis of 2-D 
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COSY, and NOESY experiments. Ratios of diastereomers were determined by 1H NMR analysis. 
The reported optical rotation values refer to measurements taken of the isolated mixtures of 
diastereomers upon which chemical yields were based. Ratios of enantiomers were determined 
by HPLC analysis. Although diastereomers were not easily separable by chromatography, for 
most examples (with the exception of 3-5i and 3-5j) it was possible to separate small amounts of 
the pure (>20:1 dr) major diastereomer for chiral HPLC analysis. 
 
Preparation and Characterization of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide 
Substrates 
 
 
(±)-tert-Butyl octa-1,7-dien-4-ylcarbamate (3-6). The title compound was prepared by 
modifying a procedure published by Veenstra.89 A flame-dried flask was cooled under a stream 
of N2, charged with dichloromethane (60 mL) and cooled to 0 OC. Pent-4-enal (2.96 mL, 30 
mmol), allyltrimethylsilane (4.77 mL, 30 mmol) and tert-butyl carbamate (3.5 g, 30 mmol) were 
added to the flask and the resulting solution was stirred for 15 min at 0 OC. Distilled BF3OEt2 
(2.3 mL, 18 mmol) was added and the reaction mixture was stirred for 30 min at 0 OC. The 
mixture was gradually warmed to rt and stirred for 30 min. The reaction was then quenched with 
saturated aqueous NaHCO3 (20 mL) and stirred for 5 min at rt. The mixture was transferred to a 
separatory funnel and the layers were separated. The organic layer was washed with saturated 
aqueous NaHCO3 (20 mL) and then the combined aqueous layers were extracted with 
dichloromethane (15 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 3.8 g (56%) of the title compound as a clear colorless oil. 
This compound was found to exist as a mixture of rotamers as judged by 1H and 13C NMR 
analysis; data are for the mixture.  1H NMR (500 MHz, CDCl3) δ 5.84–5.73 (m, 2 H), 5.10–4.95 
(m, 4 H), 4.33 (d, br, J = 7.5 Hz, 1 H), 3.66 (d, br, J = 4.5 Hz, 1 H), 2.26–2.07 (m, 4 H), 1.60–
1.55 (m, 1 H), 1.48–1.40 (m, 1 H), 1.43 (s, 9 H); 13C NMR (175 MHz, CDCl3) δ 155.5, 138.0, 
134.4, 117.7, 114.9, 79.0, 49.6, 39.5, 33.9, 30.2, 28.4; IR (film) 3337,1684 cm–1. MS (ESI) 
248.1621 (248.1621 calcd for C13H23NO2, M + Na+). 
HN Boc
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(±)-(E,2R*,5S*)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (3-7). 
A flame-dried Schlenk flask was cooled under a stream of N2 and charged with Pd2(dba)3 (81 
mg, 0.089 mmol), tri(2-furyl)phosphine (82 mg, 0.36 mmol) and NaOtBu (853 mg, 8.9 mmol). 
The flask was purged with N2, then a solution of 3-6 (1.0 g, 4.4 mmol) in freshly distilled xylenes 
(22.2 mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. (E)-(2-
bromovinyl)trimethylsilane (1.36 mL, 8.9 mmol) was added and the flask was heated to 137 ºC 
and stirred overnight (ca. 14 h). The mixture was cooled to room temperature and saturated 
aqueous NH4Cl (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the 
organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl 
acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. The crude material was purified by flash chromatography on silica gel to afford 1.11 g 
(77%) of the title compound as a dark red-brown oil. This compound was found to exist as a 
mixture of rotamers as judged by 1H and 13C NMR analysis; data are for the mixture. 1H NMR 
(500 MHz, CDCl3) δ 5.98–5.92 (m, 1 H), 5.78–5.70 (m, 1 H), 5.68 (d, J = 18.5 Hz, 1 H), 5.06–
5.01 (m, 2 H), 3.92–3.68 (m, 2 H), 2.64–2.41 (m, 2 H), 2.34 (dt, J = 8.0, 13.0 Hz, 1 H), 2.09 (dt, 
J = 8.0, 13.0 Hz, 1 H), 1.87–1.82 (m, 2 H), 1.68–1.64 (m, 2 H), 1.46 (s, 9 H), 0.03 (s, 9 H); 13C 
NMR (125 MHz, CDCl3) δ 154.7, 143.2, 135.4, 132.9, 116.8, 79.0, 58.0, 57.9, 42.1, 42.0, 40.0, 
39.8, 28.5, –1.2; IR (film) 1692 cm–1. MS (ESI) 346.2174 (346.2173 calcd for C18H33NO2Si, M + 
Na+). 
 
General Procedure for Synthesis of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide 
Substrates 3-4. A round-bottom flask equipped with a stirbar was charged with 3-7  (1.0 equiv) 
and dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was added to the flask and the 
mixture was heated to reflux and stirred overnight. The solution was cooled to rt, diluted with 
water, basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
N
Boc
TMS
H H
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product was dissolved in dichloromethane (0.2 M) and the appropriate isocyanate (1.1 equiv) 
was added. The reaction mixture was stirred at rt until starting material had been completely 
consumed as judged by TLC analysis (ca. 1 h). The crude reaction mixture was concentrated in 
vacuo, and purified by flash chromatography on silica gel. 
 
 
(2S,5R)-2,5-Diallyl-N-(4-methoxyphenyl)pyrrolidine-1-carboxamide (3-4a). The title 
compound was prepared from 3-7 (2.13 g, 6.6 mmol) and 4-methoxyphenyl isocyanate (940 µL, 
7.3 mmol) in two steps via the general procedure described above. This procedure afforded 1.2 g 
(61%) of the title compound as a white solid: mp = 63–65 ºC. 1H NMR (700 MHz, CDCl3) δ 7.25 
(d, J = 8.4 Hz, 2 H), 6.82 (d, J = 9.1 Hz, 2 H), 6.33 (s, 1H), 5.91–5.85 (m, 2 H), 5.20–5.15 (m, 4 
H), 3.99–3.96 (m, 2 H), 3.77 (s, 3 H), 2.55 (dt, J = 14.0, 7.0 Hz, 2 H), 2.24 (dt, J = 7.0, 14.0 Hz, 
2 H), 2.02–1.97 (m, 2 H), 1.78–1.74 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 155.5, 155.2, 
135.2, 132.3, 121.4, 118.0, 114.1, 58.8, 55.5, 40.2, 29.5; IR (film) 3311, 1635 cm–1. MS (ESI) 
301.1917 (301.1911 calcd for C18H24N2O2, M + H+).  
 
 
(2S,5R)-2,5-Diallyl-N-(3,4-dimethoxyphenyl)pyrrolidine-1-carboxamide (3-4b). The title 
compound was prepared from 3-7 (965 mg, 2.98 mmol) and 3,4-dimethoxyphenyl isocyanate 
(488 µL, 3.3 mmol) in two steps via the general procedure described above. This procedure 
afforded 542 mg (55%) of the title compound as a tan solid: mp = 112–114 ºC.  1H NMR (500 
MHz, CDCl3) δ 7.27 (d, J = 2.1 Hz, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 6.62 (dd, J = 2.8, 8.4 Hz, 1 
N
NHO
OMe
HH
N
NHO
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H), 6.36 (s, 1H), 5.91–5.86 (m, 2 H), 5.21–5.16 (m, 4 H), 4.01–3.97 (m, 2 H), 3.88 (s, 3 H), 3.84 
(s, 3 H), 2.57 (dt, J = 6.3,13.3 Hz, 2 H), 2.25 (dt, J = 7.7, 13.3 Hz, 2 H), 2.03–1.99 (m, 2 H), 
1.79–1.75 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 155.1, 149.1, 144.8, 135.2, 133.0, 118.1, 
111.4, 110.9, 104.7, 58.7, 56.2, 55.9, 40.2, 29.5; IR (film) 3327, 1635 cm–1. MS (ESI) 331.2018 
(331.2016 calcd for C19H26N2O3, M + H+). 
 
 
(2S,5R)-2,5-Diallyl-N-(4-chlorophenyl)pyrrolidine-1-carboxamide (3-4c). The title compound 
was prepared from 3-7 (1.05 g, 3.2 mmol) and 4-chlorophenyl isocyanate (541 mg, 3.5 mmol) in 
two steps via the general procedure described above. This procedure afforded 574 mg (58%) of 
the title compound as a white solid: mp = 91–93 ºC. 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 
9.0 Hz, 2 H), 7.21 (d, J = 9.0 Hz, 2 H), 6.51 (s, 1H), 5.91–5.85 (m, 2 H), 5.22–5.16 (m, 4 H), 
4.00–3.95 (m, 2 H), 2.55 (dt, J = 14.0, 6.5 Hz, 2 H), 2.25 (dt, J = 14.0, 7.5 Hz, 2 H), 2.03–1.97 
(m, 2 H), 1.79–1.74 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 154.5, 137.9, 135.1, 128.7, 127.4, 
120.3, 118.3, 58.9, 40.1, 29.6; IR (film) 3318, 1640 cm–1. MS (ESI) 327.1242 (327.1235 calcd 
for C17H21ClN2O, M + Na+). 
 
 
(2S,5R)-2,5-Diallyl-N-(4-bromophenyl)pyrrolidine-1-carboxamide (3-4d). The title 
compound was prepared from 3-7 (1.2 g, 3.7 mmol) and 4-bromophenyl isocyanate (806 mg, 4.1 
mmol) in two steps via the general procedure described above. This procedure afforded 827 mg 
(64%) of the title compound as a off-white solid: mp = 101–104 ºC. 1H NMR (700 MHz, CDCl3) 
N
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δ 7.37 (d, J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.91–5.85 (m, 2 H), 5.21–5.17 
(m, 4 H), 3.99–3.97 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 
2.03–1.99 (m, 2 H), 1.80–1.77 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 154.5, 138.4, 135.1, 
131.7, 120.7, 118.3, 115.0, 58.9, 40.1, 29.6; IR (film) 3316, 1635 cm–1. MS (ESI) 349.0912 
(349.0910 calcd for C17H21BrN2O, M + H+). 
 
 
(2S,5R)-2,5-Diallyl-N-(4-cyanophenyl)pyrrolidine-1-carboxamide (3-4e). The title compound 
was prepared from 3-7 (1.12 g, 3.46 mmol) and 4-cyanophenyl isocyanate (549 mg, 3.81 mmol) 
in two steps via the general procedure described above. This procedure afforded 613 mg (60%) 
of the title compound as a off-white solid: mp = 76–79 ºC. 1H NMR (700 MHz, CDCl3) δ 7.36 (d, 
J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.92–5.86 (m, 2 H), 5.21–5.17 (m, 4 H), 
4.02–3.96 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 2.03–1.99 
(m, 2 H), 1.80–1.77 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.9, 143.5, 135.0, 133.1, 119.2, 
118.6, 118.6, 105.1, 59.1, 39.9, 29.6; IR (film) 3365, 1652 cm–1. MS (ESI) 296.1756 (296.1757 
calcd for C18H21N3O, M + H+). 
 
 
 
(2S,5R)-2,5-Diallyl-N-(4-nitrophenyl)pyrrolidine-1-carboxamide (3-4f). The title compound 
was prepared from 3-7 (660 mg, 2.04 mmol) and 4-nitrophenyl isocyanate (368 mg, 2.24 mmol) 
N
NHO
CN
HH
N
NHO
NO2
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in two steps via the general procedure described above. This procedure afforded 366 mg (57%) 
of the title compound as a pale-yellow solid: mp = 96–97 ºC. 1H NMR (700 MHz, CDCl3) δ 8.15 
(d, J = 9.1 Hz, 2 H), 7.50 (d, J = 9.1 Hz, 2 H), 6.93 (s, 1H), 5.94–5.88 (m, 2 H), 5.25–5.21 (m, 4 
H), 4.04–4.01 (m, 2 H), 2.56 (dt, J = 7.0, 13.3 Hz, 2 H), 2.29 (dt, J = 7.0, 14.0 Hz, 2 H), 2.07–
2.03 (m, 2 H), 1.83–1.79 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.7, 145.5, 142.2, 135.0, 
125.1, 118.8, 117.8, 59.2, 39.9, 29.7; IR (film) 3331, 1652 cm–1. MS (ESI) 316.1656 (316.1656 
calcd for C17H21N3O3, M + H+). 
 
Preparation and Characterization of Bicyclic Urea Products 
 
General Procedure for Synthesis of Racemic Bicyclic Ureas (for HPLC assays). A flame-
dried Schlenk tube was cooled under vacuum and charged with the appropriate meso-N-aryl-2,5-
diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), Pd2(dba)3 (0.02 equiv), PCy3HBF4 
(0.08 equiv), and NaOtBu (1.5 equiv). The flask was evacuated and purged with N2. Toluene (0.2 
M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate 
aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 ºC and stirred for 2 
h. The mixture was cooled to room temperature and saturated aqueous NH4Cl (5 mL/mmol 
substrate) and ethyl acetate (5 mL/mmol substrate) were added. The layers were separated, the 
organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl 
acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude material was purified by flash chromatography on silica 
gel. 
 
General Procedure for Synthesis of Enantiomerically-Enriched Bicyclic Ureas 3-5 
A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate meso-N-
aryl-2,5-diallylpyrrolidine-1-carboxamide substrate 3-4 (1.0 equiv), Pd2(dba)3 (0.02 equiv), (S)-
Siphos-PE (0.08 equiv), and NaOtBu or NaOMe (1.5 equiv). The flask was evacuated and 
purged with N2. Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at rt 
for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was 
heated to 100 ºC. The solution was stirred for 2 h or until the starting material was completely 
consumed as judged by TLC analysis. The mixture was cooled to room temperature and 
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saturated aqueous NH4Cl (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were 
added. 6 M HCl was used instead of NH4Cl to remove aniline side products if column 
chromatography could not separate the desired product from aniline side products. The layers 
were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was 
washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
 
 
(+)-(Z,3S,4aS,7R)-7-Allyl-2-(4-methoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5a). The general procedure was employed for the coupling of 3-4a 
(60 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), 
using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 
mmol). This procedure afforded 48 mg (68%) of the title compound as a brown oil and as a 7:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D +9.5 (c 4.3, CH2Cl2).  Data 
are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.14 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 8.4 
Hz, 2 H), 5.77–5.71 (m, 1 H), 5.43 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.03 (d, J = 
17.5 Hz, 1 H), 5.00 (d, J = 9.8 Hz, 1 H), 3.99 (dt, J = 2.1, 9.1 Hz, 1 H), 3.82–3.78 (m, 1 H), 3.79 
(s, 3 H), 3.65 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.29–2.27 (m, 1 
H), 2.18–2.15 (m, 2 H), 2.08 (dt, J = 8.4, 13.3 Hz, 1 H) 1.99–1.88 (m, 4 H), 1.83 (dd, J = 6.3, 
12.6 Hz, 1 H) 1.68–1.60 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 
157.6, 154.2, 135.8, 135.1, 134.6, 129.3, 124.2, 116.8, 114.1, 58.3, 57.3, 55.4, 52.7, 37.8, 31.3, 
31.0, 30.9, 27.8, 20.7, 14.0; IR (film) 1642 cm–1. MS (ESI) 355.2382 (355.2380 calcd for 
C22H30N2O2, M + H+). The enantiopurity was determined to be 86:14 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 2.5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 44.2 and 
49.1 min). 
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(+)-(Z,3S,4aS,7R)-7-Allyl-2-(3,4-dimethoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5b). The general procedure was employed for the coupling of 3-4b 
(66 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), 
using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 
mmol). This procedure afforded 30 mg (39%) of the title compound as a brown oil and as a 7:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D +7.0 (c 2.9, CH2Cl2).  Data 
are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 6.83 (d, J = 8.4 Hz, 1 H), 6.78–6.77 (m, 
2 H), 5.77–5.71 (m, 1 H), 5.44 (dt, J = 7.0, 10.5 Hz, 1 H) 5.13–5.09 (m, 1 H), 5.03 (d, J = 16.8 
Hz, 1 H), 5.00 (d, J = 10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 9.1 Hz, 1 H), 3.86 (s, 6 H), 3.85–3.81 (m, 
1 H), 3.66 (ddt, J = 2.1, 5.6, 11.2 Hz, 1 H), 2.80 (dd, J = 5.6, 12.6 Hz, 1 H), 2.30–2.28 (m, 1 H), 
2.18–2.15 (m, 2 H), 2.07 (dt, J = 8.4, 13.3 Hz, 1 H) 2.00–1.96 (m, 1 H), 1.93–1.87 (m, 3 H), 1.83 
(dd, J = 7.0, 12.6 Hz, 1 H) 1.69–1.63 (m, 2 H), 0.89 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 154.1, 148.9, 147.2, 135.8, 135.4, 134.7, 124.2, 120.1, 116.8, 112.3, 111.1, 58.5, 57.3, 
56.0, 55.9, 52.7, 37.8, 31.3, 31.1, 30.9, 27.7, 20.7, 14.1;  IR (film) 1641 cm–1. MS (ESI) 
385.2486 (385.2486 calcd for C23H32N2O3, M + H+). The enantiopurity was determined to be 
82:18 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 
mL/min, λ 205 nm, RT= 20.4 and 23.5 min). 
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(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5c). The general procedure was employed for the coupling of 3-4c 
(305 mg, 1.0 mmol) and (Z)-1-bromobut-1-ene (750 µL, 1.5 mmol, 2.0 M solution in toluene), 
using a catalyst composed of Pd2dba3 (18.3 mg, 0.02 mmol), and (S)-Siphos-PE (40.4 mg, 0.08 
mmol). This procedure afforded 288 mg (80%) of the title compound as a yellow oil: [α]23D –
14.3 (c 5.3, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 7.31 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 
2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, J = 7.0, 10.5 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 16.8 
Hz, 1 H), 5.01 (d, J = 10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 9.1 Hz, 1 H), 3.90 (dt, J = 4.2, 10.5 Hz, 1 
H), 3.66 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 
2.07 (dt, J = 9.1, 13.3 Hz, 1 H) 1.99 (dt, J = 6.3, 11.2 Hz, 1 H), 1.93–1.88 (m, 3 H), 1.84 (dd, J = 
6.3, 12.6 Hz, 1 H) 1.69–1.64 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 
153.7, 140.8, 135.6, 134.9, 131.2, 129.3, 128.9, 123.8, 117.0, 58.0, 57.4, 52.8, 37.7, 31.3, 31.0, 
30.9, 27.8, 20.7, 14.0;  IR (film) 1643 cm–1. MS (ESI) 359.1887 (359.1885 calcd for 
C21H27ClN2O, M + H+). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 18.1 
min). 
 
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-bromophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5d). The general procedure was employed for the coupling of 3-4d 
(70 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), 
using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 
mmol). This procedure afforded 15 mg (18%) of the title compound as a brown oil and as a 18:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D –21.1 (c 0.5, CH2Cl2). This 
material also contained ca. 20% of an unidentified side product. Data are for the major isomer.  
1H NMR (700 MHz, CDCl3) δ 7.46 (d, J = 8.4 Hz, 2 H), 7.14 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 
N
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1 H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J = 
10.5 Hz, 1 H), 4.01 (dt, J = 2.8, 8.4 Hz, 1 H), 3.90 (dt, J = 4.9, 10.5 Hz, 1 H), 3.66 (ddt, J = 2.8, 
5.6, 11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, J = 8.4, 13.3 
Hz, 1 H) 1.99 (dt, J = 5.6, 11.9 Hz, 1 H), 1.95–1.88 (m, 3 H), 1.84 (dd, J = 6.3, 12.6 Hz, 1 H) 
1.69–1.63 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.6, 141.4, 135.6, 
134.9, 131.9, 129.7, 123.8, 119.2, 117.0, 57.9, 57.4, 52.7, 37.7, 31.3, 31.0, 30.8, 27.7, 20.7, 14.0;  
IR (film) 1645 cm–1. MS (ESI) 403.1379 (403.1380 calcd for C21H27BrN2O, M + H+). The 
enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 14.5 and 20.0 min). 
 
 
 
 
(–)-4-[(Z,3S,4aS,7R)-7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-
2(1H)-yl]benzonitrile (3-5e). The general procedure was employed for the coupling of 3-4e (59 
mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M solution in toluene), using a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 29 mg (41%) of the title compound as a brown oil and as a 17:1 mixture 
of diastereomers as determined by 1H NMR analysis: [α]23D –71.0 (c 2.9, CH2Cl2). This material 
also contained ca. 5% of 4-aminobenzonitrile. Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.62 (d, J = 9.1 Hz, 2 H), 7.39 (d, J = 9.1 Hz, 2 H), 5.76–5.71 (m, 1 H),  5.45 (dt, 
J = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, J = 16.1 Hz, 1 H), 5.02 (d, J = 9.1 Hz, 1 H), 
4.07 (dt, J = 4.9, 10.5 Hz, 1 H), 4.02 (dt, J = 2.1, 8.4, Hz 1 H), 3.68 (ddt, J = 2.1, 5.6, 11.2 Hz, 1 
H), 2.76 (dd, J = 6.3, 12.6 Hz, 1 H), 2.23 (d, J = 12.6 Hz, 1 H), 2.20–2.14 (m, 2 H), 2.06 (dt, J = 
8.4, 13.3 Hz, 1 H), 2.03–2.00 (m, 1 H), 1.97–1.85 (m, 4 H), 1.71–1.63 (m, 2 H), 0.89 (t, J = 7.7 
Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.1, 146.6, 135.3, 135.2, 132.6, 127.8, 123.4, 118.9, 
N
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117.2, 108.5, 57.7, 57.4, 52.7, 37.4, 31.4, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1648 cm–1. MS 
(ESI) 350.2227 (350.2227 calcd for C22H27N3O, M + H+). The enantiopurity was determined to 
be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 
mL/min, λ 205 nm, RT= 33.2 and 42.9 min). 
 
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-nitrophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5f). A modification of the general procedure was employed for the 
coupling of 3-4f (63 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 µL, 0.3 mmol, 2.0 M 
solution in toluene), using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-
PE (8 mg, 0.016 mmol). In contrast to the general procedure, this reaction was run overnight (16 
h) at 120 oC. This procedure afforded 18 mg (24%) of the title compound as a yellow oil and as a 
20:1 mixture of diastereomers as determined by 1H NMR analysis: [α]23D –281.3 (c 1.1, CH2Cl2).  
This material also contained ca. 8% of unreacted starting material and ca. 3% of a bicyclic urea 
side product lacking the butenyl group (tentatively assigned as 7-allyl-3-methyl-2-(4-
nitrophenyl)-4a,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-1(2H)-one). Data are for the major 
isomer. 1H NMR (700 MHz, CDCl3) δ 8.21 (d, J = 9.1 Hz, 2 H), 7.46 (d, J = 9.1 Hz, 2 H), 5.77–
5.71 (m, 1 H), 5.46 (dt, J = 7.0, 11.2 Hz, 1 H), 5.12 (ddt, J = 2.1, 8.4, 17.5 Hz, 1 H), 5.07–5.03 
(m, 2 H), 4.15 (dt, J = 4.,9 9.8 Hz, 1 H), 4.05 (dt, J = 2.8, 9.1 Hz, 1 H), 3.70 (ddt, J = 2.8, 5.6, 
11.2 Hz, 1 H), 2.78 (dd, J = 5.6, 13.3 Hz, 1 H), 2.25 (d, J = 13.3 Hz, 1 H), 2.23–2.16 (m, 2 H), 
2.10–2.02 (m, 2 H) 1.97–1.87 (m, 4 H), 1.73–1.66 (m, 2 H), 0.90 (t, J = 7.7 Hz, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 153.0, 148.5, 144.4, 135.3, 135.3, 127.2, 124.1, 123.3, 117.3, 57.8, 57.4, 
52.7, 37.3, 31.5, 31.0, 30.8, 27.7, 20.8, 14.0; IR (film) 1649 cm–1. MS (ESI) 370.2126 (370.2125 
calcd for C21H27N3O3, M + H+). The enantiopurity was determined to be 96:4 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 1.5 mL/min, λ 310 nm, RT= 19.1 
and 26.2 min). 
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(–)-(E,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5g). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and (E)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the 
workup to remove 4-chloroaniline side product. This procedure afforded 44 mg (57%) of the title 
compound as a yellow oil: [a]23D –30.3 (c 1.9, CH2Cl2). This material also contained ca. 15% of a 
regioisomeric bicyclic urea product generated from the coupling of 3-4c and 2-bromohex-1-ene 
(tentatively assigned as (3S,4aS,7R)-7-allyl-2-(4-chlorophenyl)-3-(2-
methylenehexyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one). Data are for the major isomer.  
1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.17 (d, J = 9.0 Hz, 2 H), 5.78–5.70 (m, 
1 H), 5.41–5.36 (m, 1 H), 5.17–5.10 (m, 1 H), 5.05–5.00 (m, 2 H), 4.00 (dt, J = 2.5, 8.5 Hz, 1 H), 
3.92–3.87 (m, 1 H), 3.65 (ddt, J = 2.5, 5.5, 11.0 Hz, 1 H), 2.79 (dd, J = 6.0, 13.5 Hz, 1 H), 2.28–
2.23 (m, 2 H), 2.10–1.98 (m, 3 H), 1.95–1.87 (m, 3 H), 1.84 (dd, J = 6.5, 12.5 Hz, 1 H) 1.69–
1.62 (m, 2 H), 1.29–1.26 (m, 4 H), 0.87 (t, J = 7.0 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 
153.7, 140.9, 135.6, 134.6, 131.2, 129.4, 128.8, 125.1, 116.9, 57.9, 57.4, 52.6, 37.7, 36.9, 32.2, 
31.4, 30.8, 27.8, 22.1, 13.9 (one carbon signal is absent due to incidental equivalence);  IR (film) 
1643 cm–1. MS (ESI) 387.2207 (387.2198 calcd for C23H31ClN2O, M + H+). The enantiopurity 
was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% 
IPA/Hexanes, 1.5 mL/min, λ 205 nm, RT= 20.0 and 37.5 min). 
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(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-4h). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and (Z)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the 
workup to remove 4-chloroaniline side product. This procedure afforded 47 mg (61%) of the title 
compound as a yellow brown oil: [α]23D –14.8 (c 3.5, CH2Cl2). Data are for the major isomer. 1H 
NMR (700 MHz, CDCl3) δ 7.31 (d, J = 9.1 Hz, 2 H), 7.19 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 
H), 5.45 (dt, J = 7.0, 11.2 Hz, 1 H), 5.15–5.11 (m, 1 H), 5.05–5.00 (m, 2 H), 4.01 (dt, J = 2.8, 8.4 
Hz, 1 H), 3.91–3.88 (m, 1 H), 3.66 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.78 (dd, J = 8.4, 13.3 Hz, 1 
H), 2.24–2.14 (m, 3 H), 2.07 (dt, J = 8.4, 14.0 Hz, 1 H), 2.00–1.97 (m, 1 H) 1.95–1.83 (m, 4 H), 
1.70–1.62 (m, 2 H), 1.25–1.24 (m, 4 H), 0.86 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 
153.7, 140.8, 135.6, 133.4, 131.3, 129.4, 128.9, 124.4, 117.0, 58.1, 57.4, 52.8, 37.7, 31.6, 31.3, 
31.0, 30.8, 27.8, 27.2, 22.3, 13.9;  IR (film) 1642 cm–1. MS (ESI) 387.2203 (387.2198 calcd for 
C23H31ClN2O, M + H+). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 254 nm, RT= 20.9 and 36.2 
min). 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5i). The general procedure was employed for the coupling of 3-4c (61 
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mg, 0.2 mmol) and 1-bromo-2-methyl-1-propene (31 µL, 0.3 mmol), using a catalyst composed 
of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure 
afforded 37 mg (52%) of the title compound as a yellow oil and as a 10:1 mixture of 
diastereomers as determined by 1H NMR analysis: [α]23D –37.9 (c 2.2, CH2Cl2). Data are for the 
major isomer.  1H NMR (700 MHz, CDCl3) δ 7.30 (d, J = 7.7 Hz, 2 H), 7.18 (d, J = 9.1 Hz, 2 H), 
5.74 (dddd, J = 6.3, 7.7, 10.5, 16.8 Hz, 1 H), 5.04 (dd, J = 2.1, 16.8 Hz, 1 H), 5.01 (d, J = 10.5 
Hz, 1 H), 4.89 (dt, J = 1.4, 7.0 Hz, 1 H), 4.00 (dt, J = 2.8, 9.1 Hz, 1 H), 3.88–3.85 (m, 1 H), 3.66 
(ddt, J = 2.8, 5.6, 11.2 Hz, 1 H), 2.79 (dd, J = 6.3, 12.6 Hz, 1 H), 2.21–2.16 (m, 2 H), 2.09–2.04 
(m, 2 H), 2.02–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.84 (dd, J = 7.0, 12.6 Hz, 1 H) 1.68–1.62 (m, 
2 H), 1.64 (s, 3 H), 1.47 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 153.7, 140.9, 135.6, 134.9, 
131.1, 129.3, 128.8, 119.6, 117.0, 58.3, 57.4, 52.8, 37.7, 32.2, 31.1, 30.9, 27.7, 25.7, 17.9; IR 
(film) 1643 cm–1. MS (ESI) 359.1895 (359.1885 calcd for C21H27ClN2O, M + H+). The 
enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 13.8 and 24.0 min). 
 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylallyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5j). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and 2-bromopropene (89 µL, 1.0 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 
39 mg (56%) of the title compound as a yellow oil and as a 20:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –33.5 (c 2.9, CH2Cl2). Data are for the major isomer.  1H 
NMR (700 MHz, CDCl3) δ 7.31 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 9.1 Hz, 2 H), 5.77–5.71 (m, 1 
H), 5.06–5.01 (m, 2 H), 4.79 (s, 1 H), 4.66 (s, 1 H), 4.09–4.06 (m, 1 H), 4.00 (dt, J = 2.8, 8.4 Hz, 
1 H), 3.66 (ddt, J = 2.8, 4.9, 11.2 Hz, 1 H), 2.79 (dd, J = 6.3, 12.6 Hz, 1 H), 2.27–2.23 (m, 2 H), 
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2.12 (dd, J = 11.2, 14.0 Hz, 1 H) 2.07 (dt, J = 8.4, 13.3 Hz, 1 H), 2.03–1.99 (m, 1 H), 1.95–1.89 
(m, 1 H), 1.85 (dd, J = 7.0, 12.6 Hz, 1 H) 1.68–1.64 (m, 2 H), 1.55 (s, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 153.7, 141.5, 140.7, 135.6, 131.2, 129.3, 128.9, 117.0, 113.9, 57.5, 55.8, 52.6, 41.8, 
37.7, 30.8, 30.5, 27.8, 22.0; IR (film) 1641 cm–1. MS (ESI) 345.1735 (345.1728 calcd for 
C20H25ClN2O, M + H+). The enantiopurity was determined to be 88:12 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 22.8 
and 28.4 min). 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methylbenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5k). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and 4-bromotoluene (37 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg 
(83%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –125.6 (c 3.1, CH2Cl2).  Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.06 (d, J = 
8.4 Hz, 2 H), 6.86 (d, J = 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, J = 16.8 Hz, 1 H), 5.01 (d, J 
= 10.5 Hz, 1 H), 4.10 (dt, J = 4.9 11.2 Hz, 1 H), 4.03 (dt, J = 2.8, 8.4, Hz 1 H), 3.76 (ddt, J = 2.8, 
5.6, 11.2 Hz, 1 H), 2.90 (dd, J = 2.8, 13.3 Hz, 1 H), 2.81–2.78 (m, 1 H), 2.53 (dd, J = 11.2, 14.0 
Hz, 1 H), 2.30 (s, 3 H), 2.09–2.04 (m, 2 H), 2.00 (dt, J = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 
1.85 (dd, J = 5.6, 12.6 Hz, 1 H) 1.64–1.59 (m, 1 H), 1.56 (dt, J = 6.3, 12.6 Hz, 1 H); 13C NMR 
(175 MHz, CDCl3) δ 153.6, 140.8, 136.2, 135.6, 134.5, 131.3, 129.3, 129.3, 129.0, 128.9, 117.0, 
59.8, 57.5, 52.6, 39.2, 37.6, 30.8, 30.1, 27.8, 21.0;  IR (film) 1642 cm–1. MS (ESI) 395.1887 
(395.1885 calcd for C24H27ClN2O, M + H+). The enantiopurity was determined to be 92:8 er by 
chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 
nm, RT= 17.3 and 19.4 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methoxybenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5l). The general procedure was employed for the coupling of 3-4c (61 
mg, 0.2 mmol) and 4-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 58 mg 
(70%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –169.4 (c 2.2, CH2Cl2).  Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.35 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 8.4 Hz, 2 H), 6.89 (d, J = 
9.1 Hz, 2 H), 6.79 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, J = 17.5 Hz, 1 H), 5.01 (d, J 
= 10.5 Hz, 1 H), 4.08 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 
3.77–3.72 (m, 1 H), 2.87 (dd, J = 3.5. 14.0 Hz, 1 H), 2.80 (dd, J = 6.3, 14.0 Hz, 1 H), 2.51 (dd, J 
= 11.2, 13.3 Hz, 1 H), 2.09–2.04 (m, 2 H), 2.00 (dt, J = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 
1.85 (dd, J = 7.0, 12.6 Hz, 1 H) 1.65–1.54 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 158.3, 153.6, 
140.8, 135.6, 131.3, 130.0, 129.6, 129.3, 129.0, 117.0, 114.0, 59.9, 57.5, 55.2, 52.6, 38.7, 37.6, 
30.8, 30.1, 27.8; IR (film) 1642 cm–1. MS (ESI) 411.1834 (411.1834 calcd for C24H27ClN2O2, M 
+ H+). The enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 204 nm, RT= 49.3 and 55.7 min). 
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(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)hexahydropyrrolo[1,2-c]pyrimidin-
1(2H)-one (3-5m). The general procedure was employed for the coupling of 3-4c (61 mg, 0.2 
mmol) and bromobenzene (32 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 
0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (83%) of 
the title compound as a pale brown foam oil and as a 7:1 mixture of diastereomers as determined 
by 1H NMR analysis: [α]23D –61.2 (c 5.6, CH2Cl2). Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.36 (d, J = 9.1 Hz, 2 H), 7.27–7.25 (m, 4 H), 7.21–7.20 (m, 1 H), 6.98 (d, J = 
7.0 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.00 (m, 2 H), 4.14 (dt, J = 4.9, 11.2 Hz, 1 H), 4.03 (dt, J 
= 2.1, 8.4 Hz, 1 H), 3.77 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 2.94 (dd, J = 3.5, 14.0 Hz, 1 H), 2.80 
(dd, J = 6.3, 13.3 Hz, 1 H), 2.57 (dd, J = 11.2, 14.0 Hz, 1 H), 2.10–2.04 (m, 2 H), 2.03–2.00 (m, 
1 H), 1.97–1.91 (m, 1 H), 1.86 (dd, J = 6.3, 12.6 Hz, 1 H) 1.66–1.54 (m, 2 H); 13C NMR (175 
MHz, CDCl3) δ 153.6, 140.8, 137.6, 135.6, 131.4, 129.3, 129.1, 129.0, 128.6, 126.6, 117.0, 59.7, 
57.5, 52.7, 39.6, 37.6, 30.8, 30.2, 27.8; IR (film) 1642 cm–1. MS (ESI) 381.1736 (381.1728 calcd 
for C23H25ClN2O, M + H+). The enantiopurity was determined to be 90:10 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 21.1 
and 24.2 min). 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-5n). The general 
procedure was employed for the coupling of 3-4c (61 mg, 0.2 mmol) and 4-
bromobenzotriflouride (42 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 0.004 
mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (74%) of the title 
compound as a pale yellow oil and as a 5:1 mixture of diastereomers as determined by 1H NMR 
analysis: [α]23D –46.1 (c 6.0, CH2Cl2).  Data are for the major isomer. 1H NMR (700 MHz, 
CDCl3) δ 7.51 (d, J = 7.7 Hz, 2 H), 7.36 (d, J = 9.1 Hz, 2 H), 7.24 (d, J = 9.1 Hz, 2 H), 7.09 (d, J 
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= 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.16 (dt, J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, 
J = 2.1, 9.1 Hz, 1 H), 3.76 (ddt, J = 2.1, 5.6, 11.9 Hz, 1 H), 3.00 (dd, J = 3.5, 14.0 Hz, 1 H), 2.79 
(dd, J = 5.6, 13.3 Hz, 1 H), 2.66 (dd, J = 11.2, 13.3 Hz, 1 H), 2.09–2.00 (m, 3 H), 1.98–1.93 (m, 
1 H), 1.87 (dd, J = 6.3, 11.9 Hz, 1 H) 1.66–1.56 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 153.5, 
141.7, 140.6, 135.5, 131.6, 129.4, 129.3, 129.2 (q, J = 37 Hz), 129.1, 125.6 (q, 3.3 Hz), 124.0 (q, 
J = 270 Hz), 117.1, 59.5, 57.6, 52.6, 39.6, 37.6, 30.8, 30.3, 27.8;  IR (film) 1642 cm–1. MS (ESI) 
449.1600 (449.1602 calcd for C24H24ClF3N2O, M + H+). The enantiopurity was determined to be 
85:15 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 
mL/min, λ 205 nm, RT= 19.9 and 27.5 min). 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-5n). A modified 
general procedure was employed for the coupling of 3-4c (61 mg, 0.2 mmol) and 4-
bromobenzotriflouride (42 µL, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 54 mg (60%) of the title compound as a pale yellow oil and as a 10:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D –51.1 (c 2.3, CH2Cl2).  The 
enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.4 and 26.7 min). Spectroscopic data 
were identical to those provided above. 
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(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-5o). The general 
procedure was employed for the coupling of 3-4c (61 mg, 0.2 mmol) and 1-bromo-4-
(trifluoromethoxy)benzene (45 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 (3.7 mg, 
0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (68%) of 
the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by 
1H NMR analysis: [α]23D –48.7 (c 5.7, CH2Cl2). Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.35 (d, J = 9.1 Hz, 2 H), 7.24 (d, J = 9.1 Hz, 2 H), 7.10 (d, J = 7.7 Hz, 2 H), 
6.99 (d, J = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.13 (dt, J = 4.2, 11.2 Hz, 1 
H), 4.03 (dt, J = 2.8, 8.4 Hz, 1 H), 3.75 (ddt, J = 2.8, 4.9, 11.2 Hz, 1 H), 2.93 (dd, J = 4.2, 14.0 
Hz, 1 H), 2.79 (dd, J = 6.3, 13.3 Hz, 1 H), 2.60 (dd, J = 10.5, 14.0 Hz, 1 H), 2.10–2.00 (m, 3 H), 
1.98–1.92 (m, 1 H), 1.86 (dd, J = 6.3, 12.6 Hz, 1 H) 1.67–1.57 (m, 2 H); 13C NMR (175 MHz, 
CDCl3) δ 153.5, 147.9, 140.7, 136.7, 135.5, 131.5, 130.3, 129.3, 129.1, 121.2, 117.0, 59.6, 57.5, 
52.6, 39.1, 37.6, 30.8, 30.3, 27.8 (the CF3 carbon signal could not be determined due to the 
appearance of carbon signals from the minor diastereomer in the CF3 region of the spectrum); IR 
(film) 1642 cm–1. MS (ESI) 465.1557 (465.1551 calcd for C24H24ClF3N2O2, M + H+). The 
enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 17.1 and 19.8 min). 
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(–)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-
(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-5o). A modified 
general procedure was employed for the coupling of 3-4c (61 mg, 0.2 mmol) and 1-bromo-4-
(trifluoromethoxy)benzene (45 µL, 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a 
catalyst composed of Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). 
This procedure afforded 48 mg (52%) of the title compound as a pale yellow oil and as an 17:1 
mixture of diastereomers as determined by 1H NMR analysis: [α]23D –55.6 (c 1.5, CH2Cl2). The 
enantiopurity was determined to be 93:7 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 
mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 16.8 and 19.8 min). Spectroscopic data 
were identical to those provided above. 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methoxybenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5p). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and 3-bromoanisole (38 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 61 mg 
(74%) of the title compound as a yellow brown solid and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –65.1 (c 2.8, CH2Cl2). Mp = 132–137 ºC.  Data are for 
the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 9.1 Hz, 2 
H), 7.18 (t, J = 8.4 Hz, 1 H), 6.74 (dd, J = 2.1, 8.4 Hz, 1 H), 6.57 (d, J = 7.0 Hz, 1 H), 6.50 (s, 1 
H), 5.77–5.71 (m, 1 H), 5.04 (dd, J = 1.4, 16.8 Hz, 1 H), 5.01 (dd, J = 1.4, 9.8 Hz, 1 H), 4.14 (dt, 
J = 4.2, 11.2 Hz, 1 H), 4.03 (dt, J = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.78–3.73 (m, 1 H), 2.91 (dd, 
J = 3.5, 13.3 Hz, 1 H), 2.80 (dd, J = 5.6, 13.3 Hz, 1 H), 2.54 (dd, J = 11.2, 14.0 Hz, 1 H), 2.10–
2.04 (m, 2 H), 2.03–1.99 (m, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, J = 6.3, 12.6 Hz, 1 H), 1.65–
1.56 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 159.7, 153.6, 140.7, 139.2, 135.6, 131.4, 129.6, 
129.3, 129.0, 121.4, 117.0, 115.3, 111.3, 59.6, 57.5, 55.2, 52.7, 39.7, 37.6, 30.8, 30.3, 27.8; IR 
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(film) 1642 cm–1. MS (ESI) 411.1841 (411.1834 calcd for C24H27ClN2O2, M + H+). The 
enantiopurity was determined to be 87:13 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 
4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 248 nm, RT= 27.2 and 30.6 min). 
 
 
(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(napthalen-2-ylmethyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5q). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and 2-bromonapthanlene (62 mg, 0.3 mmol), using a catalyst composed of 
Pd2dba3 (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 
66 mg (77%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –77.9 (c 4.6, CH2Cl2). Data are for the major isomer. Mp 
= 63–65 ºC. 1H NMR (700 MHz, CDCl3) δ 7.80 (d, J = 7.7 Hz, 1 H), 7.75 (t, J  = 7.7 Hz, 2 H), 
7.47–7.44 (m, 3 H), 7.38 (d, J = 9.1 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 7.07 (dd, J = 0.7, 8.4 Hz, 
1 H), 5.78–5.72 (m, 1 H), 5.04 (d, J = 16.8 Hz, 1 H), 5.02 (d, J = 9.8 Hz, 1 H), 4.25 (dt, J = 4.2, 
11.2 Hz, 1 H), 4.06 (dt, J = 2.1, 9.8 Hz, 1 H), 3.84 (ddt, J = 2.1, 4.9, 11.2 Hz, 1 H), 3.11 (dd, J = 
3.5, 14.0 Hz, 1 H), 2.81 (dd, J = 5.6, 13.3 Hz, 1 H), 2.74 (dd, J = 11.9, 14.0, Hz, 1 H), 2.11–2.05 
(m, 2 H), 2.04–1.94 (m, 2 H), 1.86 (dd, J = 7.0, 12.6 Hz, 1 H), 1.65–1.56 (m, 2 H); 13C NMR 
(175 MHz, CDCl3) δ 153.6, 140.8, 135.6, 135.1, 133.4, 132.2, 131.4, 130.4, 129.4, 129.1, 128.4, 
127.7, 127.3, 127.1, 126.3, 125.7, 117.0, 59.6, 57.5, 52.7, 37.6, 30.8, 31.0, 30.2, 27.8;  IR (film) 
1646 cm–1. MS (ESI) 431.1886 (431.1885 calcd for C27H27ClN2O, M + H+). The enantiopurity 
was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% 
IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 24.4and 28.2 min). 
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(–)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylbenzyl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (3-5r). The general procedure was employed for the coupling of 3-4c 
(61 mg, 0.2 mmol) and 2-bromotoluene (36 µL, 0.3 mmol), using a catalyst composed of Pd2dba3 
(3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 65 mg 
(82%) of the title compound as a pale brown oil and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis: [α]23D –30.1 (c 5.7, CH2Cl2). Data are for the major isomer. 1H 
NMR (700 MHz, CDCl3) δ 7.36 (d, J = 9.1 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.11–7.08 (m, 3 
H), 6.93–6.92 (m, 1 H), 5.78–5.71 (m, 1 H), 5.04 (dd, J = 1.4, 17.5 Hz, 1 H), 5.01 (dd, J = 1.4, 
10.5 Hz, 1 H), 4.09 (dt, J = 4.2, 12.6 Hz, 1 H), 4.04 (dt, J = 2.8, 9.1 Hz, 1 H), 3.86 (ddt, J = 2.8, 
5.6, 11.2 Hz, 1 H), 2.93 (dd, J = 3.5, 14.0 Hz, 1 H), 2.80 (dd, J = 5.6, 12.6 Hz, 1 H), 2.62 (dd, J = 
11.2, 14.0 Hz, 1 H), 2.11–2.02 (m, 3 H), 2.01 (s, 3 H), 1.99–1.94 (m, 1 H), 1.87 (dd, J = 6.3, 12.6 
Hz, 1 H), 1.65 (ddd, J = 6.3, 11.2, 17.5 Hz, 1 H), 1.58 (dt, J = 5.6, 12.6 Hz, 1 H); 13C NMR (175 
MHz, CDCl3) δ 153.6, 140.7, 136.3, 135.7, 135.6, 131.5, 130.6, 130.3, 129.6, 129.0, 126.8, 
126.0, 117.0, 58.4, 57.5, 52.9, 37.7, 36.8, 30.8, 30.1, 27.8, 19.2; IR (film) 1642 cm–1. MS (ESI) 
395.1885 (395.1885 calcd for C24H27ClN2O, M + H+). The enantiopurity was determined to be 
71:29 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 
mL/min, λ 215 nm, RT= 20.1 and 24.3 min). 
 
Deprotection of Bicyclic Urea Product 3-5c 
 
N
NO
H
H
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H
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(–)-(Z,3S,4aS,7R)-N-{4-[7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-
2(1H)-yl]phenyl}acetamide (3-8). A flame-dried screwtop-flask was cooled under vacuum and 
charged with Pd2(dba)3 (5.2 mg, 0.006 mmol), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-
2’,4’,6’-triisopropyl-1,1’-biphenyl (13.7 mg, 0.03 mmol), K3PO4 (182 mg, 0.86 mmol) and 
acetamide (50.8 mg, 0.86 mmol). The flask was evacuated and backfilled with N2, and then a 
solution of 3-5c (206 mg, 0.57 mmol) in tert-butanol (3 mL) was added via syringe. The flask 
was sealed, heated to 110 ºC and stirred overnight (14 h). The mixture was cooled to room 
temperature and the mixture was filtered through a plug of celite, eluted with EtOAc (10 mL), 
and concentrated in vacuo. The crude material was purified by flash chromatography on silica 
gel to afford 191 mg (88%) of the title compound as a foamy brown solid: mp = 38–42 ºC. [α]23D 
–25.2 (c 5.3, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 8.93 (s, 1 H), 7.21 (d, J = 8.4 Hz, 2 H), 
6.98 (d, J = 8.4 Hz, 2 H), 5.77–5.72 (m, 1 H), 5.49–5.40 (m, 1 H), 5.07–5.03 (m, 3 H), 4.03 (dt, J 
= 2.8, 9.1 Hz, 1 H), 3.77 (dt, J = 4.2, 10.5 Hz, 1 H), 3.67 (ddt, J = 2.8, 4.9, 8.4 Hz, 1 H), 2.80 
(dd, J = 4.9, 12.6 Hz, 1 H), 2.25–2.08 (m, 4 H), 2.05 (s, 3 H) 2.02–1.98 (m, 1 H), 1.95–1.85 (m, 
4 H), 1.70–1.64 (m, 2 H), 0.88 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 168.8, 154.5, 
137.3, 136.6, 135.5, 134.8, 128.3, 124.0, 121.3, 117.1, 58.5, 57.3, 52.8, 37.8, 31.2, 31.0, 30.8, 
27.7, 24.0, 20.8, 14.1; IR (film) 3263, 1687, 1624 cm–1. MS (ESI) 382.2493 (382.2489 calcd for 
C23H31N3O2, M + H+). 
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(–)-(Z,3S,4aS,7R)-7-Allyl-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-
9).  A Schlenk tube was charged with a stirbar, 3-8 (39 mg, 0.1 mmol) and CH3CN (1 mL). A 
solution of ceric ammonium nitrate (164 mg, 0.3 mmol) in H2O (1 mL) was added to the reaction 
flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 oC for 15 min 
before being cooled to rt, at which time EtOAc (5 mL) was added. The mixture was transferred 
to a separatory funnel and the layers were separated. The organic layer was washed with 
saturated aqueous Na2SO3 (5 mL), saturated aqueous NaHCO3 (5 mL), and brine (5 mL). The 
organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude material was purified by flash chromatography (2% MeOH in CH2Cl2) on silica gel to 
afford 19 mg (77%) of the title compound as a yellow brown solid: [α]23D –63.2 (c 0.5, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 5.80–5.72 (m, 1 H), 5.57–5.51 (m, 1 H), 5.30–5.25 (m, 1 H), 
5.06–5.02 (m, 2 H), 4.73 (s, 1 H), 4.00 (dt, J = 3.0, 8.5 Hz, 1 H), 3.49 (ddt, J = 3.0, 5.5, 11.5 Hz, 
1 H), 3.46–3.41 (m, 1 H), 2.72 (d, J = 14.5 Hz, 1 H), 2.26–2.20 (m, 1 H), 2.13–1.93 (m, 6 H), 
1.88–1.77 (m, 2 H), 1.61–1.52 (m, 2 H), 0.96 (t, J = 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 
155.1, 135.6, 135.2, 124.0, 117.0, 56.2, 52.9, 50.0, 38.1, 35.7, 32.3, 30.7, 27.4, 20.8, 14.1; IR 
(film) 3207, 1652 cm–1. MS (ESI) 249.1963 (249.1961 calcd for C15H24N2O, M + H+). 
 
Conversion of Bicyclic Urea Product 3-5c to Tricyclic Guanidine 3-10 
 
 
(–)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-imine hydrochloride (3-11). A flame-dried flask was cooled under a stream 
of N2 and charged with 3-5c (177 mg, 0.49 mmol) and toluene (5 mL). Freshly distilled POCl3 
(2.5 mL, 27 mmol) was added and the mixture was stirred at rt until the starting material had 
been consumed as judged by ESI+ MS analysis (ca. 3 hr).  The reaction mixture was cooled to rt 
and concentrated in vacuo. The crude product was dissolved in acetonitrile (5 mL) and a solution 
N
NHN
H
H C2H5
H
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of ammonia (20 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting 
material had been consumed as judged by ESI+ MS analysis (ca. 1 hr). The reaction mixture was 
concentrated and dissolved in methylene chloride (5 mL). Water (5 mL) was added and the 
mixture was transferred to a separatory funnel. The layers were separated and the organic layer 
was washed with saturated aqueous NaCl (3 x 10 mL). The combined aqueous layers were 
extracted with methylene chloride (3 x 10 mL). The combined organics layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified 
by flash chromatography on silica gel to afford 146 mg (75%) of the title compound as a pale 
white-yellow foam: [α]23D –45.5(c 1.1, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 7.48 (d, J = 7.7 
Hz, 1 H), 7.40 (d, J = 7.7 Hz, 1 H), 7.29 (d, J = 7.0 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 5.96–5.90 
(m, 1 H), 5.45 (dt, J = 7.0, 10.5 Hz, 1 H), 5.00–4.93 (m, 4 H), 3.75–3.72 (m, 1 H), 3.62–3.58 (m, 
1 H), 2.67 (d, J = 13.3 Hz, 1 H), 2.25 (dd, J = 2.1, 14.0 Hz, 1 H), 2.18–2.16 (m, 1 H) 2.12–2.06 
(m, 3 H), 2.03–1.93 (m, 2 H), 1.81–1.68 (m, 4 H), 0.82 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 151.3, 136.6, 136.1, 135.8, 134.5, 131.5, 131.4, 130.8, 128.9, 121.7, 118.3, 59.5, 59.1, 
53.1, 36.2, 30.8, 30.4, 29.6, 28.1, 20.8, 13.9; IR (film) 3457, 3275, 1636 cm–1. MS (ESI) 
358.2048 (358.2045 calcd for C21H29ClN3, M+).  
 
 
(–)-(Z,2aS,4S,7S,8aR)-5-(4-Chlorophenyl)-7-methyl-4-(pent-2-en-1-yl)-1,2,2a,3,4,5,6,7,8,8a-
decahydro-2a1,5,6-triazaacenaphthylen-2a1-ium chloride (3-10). A test tube was charged with 
3-11 (39.4 mg, 0.1 mmol), PdCl2 (3.5 mg, 0.02 mmol), and CuCl (14.8 mg, 0.15 mmol). The 
tube was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-
filled balloon attached to a needle (via an adaptor) was connected to the tube through the septum.  
A solution of THF and H2O (7:1, 1.0 mL) was added to the test tube and the mixture was stirred 
at rt until the starting material had been consumed as judged by ESI+ MS analysis (ca. 4 hr). 
Methanol (1 mL) and NaCNBH3 (62.8 mg, 1.0 mmol) was added and the mixture was heated to 
Cl
N
H
N
N
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50 oC until the starting material had been consumed as judged by ESI+ MS analysis (ca. 3 hr). 
The reaction mixture was cooled to rt and concentrated in vacuo. The crude product was 
dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and 
2 M HCl (10 mL) was added. The layers were separated and the organic layer was washed with 
NH4OH (10 mL) to potentially remove any excess copper. The layers were separated and the 
organic layer was washed with 2 M HCl (10 mL). The organics layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 31 mg (79%) of the title compound as a pale white-tan oil 
and as a 5:1 mixture of diastereomers as determined by 1H NMR analysis: [α]23D –38.1 (c 0.6, 
CH2Cl2). Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.5 Hz, 2 H), 
7.34 (d, J = 8.5 Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 
H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, J = 3.5, 13.0 Hz, 1 H), 
1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, J = 6.5 Hz, 3 H), 0.93 (t, J 
= 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 148.6, 136.6, 136.5, 135.2, 132.0–129.0 (br, 2 C), 
121.9, 59.8, 57.7, 52.1, 47.4, 34.8, 30.0, 29.9, 29.6, 29.4, 20.9, 20.6, 14.0; IR (film) 3276, 1607 
cm–1. MS (ESI) 358.2047 (358.2045 calcd for C21H29ClN3, M +).  
 
Conversion of Bicyclic Urea Product 3-5c to 9-epi-Batzelladine K 3-13 
 
 
(–)-(Z,3S,4aS,7R)-N-{4-[1-Oxo-7-(2-oxopropyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-2(1H)-yl]phenyl}acetamide (3-14). A test tube was charged with 3-5c (300 mg, 
0.79 mmol), PdCl2 (28 mg, 0.16 mmol), and CuCl (117 mg, 1.18 mmol). The tube was capped 
with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon 
attached to a needle (via an adaptor) was connected to the tube through the septum.  A solution 
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of DMF and H2O (7:1, 8.0 mL) was added to the test tube and the mixture was stirred at rt until 
the starting material had been consumed as judged by ESI+ MS analysis (ca. 4 hr). EtOAc (20 
mL) and brine (20 mL) was added and the mixture was transferred to a separatory funnel. The 
layers were separated and the organic layer was washed with NH4OH (5 mL) to potentially 
remove any excess copper. The combined aqueous layers were than extracted with EtOAc (20 
mL). The organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude material was purified by flash chromatography on silica gel to afford 230 mg 
(74%) of the title compound as a pale yellow-pink solid: mp = 68–72 ºC. [α]23D –38.8 (c 0.8, 
CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 8.66 (s, 1 H), 7.25 (d, J = 8.4 Hz, 2 H), 7.01 (d, J = 9.1 
Hz, 2 H), 5.44–5.41 (m, 1 H), 5.06–5.03 (m, 1 H), 4.37–4.34 (m, 1 H), 3.80–3.77 (m, 1 H), 3.66 
(ddd, J = 2.8, 4.9, 11.2 Hz, 1 H), 3.44 (dd, J = 2.8, 9.8 Hz, 1 H), 2.31 (dd, J = 9.8, 16.8 Hz, 1 H), 
2.26–2.13 (m, 3 H), 2.10 (s, 3 H), 2.06 (s, 3 H), 2.09–2.03 (m, 2 H), 1.91–1.86 (m, 2 H), 1.77 
(dd, J = 7.0, 13.3 Hz, 1 H), 1.65–1.58 (m, 2 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 207.5, 168.7, 154.2, 137.2, 136.7, 134.9, 128.3, 123.8, 121.1, 58.5, 53.7, 52.8, 47.6, 
31.1, 30.8, 30.2, 29.4, 24.0, 20.8, 14.0 (one carbon signal is absent due to incidental 
equivalence); IR (film) 3261, 1711, 1687, 1621 cm–1. MS (ESI) 398.2439 (398.2438 calcd for 
C23H31N3O3, M + H+).  
 
 
(–)-(3S,4aS,7R)-7-(2-Oxopropyl)-3-pentylhexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-
15). 
A flame-dried flask was cooled under vacuum and charged with 3-14 (100 mg, 0.25 mmol) and 
Pd/C (10 mg). The flask was capped with a rubber septum, was briefly flushed with hydrogen 
and then a hydrogen-filled balloon attached to a needle (via an adaptor) was connected to the 
flask through the septum.  Methanol (2.5 mL) was added to the flask and the mixture was stirred 
at rt until the starting material had been consumed as judged by ESI+ MS analysis (ca. 45 min). 
The crude product was then filtered through a plug of celite to remove the Pd/C and washed with 
methanol (5 mL). The crude material was concentrated in vacuo and carried on to the next step 
N
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without further purification. The crude product was dissolved in CH3CN (10 mL) and transferred 
to a round-bottom flask charged with a stirbar. A solution of ceric ammonium nitrate (123 mg, 
0.75 mmol) in H2O (30 mL) was added to the reaction flask and the mixture was stirred at rt for 5 
min. The mixture was then heated at 50 oC for 4 hr before being cooled to rt, at which time 
EtOAc (25 mL) was added. The mixture was transferred to a separatory funnel and the layers 
were separated. The organic layer was washed with saturated aqueous Na2SO3 (15 mL), saturated 
aqueous NaHCO3 (15 mL), and brine (15 mL). The organic layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 34 mg (51%) of the title compound as a white solid: mp = 
84–88 ºC. [α]23D –11.7 (c 2.5, CH2Cl2). 1H NMR (700 MHz, CDCl3) δ 4.79 (s, 1 H), 4.30–4.28 
(m, 1 H), 3.48–3.45 (m, 1 H), 3.43–3.39 (m, 2 H), 2.29 (dd, J = 9.8, 16.8 Hz, 1 H), 2.10 (s, 3 H), 
2.03–1.98 (m, 2 H), 1.95–1.94 (m, 1 H), 1.72 (dd, J = 7.7, 12.6 Hz, 1 H),  1.54–1.46 (m, 3 H), 
1.38–1.25 (m, 7 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 207.7, 155.0, 52.8, 
52.8, 50.0, 47.6, 37.8, 32.9, 31.6, 30.6, 30.3, 29.0, 25.5, 22.6, 14.0; IR (film) 3207, 1709, 1649 
cm–1. MS (ESI) 267.2065 (267.2067 calcd for C15H26N2O2, M + H+). 
 
 
(–)-9-epi-Batzelladine K (3-13). A flame-dried flask was cooled under vacuum and charged 
with 3-15 (25 mg, 0.09 mmol) and dichloromethane (0.9 mL). 2,6-di-tert-butylpyridine (203 µL, 
0.94 mmol) and MeOTf (103 µL, 0.94 mmol) were added and the mixture was stirred at rt until 
the starting material had been consumed as judged by ESI+ MS analysis (ca. 1 hr). The solvent 
was then removed in a hood by blowing a constant stream of N2 over the stirring mixture. The 
solution was then poured in diethyl ether (20 ml) and washed with 1 M NaOH (10 mL) and brine 
(10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. The crude material was used without further purification. The crude O-methylisourea 
was dissolved in methanol (2 mL) and transferred to a thick walled glass vial at which time 
ammonium chloride (10.1mg, 0.19 mmol) was added to this solution. Anhydrous ammonia was 
bubbled through this solution for ~15 min before the reaction vessel was sealed and heated to 60 
N
H
N
N
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oC overnight (14 hr).  The reaction was cooled to rt and concentrated in vacuo. The crude 
guanidine product 3-16 was used without further purification. Crude product 3-16 was dissolved 
in methanol (3 mL), NaCNBH3 (59 mg, 0.94 mmol) was added and the mixture was heated to 50 
oC until the starting material had been consumed as judged by ESI+ MS analysis (ca. 12 hr). The 
reaction mixture was cooled to rt and concentrated in vacuo. The crude product was dissolved in 
methylene chloride (20 mL), the mixture was transferred to a separatory funnel and washed with 
2 M HCl (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude material was determined to be a 3:1 
mixture of diastereomers by 1H NMR analysis. The crude material was purified by flash 
chromatography on silica gel to afford 13 mg (48%) of the title compound as a pale yellow oil. 
The following data is for the pure isolated major diastereomer. [α]23D –43.8 (c 0.5, CH2Cl2). 1H 
NMR (700 MHz, CDCl3) δ 3.80–3.73 (m, 2 H), 3.58–3.53 (m, 1 H), 3.52–3.49 (m, 1 H), 2.26–
2.21 (m, 3 H), 2.19 (dd, J = 4.2, 13.3 Hz, 1 H), 1.73–1.64 (m, 2 H), 1.60–1.56 (m, 2 H), 1.52–
1.47 (m, 1 H), 1.44–1.27 (m, 7 H), 1.27 (d, J = 6.3 Hz, 3 H), 0.93 (t, J = 7.0 Hz, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 149.4, 56.3, 51.6, 48.4, 45.8, 36.2, 35.5, 31.5, 31.2, 30.5, 30.2, 25.5, 22.4, 
20.5, 14.0; 1H NMR (700 MHz, CD3OD) δ 7.56 (d, J = 7.5 Hz, 2 H), 7.34 (d, J = 8.5 Hz, 2 H), 
5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 (m, 1 H), 
3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, J = 3.5, 13.0 Hz, 1 H), 1.99–1.93 (m, 3 H), 
1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, J = 6.5 Hz, 3 H), 0.93 (t, J = 7.5 Hz, 3 H); 13C 
NMR (175 MHz, CD3OD) δ 150.4, 57.5, 53.5, 50.2, 47.3, 36.8, 36.1, 32.7, 31.9, 31.3, 30.7, 26.8, 
23.6, 20.8 14.3; IR (film) 3284, 3202, 1637 cm–1. MS (ESI) 250.2278 (250.2278 calcd for 
C15H28N3, M+).  
 
Assignment of Stereochemistry 
The relative stereochemistry of compound 3-5k was assigned on the basis of observed 1H NMR 
nOe experiments. Significant nOe relationships are shown below. The stereochemistry of all 
other bicyclic urea products was assigned based on analogy to 3-5k. 
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The relative stereochemistry of compounds 3-10 and 3-13 were assigned on the basis of observed 
1H NMR nOe experiments. Significant nOe relationships are shown below. 
 
 
The absolute stereochemistry of the urea products was assigned via the synthesis of compound 
ent-3-5c from pent-4-enal via the route illustrated below in Scheme 3-6. The optical rotation of 
product ent-3-5c prepared via this route was opposite that of the product 3-5c generated in the 
Pd-catalyzed carboamination reaction between 3-4c and Z-bromobutene. In addition, analysis of 
product ent-3-5c by chiral HPLC indicated that ent-3-5c was the enantiomer of product 3-5c 
formed in the catalytic reaction. 
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Scheme 3.6 Synthesis of ent-3-5c to determine absolute stereochemistry. 
 
 
 
(–)-(RS)-2-Methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide (3-S1). This compound was 
prepared according to the procedure reported by Ellman.64 A flame-dried flask was cooled under 
a stream of N2 and charged with pent-4-enal (1.38 mL, 14 mmol) and THF (40 mL). Titanium 
ethoxide (4.2 mL, 20 mmol) was added and the reaction mixture was stirred at rt for 5 min. (R)- 
tert-butanesulfinamide (1.21 g, 10 mmol) was added in one portion and the mixture was stirred 
overnight (ca. 14 h) at rt. The reaction mixture was poured into brine (40 mL) and stirred for 10 
min. Ethyl acetate (20 mL) was added, the mixture was filtered through celite and the celite was 
washed with ethyl acetate (50 mL). The mixture was transferred to a separatory funnel, brine (20 
mL) was added, and the layers were separated. The aqueous phase was extracted with ethyl 
acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel to afford 1.38 g (74%) of the title compound as a colorless oil. Spectroscopic properties 
are identical to those previously reported.60 1H NMR (500 MHz, CDCl3) δ 8.08 (t, J = 4.5 Hz, 1 
H), 5.84 (ddt, J = 4.5, 10.0, 17.0 Hz, 1 H), 5.08 (dd, J = 1.5, 17.0 Hz, 1 H), 5.02 (dd, J = 1.5, 
10.0 Hz, 1 H), 2.63 (td, J = 4.0, 7.5 Hz, 2 H), 2.40 (q, J = 7.0 Hz, 2 H), 1.19 (s, 9 H). 
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(RS, 4R)-2-Methyl-N-(octa-1,7-dien-4-yl)propane-2-sulfinamide (3-S2). A flame-dried flask 
was cooled under a stream of N2 and charged with freshly ground magnesium turnings (720 mg, 
4 equiv). The magnesium was suspended in ether (14.8 mL, 1 M), cooled to 0 oC in an ice/water 
bath and allyl bromide (1.28 mL, 14.8 mmol) was added dropwise. After addition, the ice bath 
was removed, and the reaction mixture was stirred at rt for 30 min. Stirring was stopped and the 
solution was filtered through glass wool prior to addition to 3-S1. A flame-dried flask was cooled 
under a stream of N2 and charged with 3-S1 (1.38 g, 7.4 mmol) and THF (37 mL, 0.2 M). The 
sulfinyl imine solution was cooled to 0 oC in an ice/water bath before the filtered Grignard 
reagent solution was added dropwise. The reaction mixture was stirred at 0 oC until the starting 
material had been completely consumed as judged by TLC analysis (1 h). Water was then added 
dropwise until precipitation of magnesium salts occurred and the resulting solution was decanted 
into a separate flask. The solution was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. Analysis of the crude product by 1H NMR indicated that a 10:1 mixture of 
diastereomers had formed. The crude material was purified by flash chromatography on silica gel 
to afford 1.02 g (60%) of the title compound as a 10:1 mixture of diastereomers as a clear 
colorless oil. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 5.83–5.74 (m, 2 H), 
5.18–4.97 (m, 4 H), 3.36–3.32 (m, 1 H), 3.21 (d, J = 6.5 Hz, 1 H), 2.45–2.40 (m, 1 H), 2.37–2.32 
(m, 1 H), 2.18–2.08 (m, 2 H), 1.62–1.58 (m, 2 H), 1.21 (s, 9 H). 
 
 
(R)-tert-Butyl octa-1,7-dien-4-ylcarbamate [(R)-3-6]. A flame-dried flask was cooled under a 
stream of N2 and charged with 3-S2 (1.02 g, 4.4 mmol) and methanol (22 mL). A solution of 
anhydrous hydrochloric acid (4.4 mL, 17.7 mmol, 4 M in dioxane) was added and the mixture 
was stirred at rt for 1 h, at which time TLC analysis indicated that the starting material had been 
completely consumed. The reaction mixture was diluted with water (10 mL) and CH2Cl2 (10 
mL), basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
NHS
tBu
O
NHBoc
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separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was dissolved in THF (44 mL, 0.1 M), solid di-tert-butyldicarbonate (1.2 g, 5.3 mmol) 
was added and the reaction mixture was stirred at rt for 3 h. 1 M NaOH (5 mL) was added and 
the resulting biphasic mixture was stirred for 1 h at rt. The mixture was transferred to a 
separatory funnel, the layers were separated and the aqueous layer was extracted with ethyl 
acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel to afford 941 mg (94%) of the title compound as a clear colorless oil. The spectroscopic 
properties of this compound were identical to that of compound (±)-3-6 described above. 
 
 
(E,2R,5S)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate [(E,2R,5S)3-
7]. A flame-dried Schlenk flask was cooled under a stream of N2 and charged with Pd2(dba)3 (77 
mg, 0.084 mmol), tri(2-furyl)phosphine (77 mg, 0.33 mmol) and NaOtBu (802 mg, 8.4 mmol). 
The flask was purged with N2, then a solution of (R)-3-6 (941 mg, 4.2 mmol) in freshly distilled 
xylenes (21 mL) was added via syringe and the resulting mixture was stirred at rt for 2 min. (E)-
(2-bromovinyl)trimethylsilane (1.28 mL, 8.4 mmol) was added and the flask was heated to 140 
ºC and stirred for 3 h. The mixture was cooled to room temperature and saturated aqueous NH4Cl 
(10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer was 
filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 mL). 
The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude material was purified by flash chromatography on silica gel to afford 647 g (48%) of the 
title compound as a dark brown oil. The spectroscopic properties of this compound were 
identical to that of compound (±)-3-7 described above. 
 
N
Boc
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(E,2R,5S)-2-Allyl-N-(4-chlorophenyl)-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxamide 
(3-S3). A round-bottom flask equipped with a stirbar was charged with (E,2R,5S)-3-7 (647 mg, 
2.0 mmol) and dichloromethane (20 mL, 0.1 M). Trifluoroacetic acid (2.0 mL, 1.0 M) was added 
to the flask and the mixture was stirred for 20 min at rt. The solution was diluted with water, 
basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was dissolved in dichloromethane (20 mL, 0.1 M) and 4-chlorophenyl isocyanate (369 
mg, 1.2 equiv) was added. The reaction mixture was stirred at rt for 1 h until starting material 
had been completely consumed as judged by TLC analysis. The crude reaction mixture was 
concentrated in vacuo, and purified by flash chromatography on silica gel to afford 244 mg 
(32%) of the title compound as a orange brown oil.  1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 
9.0 Hz, 2 H), 7.22 (d, J = 9.0 Hz, 2 H), 6.41 (s, 1 H), 6.04 (dt, J = 7.0, 18.5 Hz, 1 H), 5.93–5.84 
(m, 1 H), 5.82 (d, J = 18.5 Hz, 1 H), 5.22–5.17 (m, 2 H), 4.02–3.95 (m, 2 H), 2.61–2.52 (m, 2 H), 
2.35 (dt, J = 7.0, 13.5 Hz, 1 H), 2.24 (dt, J = 7.5, 14.0 Hz, 1 H), 2.02–1.96 (m, 2 H), 1.80–1.74 
(m, 2 H), 0.05 (s, 9 H). 
 
 
(E,Z,3R,4aR,7S)-2-(4-Chlorophenyl)-3-(pent-2-en-1-yl)-7-[3-
(trimethylsilyl)allyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (3-S4). A flame-dried 
Schlenk tube was cooled under vacuum and charged with Pd2(dba)3 (3.1 mg, 0.003 mmol), 
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PCy3.HBF4 (5.0 mg, 0.014 mmol) and NaOtBu (25 mg, 0.26 mmol). The flask was evacuated and 
purged with N2. A solution of 3-S3 (65 mg, 0.17 mmol) in toluene (0.85 mL) was added via 
syringe and the resulting mixture was stirred at rt for 2 min. (Z)-1-bromobut-1-ene (130 µL, 0.26 
mmol, 2.0 M solution in toluene) was added and the tube was heated to 100 ºC and stirred until 
the starting material was completely consumed as judged by TLC analysis (1 h). The mixture 
was cooled to room temperature and saturated aqueous NH4Cl (1 mL) and ethyl acetate (1 mL) 
were added. The layers were separated, the organic layer was filtered through a plug of silica gel, 
and the silica gel was washed with ethyl acetate (1 mL). The filtrate was dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 53 mg (71%) of the title compound as a yellow oil.  1H 
NMR (500 MHz, CDCl3) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.19 (d, J = 9.0 Hz, 2 H), 5.94 (ddd, J = 
6.0, 7.5, 18.5 Hz, 1 H), 5.68 (d, J = 18.5 Hz, 1 H), 5.47–5.42 (m, 1 H), 5.12–5.07 (m, 1 H), 4.03 
(dt, J = 2.5, 8.5 Hz, 1 H), 3.90 (dt, J = 4.5, 9.5 Hz, 1 H), 3.66 (ddt, J = 2.5, 5.0, 11.5 Hz, 1 H), 
2.73 (dd, J = 5.5, 12.5 Hz, 1 H), 2.27–2.16 (m, 4 H), 2.01–1.89 (m, 4 H), 1.84–1.81 (m, 1 H), 
1.69–1.61 (m, 2 H), 0.90 (t, J = 7.5 Hz, 3 H), 0.03 (s, 9 H). 
 
 
(+)-(Z,3R,4aR,7S)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (ent-3-5c). A Schlenk tube was charged with 3-S4 (53 mg, 0.12 mmol) 
and CH2Cl2 (1.2 mL). TFA (0.6 mL) was added and the reaction mixture was stirred overnight at 
40 ºC. The reaction mixture was then cooled to rt, diluted with water (1 mL), and basified with 
NH4OH to pH > 12. The reaction mixture was transferred to a separatory funnel and the layers 
were separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel.  
This procedure afforded 29 mg (67%) of the title compound as a yellow oil: [α]23D +17.7 (c 2.9, 
CH2Cl2). The spectroscopic properties of this compound were identical to that of compound 3-5c. 
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The enantiopurity was determined to be 10:90 er by chiral HPLC analysis (chiralcel ADH, 25 cm 
x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 17.8 min). 
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Chapter 4  
Stereocontrolled Synthesis of trans-Bicyclic Sulfamides via Pd-Catalyzed 
Carboamination Reactions 
4.1 Introduction 
As detailed in chapter 1, polycyclic guanidine natural products comprise a class of marine 
alkaloids that exhibit remarkable biological properties.1–5 Due to their therapeutic potential,6 
these alkaloids have been the subject of a number of elegant syntheses.15,16,20,30,33,35,38 However, 
these compounds remain challenging synthetic targets due to their structural and stereochemical 
complexity. Further complicating the synthesis of these compounds is the stereochemical 
diversity displayed within this particular family of alkaloids. For example, merobatzelladine B 
features a cis-relationship between the C-6 proton and the C-8 alkyl chain,12,14 where as 
batzelladine K contains a trans-relationship between these groups (Figure 4.1).70 As such, a 
general method that allows for the preparation of both stereoisomeric bicyclic cores (“cis” and 
“trans”) from a single intermediate is of tremendous interest. However, despite all of the work 
that has been directed towards the synthesis of these alkaloids, no single method allows for the 
highly stereoselective construction of both stereoisomeric cores.20 
Figure 4.1 Biologically active tricyclic guanidine natural products. 
 
 
As described in chapters 2 and 3, bicyclic ureas with the cis-stereochemical configuration (4-
1) were synthesized with excellent control of selectivity through the development of Pd-
catalyzed carboamination reactions between 2-allylpyrrolidinyl ureas 4-2 and alkenyl bromides 
(Scheme 4.1).60,88 While this method was the first to provide access to the cis-stereoisomer of the 
batzelladine alkaloids, this methodology could not be employed for the synthesis of natural 
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products that feature the trans-core, such as batzelladine K. This limitation is intrinsic to 
carboamination reactions that proceed via a syn-aminopalladation mechanism because the 
stereochemical outcome is substrate-controlled.40–42 
Scheme 4.1 Synthesis of bicyclic ureas via syn-aminopalladation. 
 
In contrast to this work, our group recently described the synthesis of cyclic sulfamides and 
ureas via Pd-catalyzed carboamination reactions that proceed via anti-aminopalladation.50 As 
shown in Scheme 4.2, the nitrogen nucleophile and carbon electrophile are added across opposite 
faces of the olefin leading to carboamination product 4-3.  In light of this work, we speculated 
that similar reaction conditions might also facilitate the transformation of allylpyrrolidinyl urea 
4-4 into bicyclic urea 4-5. It was anticipated an anti-aminopalladation mechanism might lead to a 
reversal in the stereochemical outcome previously observed and generate bicyclic ureas with the 
trans-core. Concurrent studies in our laboratory have demonstrated that the selectivity of 
carboamination reactions involving substrates bearing allylic substituents can be controlled by 
influencing the aminopalladation mechanistic pathways of the catalytic cycle through choice of 
catalyst and reaction conditions.50 Herein we report our initial findings on the synthesis of 
bicyclic ureas and sulfamides via Pd-catalyzed carboamination reactions that are believed to 
proceed via anti-aminopalladation. 
Scheme 4.2 Synthesis of cyclic ureas via anti-aminopalladation. 
 
4.2 Optimization of Reaction Conditions 
We initially elected to examine the Pd-catalyzed carboamination between 2-allylpyrrolidinyl 
urea 4-6 and phenyl triflate using the optimized anti-aminopalladation conditions described for 
the synthesis of cyclic ureas (Scheme 4.3). Gratifyingly, the desired product 4-7 was generated in 
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excellent yield (92%) and with the desired reversal in selectivity (2:1 dr trans: cis). However, 
efforts to improve the selectivity of the transformation through the use of other protecting groups, 
ligands, solvents, and reaction temperatures were largely ineffective. However, it should be 
noted that employing the ligand Trixiephos did lead to some improvement in diastereoselectivity 
(2.6:1 dr) without compromising the chemical yield of the reaction (91% NMR yield). 
Scheme 4.3 Synthesis of trans-bicyclic ureas via anti-aminopalladation. 
	  	  
We postulated that two factors might be the cause of the modest diastereoselectivity observed 
for the cross coupling of 4-6 and phenyl triflate: (1) the rates of syn- and anti-aminopalladation 
are comparable; and/or (2) the transition states/intermediates leading to the two possible 
stereoisomers are energetically similar. Both factors can be heavily influenced by the structural 
and electronic nature of the substrate. Numerous publications, including the Wolfe group’s 
original report on anti-aminopalladation,50 have demonstrated that slight changes to the substrate 
can dramatically influence the mechanism of aminopalladation reactions and in turn, the ratio of 
products resulting from syn- or anti-addition.90,91 We reasoned that employing a less nucleophilic 
substrate might favor anti-aminopalladation by decreasing the likelihood that the substrate would 
form the Pd-N bond required to undergo syn-migratory insertion. Additionally, we expected that 
changing the hybridization of the substrate would influence the stereodetermining transition 
states/intermediates leading to the two possible stereoisomers and consequently the selectivity of 
the desired transformation could be potentially improved. 
 In an effort to test the hypothesis outlined above, 2-allylpyrrolidinyl sulfamide substrate 4-8a 
was synthesized and subjected to various catalysts (Table 4.1). The coupling of PMP-protected 
sulfamide 4-8a and phenyl triflate under the previously optimized conditions led to an 
improvement in selectivity (6:1 dr trans: cis). Unfortunately, several of the ligands screened led 
to low formation of desired product 4-9a and generated significant amounts of side products 
resulting from Heck-arylation of the alkene (4-10) and/or β-hydride elimination (4-11). CPhos 
provided the best results but side products 4-10 and 4-11 were still formed in substantial 
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quantities (entry 5). Moreover, the coupling of 4-8a with phenyl triflate proved to be highly 
variable, making it difficult to obtain consistently high and reproducible yields. After some 
experimentation, it was discovered that changing the solvent from benzotrifluoride to tert-
butanol led to significantly improved and reproducible yields, and just as importantly, side 
products 4-10 and 4-11 were generated in only trace amounts (entry 6).87,92–94 
Table 4.1 Ligand screen and solvent optimization. 
	  
Entry Solvent Ligand NMR Yield 
(isolated) 
NMR Yield 
4-10 
NMR Yield 
4-11 
dr (trans:cis)  
1 PhCF3 RuPhos 50 5 <5 6:1 
2 PhCF3 DavePhos 30 10 <5 6:1 
3 PhCF3 BrettPhos 40 <5 30 6:1 
4 PhCF3 tBuXphos 30 5 40 6:1 
5 PhCF3 CPhos 80 5 10 6:1 
6 tBuOH[b] CPhos 90 (72) <5 <5 7:1 
[a] Reaction Conditions: 1.0 equiv 4-8a, 2.0 equiv Ph-OTf, 2.0 equiv LiOtBu, 4 mol % Pd(OAc)2, 10 mol % ligand, 
solvent (0.1 M), 100 °C. [b] Reaction was conducted at 82 °C. 
In light of the work described in chapter 3, in which the protecting group on the cyclizing 
nitrogen significantly influenced the selectivity of the carboamination reactions,79,88 several 
different N-protected sulfamide substrates 4-8 were prepared. As shown in Table 4.2, the 
coupling of substrates 4-8 with phenyl triflate was explored using the optimized catalyst system 
and reaction conditions. Substrate 4-8b bearing a p-chlorophenyl N-aryl group underwent the 
desired transformation in comparable yield and selectivity to that of substrate 4-9a (entry 2). 
Disappointingly, N-Benzyl and N-PMB protected substrates were converted to products 4-9c and 
4-9d respectively, with significantly lower selectivities than 4-9a or 4-9b (entries 3 and 4).  
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Table 4.2 N-Protecting group effects. 
	  
Entry Substrate PG Product Yield (%)[b] dr 
1 4-8a PMP 4-9a 72 7:1 
2 4-8b p-Cl-C6H4 4-9b 58 7:1 
3 4-8c Bn 4-9c 86[c] 3:1 
4 4-8d PMB 4-9d 82[c] 3:1 
[a] Reaction Conditions: 1.0 equiv 4-8, 2.0 equiv Ph-OTf, 2.0 equiv LiOtBu, 4 mol % Pd(OAc)2, 10 mol % C-Phos, 
tBuOH (0.1 M), 82 °C. [b] Isolated yield. [c] Reaction was conducted in PhCF3 at 100 °C. 
4.3 Synthesis of Bicyclic Sulfamides via Pd-Catalyzed Carboamination Reactions  
After exploring the impact of catalyst structure and protecting group on the reaction outcome, 
the scope of the Pd-catalyzed carboamination reactions was examined by coupling N-PMP-
protected pyrrolidinyl sulfamide substrates 4-8a and 4-8e with a variety of different aryl triflates 
(Table 4.3). Aryl triflates bearing either electron-donating or electron-withdrawing groups 
afforded bicyclic sulfamide products 4-9 in good yields and selectivities (entries 2–4 and 8). 
Additionally, the reaction of an ortho-substituted aryl triflate also proceeded in good yield and 
with similar diastereoselectivity (entry 5). 1-Cyclohexenyl triflate also proved to be a viable 
substrate, providing the desired bicyclic product in good yield (entry 6). Improved selectivities 
were observed for the cross-coupling reactions involving PMP-protected meso-2,5-diallyl-
pyrrolidinyl sulfamide substrate 4-8e (entries 7 and 8), although shorter reaction times were 
required to minimize undesired isomerization of the remaining terminal olefin. In most cases the 
Pd-catalyzed carboamination reactions did not lead to significant amounts of undesired side 
products, however Heck arylation (4-10) and β-hydride elimination (4-11) side products were 
observed occasionally. In contrast, when benzotrifluoride was employed as the solvent, 
substantial quantities of 4-10 and 4-11 were generated.  For example, when the carboamination 
reaction of 4-8e and phenyl triflate was conducted in benzotrifluoride, the yield of the desired 
product (4-9j) was modest (57%) and was not separable from β-hydride elimination side 
products 4-11 (~25%) via flash chromatography. 
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Table 4.3 Synthesis of 5-6 trans-bicyclic sulfamides. 
 
Entry Substrate R1 R Product Yield (%)[b] dr (crude) 
1 4-8a H Ph 4-9a 72 7:1  
2 4-8a H p-tBu-C6H4 4-9e 72 6:1 
3 4-8a H p-MeO-C6H4 4-9f 65 7:1 (6:1) 
4 4-8a H benzoylphenyl 4-9g 65 8:1 (5:1) 
5 4-8a H o-Me-C6H4 4-9h 84 5:1 
6 4-8a H cyclohexenyl 4-9i 73[c] 6:1 
7 4-8e allyl Ph 4-9j 62[d] 20:1 (12:1) 
8 4-8e allyl p-MeO-C6H4 4-9k 64[d] >20:1 (>10:1) 
[a] Reaction Conditions: 1.0 equiv 4-8a or 4-8e, 2.0 equiv R-OTf, 2.0 equiv LiOtBu, 4 mol % Pd(OAc)2, 10 mol % 
C-Phos, tBuOH (0.1 M), 82 °C, 16 h. [b] Isolated yield. [c] Reaction was conducted with 3.0 equiv of LiOtBu and 
3.0 equiv R-OTf. [d] Reaction time was 2 h.  
Inspired by tetraponerine alkaloids T-4 and T-8,95 which feature a trans-6-6 fused bicyclic 
ring system, 2-allylpiperidinyl sulfamide substrate 4-12 was prepared and subjected to the 
optimized reaction conditions with tert-butanol as the solvent (Scheme 4.4). As expected, the 
coupling of 4-12 and phenyl triflate proceeded in good chemical yield (84%) and with good 
stereocontrol (5:1 dr). Future work in the group is focused on exploring the scope of this 
transformation and its application to the total synthesis of tetraponerines T-4 and T-8. 
Scheme 4.4 Synthesis of 6-6 bicyclic sulfamides. 
  
Having successfully developed reaction conditions that afford trans-bicyclic sulfamides via 
an achiral Pd-catalyst, efforts to render the reactions asymmetric were undertaken. The 
successful development of an asymmetric desymmetrization reaction of meso-2,5-
diallylpyrroldinyl sulfamides would provide bicyclic compounds that could potentially serve as 
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an intermediate in the asymmetric synthesis of batzelladine K,18 or analogs thereof,19 in as few as 
ten steps (Nagasawa accomplished the only asymmetric synthesis of the alkaloid in 18 steps).34 
The previously prepared sulfamide substrate 4-8e was subjected to a variety of chiral Pd-
catalysts for the coupling with phenyl triflate (Table 4.4). Unfortunately, not a single catalyst 
system that was screened led to formation of desired product 4-9j. Despite the lack of success 
involving the initial screen of chiral ligands, further studies in this area are warranted given the 
excellent stereocontrol observed for the formation of 4-9j using a racemic catalyst and the 
potential utility of this reaction in total synthesis. 
Table 4.4 Asymmetric desymmetrization of meso-2,5-diallylpyrroldinyl sulfamides. 
 
Entry Solvent Ligand Conversion[b] Major 
Product 
Yield (%) dr (crude) er 
1 PhCF3 (S)-Siphos-PE <10 – ND –  – 
2 tBuOH (S)-Siphos-PE <10 – ND – – 
3 PhCF3 (R)-Siphos-PE <10 – ND – – 
4 tBuOH (R)-Siphos-PE <10 – ND – – 
5 tBuOH (R)-MOP ~50 heck ND – – 
6 tBuOH (R)-SDP ~75 heck ND – – 
7 tBuOH (S)-NMDPP <10 – ND – – 
 [a] Reaction Conditions: 1.0 equiv 4-8e, 2.0 equiv Ph-OTf, 2.0 equiv LiOtBu, 4 mol % Pd(OAc)2, 10 mol % Ligand, 
PhCF3 (0.1 M) at  100 °C or tBuOH (0.1 M) at 82 °C. [b] Conversion = percentage of starting material 4-8e 
consumed. 
O
O P N
Ph
Ph
(R)-Siphos-PE
O
O P N
Ph
Ph
(S)-Siphos-PE (R)-MOP (R)-SDP (S)-NMDPP
OMe
PPh2
PPh2
PPh2
Me
PPh2
N
O2S NH
PMP
N
O2S N
Ph
H
PMP
HH Pd(OAc)2 (4 mol %)Chiral Ligand (10 mol %)
LiOtBu
PhCF3, 100 oC
OR
tBuOH, 82 oC
Ph-OTf
H H
4-8e 4-9j
	   86	  
4.4 Plausible Mechanism and Stereochemical Rationale 
The mechanism of the Pd-catalyzed reactions described in this chapter for the formation of 
bicyclic sulfamides likely proceeds as depicted in Scheme 4.5.50 The catalytic cycle is initiated 
by oxidative addition of the aryl triflate to palladium (0). The non-coordinating nature of the 
triflate counterion likely leads to cationic palladium complex 4-14.96 Activation of the olefin 
through coordination of the Pd-catalyst leads to outer-sphere nucleophilic attack of the sulfamide 
group onto the alkene, resulting in anti-aminopalladation. Reductive elimination from Pd-alkyl 
intermediate 4-15 affords the desired sulfamide product (4-9) and regenerates the palladium 
catalyst.  
Scheme 4.5 Plausible catalytic cycle. 
 
The stereochemical outcome of the Pd-catalyzed reactions for the synthesis of trans-bicyclic 
sulfamides is particularly interesting given the work described in chapters 2 and 3 of this thesis. 
Despite seemingly minor changes to the substrate, catalyst and reaction conditions, the 
stereoselectivity of the reaction is dramatically altered, reversing a preference for the cis-
stereoisomer (drs as high as 20:1) to form the trans-bicycle as the major product with good levels 
of stereocontrol (up to 12:1 crude dr). While a change in selectivity was anticipated due to the 
mechanistic change involving the aminopalladation step of the catalytic cycle, the high 
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selectivity for the trans-isomer is more surprising given the low selectivity generally observed 
for transformations involving anti-aminopalladation.40,97 
While a number of mechanistic details remain unclear, the stereochemical outcome of the 
carboamination reactions can be rationalized by taking a closer look at the mechanism and the 
possible intermediates leading to the two stereoisomeric products (Scheme 4.6). Although the 
new stereocenter is formed during the aminopalladation step, the stereodetermining step can be 
either insertion or reductive elimination. For related aminopalladation transformations, it is 
known that electron-poor N-substituents decrease the rate of C-C bond-forming reductive 
elimination.47,48 Furthermore, Stahl has demonstrated that the more electron-deficient the 
nitrogen nucleophile, the more readily it undergoes β-amidate elimination (retro-
aminopalladation).98 Thus, given the electron-deficient nature of the sulfamide group, insertion is 
likely to be reversible and reductive elimination is most likely the stereodetermining step.  
Scheme 4.6 Stereochemical rationale for the synthesis of bicyclic sulfamides. 
 
As mentioned earlier, the diastereoselectivity observed for these transformations is unusually 
high for reactions proceeding via an anti-aminopalladation mechanism.40,97 However, 
rationalizing the observed stereochemical outcome of the carboamination reactions is not 
straightforward. One possibility is that the observed selectivity is thermodynamically controlled 
and arises due to differences in the stability of intermediates 4-16 and 4-17. It appears that there 
are unfavorable 1,3-diaxial interactions involving Pd-alkyl intermediate 4-17, which is formed 
following insertion of 4-18, where the olefin occupies a pseudo-axial position. The steric 
repulsions present in intermediate 4-17 likely forces the equilibrium to favor Pd-alkyl 
intermediate 4-16, which is generated via aminopalladation of intermediate 4-19. This model 
appears to be consistent with the observed stereochemical outcome as reductive elimination from 
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thermodynamically favored intermediate 4-16 leads to the major stereoisomer, whereas reductive 
elimination from 4-17 generates the minor diastereomer.  
Scheme 4.7 Possible boat-like intermediates. 
 
The rationale outlined in Scheme 4.6 deviates substantially from the work described in 
chapters 2 and 3, in which the stereochemical outcome is likely kinetically controlled and is 
proposed to arise from differences in boat-like transition states 2-7 and 2-8 (Scheme 2.2).60,88 The 
possibility that these transformations are actually under kinetic control and/or that the selectivity 
arises from boat-like transition states/intermediates similar to those described in chapters 2 and 3 
cannot be ruled out. However, boat-like intermediates 4-20 and 4-21 as depicted in Scheme 4.7, 
appear to be much higher in energy than the analogous chair-like intermediates 4-16 and 4-17 
due to increased ring strain. Moreover, chair-like intermediates, not boat-like intermediates, have 
been proposed in related anti-aminopalladation reactions for the formation of 6-membered N-
containing heterocycles.99 Furthermore, this type of model does not seem consistent with the 
selective formation of trans-bicyclic sulfamides, as the boat-like transition state leading to the 
observed major isomer appears to suffer from unfavorable steric interactions. In all, these 
transformations are most likely under thermodynamic control and the observed selectivity for the 
formation of isomer 4-9-major likely arises from the energy differences between chair-like 
intermediates 4-16 and 4-17 as depicted in Scheme 4.6. Future work in this area is aimed at 
better understanding the stereochemical outcome through the computations and exploration of 
the relative stabilities of the proposed intermediates and final products. A better understanding of 
the mechanism and origin of the stereoselectivity may facilitate the further optimization of these 
transformations and the development of an asymmetric variant of this chemistry. 
4.5 Conclusions 
In conclusion, we have developed a new method for the synthesis of bicyclic sulfamides via 
the Pd-catalyzed alkene carboamination of 2-allylpyrrolidinyl sulfamides. The reactions proceed 
in good yields (58-92%) and with good control of stereoselectivity (up to 12:1 dr). Importantly, 
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by employing reaction conditions that favor an anti-aminopalladation mechanism, the 
stereochemical outcome of the reactions is reversed relative to the Pd-catalyzed carboamination 
reactions that proceed via syn-aminopalladation. Future studies on the development of an 
asymmetric variant of this chemistry and application of this chemistry towards the total synthesis 
polycyclic guanidine alkaloids that feature the trans-core such as batzelladine K is warranted. 
 
*Part of the work described in this chapter was carried out by Grace McKenna including the 
synthesis of 4-12. 
4.6 Experimental 
General: All reactions were carried out under a nitrogen atmosphere unless otherwise noted. 
Palladium acetate was purchased from Strem Chemical Co. and used without purification. All 
phosphine ligands were obtained from commercial sources and were used without further 
purification. All other reagents were obtained from commercial sources and were used as 
obtained unless otherwise noted. (Z)-1-bromobutene63	   was prepared according to a slight 
modification of a literature procedure; the preparation was conducted at rt instead of using 
microwave heating as detailed in chapter 2. tert-Butyl 2-allylpyrrolidine-1-carboxylate,100 tert-
butyl 2-allylpiperidine-1-carboxylate,100 (±)-(E,2R*,5S*)-tert-butyl 2-allyl-5-[3-
(trimethylsilyl)allyl]pyrrolidine-1-carboxylate,88 N-(4-methoxyphenyl)-2-oxooxazolidine-3-
sulfonamide,50 N-(4-chlorophenyl)-2-oxooxazolidine-3-sulfonamide,101 N-benzyl-2-
oxooxazolidine-3-sulfonamide,50 and N-(4-methoxybenzyl)-2-oxooxazolidine-3-sulfonamide50 
were prepared according to published procedures. Lithium tert-butoxide was stored in a 
glovebox and removed only prior to use. Toluene, THF, diethyl ether and dichloromethane were 
purified using a GlassContour solvent purification system. Benzotrifluoride was purified by 
distillation under N2 prior to use. tert-Butanol was used without any purification. Yields refer to 
isolated yields of compounds estimated to be ≥95% pure as determined by 1H NMR analysis 
unless otherwise noted. The yields reported in chapter 4 and the experimental section describe 
the result of a single experiment. Structural and stereochemical assignments were made on the 
basis of 2-D COSY, and NOESY experiments. Ratios of diastereomers were determined by 1H 
NMR analysis. 
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Preparation and Characterization of Substrates 
 
(±)-2-Allyl-N-(4-nitrophenyl)pyrrolidine-1-carboxamide (4-6). A round-bottom flask 
equipped with a stirbar was charged with tert-butyl 2-allylpyrrolidine-1-carboxylate  (887 mg, 
4.2 mmol) and dichloromethane (21 mL, 0.2 M). Trifluoroacetic acid (4.2, mL, 1.0 M) was 
added to the flask and the mixture was stirred until the starting material had been completely 
consumed as judged by TLC analysis (ca. 30 min). The solution was diluted with water, basified 
with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
dissolved in dichloromethane (21 mL, 0.2 M) and 4-nitrophenyl isocyanate (1.0 g, 6.3 mmol) 
was added. The reaction mixture was stirred at rt until starting material had been completely 
consumed as judged by TLC analysis (ca. 1 h). The crude reaction mixture was concentrated in 
vacuo, and purified by flash chromatography on silica gel. The chromatographed product 
material was diluted with dichloromethane (35 mL) and washed with 1M HCl (2 x 15 mL) to 
remove any remaining 4-nitroanniline. This procedure afforded 290 mg (25%) of the title 
compound as a yellow solid: mp = 104–106 ºC. 1H NMR (700 MHz, CDCl3) δ 8.15 (d, J = 9.1 
Hz, 2 H), 7.58 (d, J = 9.1 Hz, 2 H), 6.64 (s, 1 H), 5.84–5.78 (m, 1 H), 5.17–5.09 (m, 2 H), 4.09 
(s, br, 1 H), 3.53–3.46 (m, 2 H), 2.56 (dt, J = 12.4, 5.3 Hz, 1 H), 2.25–2.18 (m, 1 H), 2.09–2.02 
(m, 1 H), 2.04–1.94 (m, 2 H), 1.85 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 152.7, 145.4, 142.3, 
134.7, 125.1, 118.0, 117.9, 57.5, 46.5, 38.5, 29.6, 23.7; IR (film) 3314, 1652, 1501, 1329 cm–1. 
MS (ESI) 276.1344 (276.1343 calcd for C14H17N3O3, M + H+). 
 
General Procedure for the Synthesis of Sulfamide Substrates 4-8 and 4-12.  
A round-bottom flask equipped with a stirbar was charged with the appropriate N-Boc-
protected amine (1.2 equiv) and dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was 
N
O NH
NO2
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added to the flask and the mixture was stirred until the starting material had been completely 
consumed as judged by TLC analysis (ca. 30 min). The solution was then concentrated in vacuo. 
Toluene was added and the reaction flask was concentrated in vacuo to remove any excess TFA. 
The crude amine (TFA salt) was used without any additional purification.   
A separate flame dried flask was charged with the appropriate oxazolidinone substrate (1.0 
equiv), 4-dimethylaminopyridine (0.2 equiv), and a stirbar, then was evacuated and backfilled 
with N2. Acetonitrile was added, followed by Et3N (3.0 equiv), and then the reaction vessel was 
placed in an oil bath at 75 OC. The appropriate amine TFA salt (1.2 equiv) as prepared above was 
added and the resulting mixture was stirred at 75 OC overnight (approximately 16 hours). The 
mixture was cooled to rt, solvent was removed via rotary evaporation, and the residue was 
partitioned between CH2Cl2 and 3 M HCl. The aqueous layer was extracted with CH2Cl2 and the 
combined organic layers were washed with brine and dried over anhydrous Na2SO4. Solvent was 
removed in vacuo and the resulting residue was purified by flash chromatography on silica gel. 
 
(±)-2-Allyl-N-(4-methoxyphenyl)pyrrolidine-1-sulfonamide (4-8a). The title compound was 
prepared from N-(4-methoxyphenyl)-2-oxooxazolidine-3-sulfonamide (825 mg, 4.0 mmol) and 
tert-butyl 2-allylpyrrolidine-1-carboxylate (1.06 g, 5.0 mmol) in two steps via the general 
procedure described above. This procedure afforded 808 mg (68%) of the title compound as a 
pale yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.18 (d, J = 9.1 Hz, 2 H), 6.85 (d, J = 9.1 Hz, 2 
H), 6.30 (s, br, 1 H), 5.70–5.61 (m, 1 H), 5.05–4.99 (m, 2 H), 3.79 (s, 3 H), 3.79–3.77 (m, 1 H), 
3.36–3.27 (m, 2 H), 2.46–2.41 (m, 1 H), 2.12 (dt, J = 13.9, 8.5 Hz, 1 H), 1.86–1.73 (m, 3 H), 
1.70–1.66 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 157.2, 134.5, 130.1, 123.7, 117.5, 114.4, 
60.3, 55.5, 49.1, 39.9, 30.1, 24.2; IR (film) 3267, 1327, 1245, 1146 cm–1. MS (ESI) 297.1274 
(297.1267 calcd for C14H20N2O3S, M + H+). 
 
N
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(±)-2-Allyl-N-(4-chlorophenyl)pyrrolidine-1-sulfonamide (4-8b). The title compound was 
prepared from N-(4-chlorophenyl)-2-oxooxazolidine-3-sulfonamide (4.1 g, 15.0 mmol) and tert-
butyl 2-allylpyrrolidine-1-carboxylate (3.8 g, 18.0 mmol) in two steps via the general procedure 
described above. This procedure afforded 1.74 g (39%) of the title compound as a pale yellow 
solid: mp = 46–49 ºC. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 9.0 Hz, 2 H), 7.15 (d, J = 8.5 
Hz, 2 H), 7.02 (s, 1 H), 5.71–5.63 (m, 1 H), 5.06–5.02 (m, 2 H), 3.88–3.84 (m, 1 H), 3.40–3.35 
(m, 1 H), 3.30–3.25 (m, 1 H), 2.48–2.44 (m, 1 H), 2.19–2.14 (m, 1 H), 1.85–1.70 (m, 4 H); 13C 
NMR (125 MHz, CDCl3) δ 136.0, 134.2, 129.8, 129.4, 121.4, 117.8, 60.4, 49.2, 39.7, 30.2, 24.2; 
IR (film) 3265, 1490, 1324, 1148 cm–1. MS (ESI) 301.0774 (301.0772 calcd for C13H17ClN2O2S, 
M + H+). 
 
 
(±)-2-Allyl-N-benzylpyrrolidine-1-sulfonamide (4-8c). The title compound was prepared from 
N-benzyl-2-oxooxazolidine-3-sulfonamide (2.1 g, 8.3 mmol) and tert-butyl 2-allylpyrrolidine-1-
carboxylate (2.1 g, 10.0 mmol) in two steps via the general procedure described above. This 
procedure afforded 1.22 g (52%) of the title compound as a pale yellow solid: mp = 38–41 ºC. 1H 
NMR (700 MHz, CDCl3) δ 7.30–7.20 (m, 5 H), 5.72–5.64 (m, 1 H), 5.03–4.96 (m, 2 H), 4.68 (s, 
br, 1 H), 4.15 (s, 2 H), 3.76 (ddt, J = 9.0, 7.8, 3.9 Hz, 1 H), 3.31–3.24 (m, 1 H), 3.16 (ddd, J = 
9.5, 6.6, 4.9 Hz, 1 H), 2.46 (dddt, J = 13.7, 6.8, 4.0, 1.4 Hz, 1 H), 2.18–2.10 (m, 1 H), 1.84–1.69 
(m, 3 H), 1.68–1.61 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 137.0, 134.6, 128.7, 127.9, 127.9, 
117.5, 59.6, 49.0, 47.4, 40.1, 30.3, 24.3; IR (film) 3282, 1312, 1143 cm–1. MS (ESI) 281.1325 
(281.1318 calcd for C14H20N2O2S, M + H+). 
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(±)-2-Allyl-N-(4-methoxybenzyl)pyrrolidine-1-sulfonamide (4-8d). The title compound was 
prepared from N-(4-methoxybenzyl)-2-oxooxazolidine-3-sulfonamide (2.4 g, 8.3 mmol) and tert-
butyl 2-allylpyrrolidine-1-carboxylate (2.1 g, 10.0 mmol) in two steps via the general procedure 
described above. This procedure afforded 1.10 g (43%) of the title compound as a yellow solid: 
mp = 39–42 ºC. 1H NMR (700 MHz, CDCl3) δ 7.25 (d, J = 9.1 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 
H), 5.77 (ddt, J = 17.2, 10.2, 7.1 Hz, 1 H), 5.12–5.04 (m, 2 H), 4.16 (s, 2 H), 3.88–3.79 (m, 1 H), 
3.80 (s, 3 H), 3.37 (dt, J = 9.9, 7.3 Hz, 1 H), 3.25 (ddd, J = 9.7, 6.7, 5.1 Hz, 1 H), 2.56–2.53 (m, 
1 H), 2.27–2.19 (m, 1 H), 1.95–1.79 (m, 3H), 1.75–1.69 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 
159.3, 134.7, 129.3, 129.0, 117.5, 114.1, 59.6, 55.3, 49.1, 47.0, 40.1, 30.3, 24.3; IR (film) 3289, 
1302, 1247, 1144 cm–1. MS (ESI) 311.1416 (311.1424 calcd for C15H22N2O3S, M + H+). 
 
 
(2S,5R)-2,5-Diallyl-N-(4-methoxyphenyl)pyrrolidine-1-sulfonamide (4-8e). The title 
compound was prepared from N-(4-methoxyphenyl)-2-oxooxazolidine-3-sulfonamide (1.6 g, 5.9 
mmol) and (±)-(E,2R*,5S*)-tert-butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate 
(2.3 g, 7.1 mmol) in two steps via the general procedure described above. This procedure 
afforded 1.46 g (73%) of the title compound as a off-white solid: mp = 57–60 ºC. 1H NMR (700 
MHz, CDCl3) δ 7.19 (d, J = 8.4 Hz, 2 H), 6.85 (d, J = 8.4 Hz, 2 H), 5.75–5.67 (m, 2 H), 5.07–
5.02 (m, 4 H), 3.79 (s, 3 H), 3.79–3.74 (m, 2 H), 2.50 (dt, J = 12.0, 5.5 Hz, 2 H), 2.16 (dt, J = 
14.8, 8.3 Hz, 2 H), 1.77–1.71 (m, 2 H), 1.68–1.62 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 
157.2, 134.6, 130.0, 123.7, 117.5, 114.4, 61.6, 55.4, 40.4, 29.0; IR (film) 3268, 1508, 1247, 1151 
cm–1. MS (ESI) 337.1580 (337.1580 calcd for C17H24N2O3S, M + H+). 
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(±)-2-Allyl-N-(4-methoxyphenyl)piperidine-1-sulfonamide (4-12). The title compound was 
prepared from N-(4-methoxyphenyl)-2-oxooxazolidine-3-sulfonamide (1.6 g, 6.0 mmol) and 
tert-butyl 2-allylpiperidine-1-carboxylate (1.6 g, 7.2 mmol) in two steps via the general 
procedure described above with one change. Instead of employing 2-allyl piperidine as the TFA 
salt, it was basified with NH4OH and used as the free base. This procedure afforded 521 mg 
(28%) of the title compound as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.11 (d, J = 8.4 Hz, 2 
H), 6.85 (d, J = 8.4 Hz, 2 H), 6.16 (s, 1 H), 5.68 (ddt, J = 17.2, 10.1, 7.1 Hz, 1 H), 5.09–5.01 (m, 
2 H), 3.97–3.93 (m, 1 H), 3.79 (s, 3 H), 3.63–3.58 (m, 1 H), 2.99 (td,  J = 13.3, 2.8 Hz, 1 H), 
2.42–2.31 (m, 2 H), 1.61–1.39 (m, 5 H), 1.35–1.23 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 
157.1, 135.0, 130.1, 123.3, 117.3, 114.4, 55.5, 55.3, 41.4, 34.1, 26.7, 24.8, 18.0; IR (film) 3272, 
1509, 1246, 1142 cm–1. MS (ESI) 311.1422 (311.1424 calcd for C15H22N2O3S, M + H+). 
 
Preparation and Characterization of Bicyclic Products 
 
General Procedure for Synthesis of Bicyclic Ureas and Sulfamides 
General Procedure A (for reactions run in benzotrifluoride): A test tube was charged with 
Pd(OAc)2 (0.04 equiv), a phosphine ligand (0.1 equiv), and LiOtBu (2.0 equiv). The test tube was 
purged with N2 then the appropriate aryl triflate (2.0 equiv) was added, followed by the 
appropriate substrate (1.0 equiv) in benzotrifluoride (0.2 M). The tube was heated to 100 ºC and 
stirred overnight or until the starting material was completely consumed as judged by TLC or 1H 
NMR analysis. The mixture was cooled to room temperature and saturated aqueous NH4Cl (5 
mL/mmol substrate) and dichloromethane (5 mL/mmol substrate) were added. The layers were 
separated and concentrated in vacuo. The crude material was purified by flash chromatography 
on silica gel. 
 
General Procedure B (for reactions run in tert-butanol): A test tube was charged with 
Pd(OAc)2 (0.04 equiv), a phosphine ligand (0.1 equiv), and LiOtBu (2.0 equiv). The test tube was 
N
O2S NH
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purged with N2 then the appropriate aryl triflate (2.0 equiv) was added, followed by the 
appropriate substrate (1.0 equiv) in tert-butanol (0.2 M). The tube was heated to 82 ºC and stirred 
overnight or until the starting material was completely consumed as judged by TLC or 1H NMR 
analysis. The mixture was cooled to room temperature and concentrated in vacuo. The crude 
material was purified by flash chromatography on silica gel. 
 
 
(±)-(3S*,4aR*)-3-Benzyl-2-(4-nitrophenyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (4-
7). General procedure A was employed for the coupling of 4-6 (55 mg, 0.2 mmol) and phenyl 
triflate (65 µL, 0.4 mmol), using a catalyst composed of Pd(OAc)2 (1.8  mg, 0.008 mmol), and 
RuPhos (9.3 mg, 0.02 mmol). This procedure afforded 66 mg (94%) of the title compound as a 
yellow solid and as a 2:1 mixture of diastereomers as determined by 1H NMR analysis: mp = 51–
55 ºC.  Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 8.26 (d, J = 9.1 Hz, 2 H), 
7.56 (d, J = 8.4 Hz, 2 H), 7.29–7.23 (m, 3 H), 7.04 (d, J = 7.0 Hz, 2 H), 4.14 (tt, J = 10.6, 3.9 Hz, 
1 H), 3.58–3.47 (m, 3 H), 2.85 (dd, J = 13.5, 3.8 Hz, 1 H), 2.32 (dd, J = 13.4, 10.1 Hz, 1 H), 
2.26–1.46 (m, 6 H); 13C NMR (175 MHz, CDCl3) δ 153.5, 147.5, 145.2, 137.0, 129.0, 128.7, 
128.6, 126.7, 124.0, 58.2, 54.7, 46.0, 41.6, 35.0, 33.5, 23.0; IR (film) 1639, 1515, 1339 cm–1. MS 
(ESI) 352.1656 (352.1656 calcd for C20H21N3O3, M + H+). 
 
 
(±)-(3S*,4aR*)-3-Benzyl-2-(4-methoxyphenyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9a). General procedure B was employed for the coupling of 
4-8a (59 mg, 0.2 mmol) and phenyl triflate (65 µL, 0.4 mmol), using a catalyst composed of 
Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 54 
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mg (72%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as 
determined by 1H NMR analysis: mp = 45–48 ºC. Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.39 (d, J = 8.4 Hz, 2 H), 7.29–7.20 (m, 3 H), 7.06 (d, J = 7.7 Hz, 2 H), 6.91 (d, 
J = 9.1 Hz, 2 H), 4.26–4.19 (m, 1 H), 3.80 (s, 3 H), 3.53 (td, J = 9.5, 5.7 Hz, 1 H), 3.38 (td, J = 
9.5, 5.8 Hz, 1 H), 2.81 (dd, J = 13.6, 4.4 Hz, 1 H), 2.21–2.08 (m, 2 H), 2.07–1.91 (m, 3 H), 1.68–
1.53 (m, 3 H); 13C NMR (175 MHz, CDCl3) δ 159.4, 137.4, 130.9, 130.4, 129.1, 128.6, 126.6, 
114.3, 61.8, 60.2, 55.4, 46.5, 40.4, 32.6, 31.3, 21.3; IR (film) 1506, 1337, 1248, 1158 cm–1. MS 
(ESI) 373.1589 (373.1580 calcd for C20H24N2O3S, M + H+). 
 
 
(±)-(3S*,4aR*)-3-Benzyl-2-(4-methoxyphenyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9b). General procedure B was employed for the coupling of 
4-8b (60 mg, 0.2 mmol) and phenyl triflate (65 µL, 0.4 mmol), using a catalyst composed of 
Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 44 
mg (58%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as 
determined by 1H NMR analysis: mp = 50–53 ºC. Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.41 (d, J = 9.1 Hz, 2 H), 7.37 (d, J = 8.4 Hz, 2 H), 7.29–7.22 (m, 3 H), 7.05 (d, 
J = 7.7 Hz, 2 H), 4.25 (m, 1 H), 3.81 (ddt, J = 11.2, 6.6, 4.2 Hz, 1 H), 3.53 (td, J = 9.5, 5.8 Hz, 1 
H), 3.43–3.35 (m, 1 H), 2.78 (dd, J = 13.6, 4.5 Hz, 1 H), 2.21 (dd, J = 13.3, 9.8 Hz, 1 H), 2.18–
2.10 (m, 1 H), 2.08–1.87 (m, 2 H), 1.69–1.52 (m, 3 H); 13C NMR (175 MHz, CDCl3) δ 136.9, 
136.6, 134.3, 131.2, 129.4, 129.0, 128.6, 126.8, 61.8, 60.2, 46.6, 40.4, 32.6, 31.3, 21.4;  IR (film) 
1486, 1338, 1159 cm–1. MS (ESI) 377.1089 (377.1085 calcd for C19H21ClN2O2S, M + H+). 
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(±)-(3S*,4aR*)-2,3-Dibenzylhexahydro-2H-pyrrolo[1,2-b][1,2,6]thiadiazine-1,1-dioxide (4-
9c). General procedure A was employed for the coupling of 4-8c (56 mg, 0.2 mmol) and phenyl 
triflate (65 µL, 0.4 mmol), using a catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and 
CPhos (8.7 mg, 0.02 mmol). This procedure afforded 61 mg (86%) of the title compound as a 
white solid and as a 3:1 mixture of diastereomers as determined by 1H NMR analysis: mp = 113–
116 ºC. Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.42 (d, J = 7.0 Hz, 2 H), 
7.34–7.18 (m, 6 H), 7.07 (d, J = 7.0 Hz, 2 H), 4.59 (d, J = 16.2 Hz, 1 H), 4.15 (d, J = 16.1 Hz, 1 
H), 4.15–4.09 (m, 1 H), 3.48 (m, 1 H), 3.26 (m, 2 H), 2.92 (dd, J = 13.4, 4.6 Hz, 1 H), 2.54 (dd, J 
= 13.4, 10.5 Hz, 1 H), 2.07–2.01 (m, 1 H), 1.98–1.90 (m, 1 H), 1.82 (m, 1 H), 1.71–1.49 (m, 3 
H); 13C NMR (175 MHz, CDCl3) δ 138.5, 137.4, 129.2, 128.5, 128.4, 127.7, 127.2, 126.7, 61.6, 
60.8, 49.6, 45.8, 40.6, 31.6, 30.7, 21.1; IR (film) 1333, 1155 cm–1. MS (ESI) 357.1632 (357.1631 
calcd for C20H24N2O2S, M + H+). 
 
 
(±)-(3S*,4aR*)-3-Benzyl-2-(4-methoxybenzyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9d). General procedure A was employed for the coupling of 
4-8d (62 mg, 0.2 mmol) and phenyl triflate (65 µL, 0.4 mmol), using a catalyst composed of 
Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 63 
mg (82%) of the title compound as a red-brown oil and as a 3:1 mixture of diastereomers as 
determined by 1H NMR analysis. Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 
7.32 (d, J = 8.4 Hz, 2 H), 7.26–7.15 (m, 3 H), 7.08 (d, J = 7.0 Hz, 2 H), 6.85 (d, J = 8.4 Hz, 2 H), 
4.51 (d, J = 15.9 Hz, 1 H), 4.08 (d, J = 16.1 Hz, 1 H), 4.11–4.03 (m, 1 H), 3.80 (s, 3 H), 3.48–
3.42 (m, 1 H), 3.27–3.21 (m, 2 H), 2.92 (dd, J = 13.3, 4.9 Hz, 1 H), 2.55 (dd, J = 13.4, 10.3 Hz, 1 
H), 2.06–1.98 (m, 1 H), 1.96–1.85 (m, 1 H), 1.82–1.76 (m, 1 H), 1.70–1.46 (m, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 158.8, 137.5, 130.4, 129.1, 129.1, 128.5, 126.6, 113.7, 61.3, 60.7, 55.2, 
49.3, 45.9, 40.7, 31.6, 30.9, 21.3; IR (film) 1332, 1245, 1155 cm–1. MS (ESI) 387.1725 
(387.1737 calcd for C21H26N2O3S, M + H+). 
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(±)-(3S*,4aR*)-3-[4-(tert-Butyl)benzyl]-2-(4-methoxyphenyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9e). General procedure B was employed for the coupling of 
4-8a (59 mg, 0.2 mmol) and 4-(tert-butyl)phenyl triflate (113 mg, 0.4 mmol), using a catalyst 
composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure 
afforded 62 mg (72%) of the title compound as a white solid and as a 7:1 mixture of 
diastereomers as determined by 1H NMR analysis: mp = 61–63 ºC. Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.39 (d, J = 9.1 Hz, 2 H), 7.27 (d, J = 7.7 Hz, 2 H), 6.98 (d, J = 
8.4 Hz, 2 H), 6.90 (d, J = 9.1 Hz, 2 H), 4.25–4.19 (m, 1 H), 3.81 (s, 3 H), 3.80–3.76 (m, 1 H), 
3.54–3.49 (m, 1 H), 3.41–3.34 (m, 1 H), 2.77 (dd, J = 13.7, 4.3 Hz, 1 H), 2.14–2.09 (m, 2 H), 
2.07–1.87 (m, 2 H), 1.70–1.52 (m, 3 H), 1.29 (s, 9 H); 13C NMR (175 MHz, CDCl3) δ 159.4, 
149.5, 134.2, 130.9, 130.4, 128.7, 125.4, 114.3, 61.8, 60.2, 55.4, 46.5, 39.9, 37.4, 34.4, 32.6, 
31.3, 21.3; IR (film) 1506, 1338, 1247, 1158 cm–1. MS (ESI) 429.2215 (429.2215 calcd for 
C24H32N2O3S, M + H+). 
 
 
(±)-(3S*,4aR*)-3-(4-Methoxybenzyl)-2-(4-methoxyphenyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9f). General procedure B was employed for the coupling of 
4-8a (59 mg, 0.2 mmol) and 4-methoxyphenyl triflate (72 µL, 0.4 mmol), using a catalyst 
composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure 
afforded 52 mg (65%) of the title compound as a white solid and as a 7:1 mixture of 
diastereomers as determined by 1H NMR analysis: mp = 48–51 ºC. Data are for the major isomer. 
1H NMR (700 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2 H), 6.97 (d, J = 8.4 Hz, 2 H), 6.91 (d, J = 
9.1 Hz, 2 H), 6.80 (d, J = 8.4 Hz, 2 H), 4.20–4.14 (m, 1 H), 3.85 (s, 3 H), 3.80 (s, 3 H), 3.80–
3.73 (m, 1 H), 3.56–3.46 (m, 1 H), 3.37 (td, J = 9.4, 5.7 Hz, 1 H), 2.74 (dd, J = 13.7, 4.4 Hz, 1 
H), 2.15–2.08 (m, 2 H), 2.04–1.91 (m, 2 H), 1.64–1.50 (m, 3 H); 13C NMR (175 MHz, CDCl3) δ 
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159.4, 158.3, 130.9, 130.4, 130.0, 129.3, 114.3, 113.9, 61.9, 60.3, 55.4, 55.2, 46.5, 39.5, 32.5, 
31.3, 21.3; IR (film) 1507, 1338, 1247, 1158 cm–1. MS (ESI) 403.1679 (403.1686 calcd for 
C21H26N2O4S, M + H+). 
 
 
(±)-(3S*,4aR*)-{4-{[2-(4-Methoxyphenyl)-1,1-dioxidohexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazin-3-yl]methyl}phenyl}(phenyl)methanone (4-9g). General procedure B was 
employed for the coupling of 4-8a (59 mg, 0.2 mmol) and 4-benzoylphenyl triflate (132 mg, 0.4 
mmol), using a catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 
mmol). The diastereoselectivity of the reaction was judged to be 5:1 dr as determined by 1H 
NMR analysis prior to flash chromatography. This procedure afforded 62 mg (65%) of the title 
compound as a white solid and as a 8:1 mixture of diastereomers as determined by 1H NMR 
analysis: mp = 58–61 ºC. Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.78 (d, J 
= 7.7 Hz, 2 H), 7.72 (d, J = 8.4 Hz, 2 H), 7.59 (t, J = 7.5 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.38 
(d, J = 8.8 Hz, 2 H), 7.18 (d, J = 7.9 Hz, 2 H), 6.91 (d, J = 8.7 Hz, 2 H), 4.33–4.28 (m, 1 H), 3.79 
(s, 3 H), 3.79–3.77 (m, 1 H), 3.54 (td, J = 9.4, 5.7 Hz, 1 H), 3.39 (td, J = 9.3, 5.8 Hz, 1 H), 2.87 
(dd, J = 13.7, 4.8 Hz, 1 H), 2.33 (dd, J = 13.7, 9.8 Hz, 1 H), 2.19–2.12 (m, 1 H), 2.01–1.95 (m, 2 
H), 1.68–1.62 (m, 3 H); 13C NMR (175 MHz, CDCl3) δ 196.2, 159.5, 142.4, 137.5, 136.1, 132.5, 
130.9, 130.4, 130.2, 130.0, 129.0, 128.3, 114.4, 61.5, 60.1, 55.4, 46.5, 40.4, 32.9, 31.4, 21.3;  IR 
(film) 1654, 1605, 1506, 1339, 1278, 1249, 1157 cm–1. MS (ESI) 477.1847 (477.1843 calcd for 
C27H28N2O4S, M + H+). 
 
 
(±)-(3S*,4aR*)-2-(4-Methoxyphenyl)-3-(2-methylbenzyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9h). General procedure B was employed for the coupling of 
4-8a (59 mg, 0.2 mmol) and 2-tolyl triflate (96 mg, 0.4 mmol), using a catalyst composed of 
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Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 65 
mg (84%) of the title compound as a white solid and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis: mp = 39–43 ºC. Data are for the major isomer. 1H NMR (700 
MHz, CDCl3) δ 7.41 (d, J = 9.1 Hz, 2 H), 7.12–7.10 (m, 3 H), 7.05–7.02 (m, 1 H), 6.91 (d, J = 
9.1 Hz, 2 H), 4.24–4.17 (m, 1 H), 3.82 (s, 3 H), 3.81–3.74 (m, 1 H), 3.55 (td, J = 9.4, 5.7 Hz, 1 
H), 3.43–3.36 (m, 1 H), 2.75 (dd, J = 13.8, 4.4 Hz, 1 H), 2.22 (dd, J = 13.8, 10.5 Hz, 1 H), 2.18 
(s, 3 H), 2.13 (ddt, J = 12.6, 9.6, 6.5 Hz, 1 H), 2.09–1.95 (m, 2 H), 1.67–1.60 (m, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 159.4, 136.3, 135.5, 130.9, 130.5, 130.4, 130.1, 126.8, 125.9, 114.3, 60.4, 
60.2, 55.4, 46.5, 37.9, 32.7, 31.3, 21.3, 19.6; IR (film) 1506, 1338, 1248, 1157 cm–1. MS (ESI) 
387.1745 (387.1737 calcd for C21H26N2O3S, M + H+). 
 
 
(±)-(3S*,4aR*)-3-(Cyclohex-1-en-1-ylmethyl)-2-(4-methoxyphenyl)hexahydro-2H-
pyrrolo[1,2-b][1,2,6]thiadiazine-1,1-dioxide (4-9i). A slight modification to general procedure 
B was employed for the coupling of 4-8a (59 mg, 0.2 mmol) and 1-cyclohexenyl triflate (63 µL, 
0.6 mmol), using a catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 
0.02 mmol) by adding more of the alkenyl triflate (3.0 equiv) and LiOtBu (48 mg, 0.6 mmol, 3.0 
equiv) to the reaction. This procedure afforded 55 mg (73%) of the title compound as a pale 
yellow oil and as a 6:1 mixture of diastereomers as determined by 1H NMR analysis. Data are for 
the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.32 (d, J = 8.4 Hz, 2 H), 6.87 (d, J = 9.1 Hz, 2 
H), 5.33 (s, 1 H), 4.13–4.07 (m, 1 H), 3.87–3.82 (m, 1 H), 3.79 (m, 3 H), 3.51 (td, J = 9.4, 5.6 
Hz, 1 H), 3.36 (td, J = 9.4, 5.8 Hz, 1 H), 2.20 (ddt, J = 12.7, 9.7, 6.5 Hz, 1 H), 2.08–1.42 (m, 15 
H); 13C NMR (175 MHz, CDCl3) δ 159.2, 133.1, 131.0, 130.4, 124.9, 114.0, 60.4, 58.5, 55.4, 
46.4, 42.8, 33.0, 31.4, 28.2, 25.2, 22.8, 22.2, 21.3; IR (film) 1506, 1337, 1248, 1156 cm–1. MS 
(ESI) 377.1903 (377.1893 calcd for C20H28N2O3S, M + H+). 
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(±)-(3S*,4aR*,7S*)-7-Allyl-3-benzyl-2-(4-methoxyphenyl)hexahydro-2H-pyrrolo[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (4-9j). General procedure B was employed for the coupling of 
4-8e (67 mg, 0.2 mmol) and phenyl triflate (65 µL, 0.4 mmol), using a catalyst composed of 
Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). The diastereoselectivity of the 
reaction was judged to be 12:1 dr as determined by 1H NMR analysis prior to flash 
chromatography.  This procedure afforded 51 mg (62%) of the title compound as a pale yellow 
oil and as a 20:1 mixture of diastereomers as determined by 1H NMR analysis. Data are for the 
major isomer. 1H NMR (700 MHz, CDCl3) δ 7.40 (d, J = 8.4 Hz, 2 H), 7.26–7.19 (m, 3 H), 7.09 
(d, J = 7.0 Hz, 2 H), 6.88 (d, J = 9.1 Hz, 2 H), 5.78 (ddt, J = 15.8, 11.2, 7.1 Hz, 1 H), 5.10–5.04 
(m, 2 H), 4.41 (tdd, J = 9.9, 5.3, 2.6 Hz, 1 H), 3.82 (s, 3 H), 3.77–3.72 (m, 1 H), 3.44 (tdd, J = 
11.3, 5.0, 3.0 Hz, 1 H), 2.82 (dd, J = 13.8, 5.3 Hz, 1 H), 2.64–2.58 (m, 1 H), 2.37 (dt, J = 14.0, 
7.8 Hz, 1 H), 2.11 (dd, J = 13.8, 10.0 Hz, 1 H), 2.01–1.94 (m, 1 H), 1.90 (ddt, J = 13.0, 10.2, 8.9 
Hz, 1 H), 1.78–1.68 (m, 2 H), 1.68–1.53 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 159.4, 137.3, 
134.4, 131.4, 130.5, 129.1, 128.5, 126.7, 117.7, 114.0, 62.8, 61.7, 57.8, 55.4, 40.0, 39.8, 32.9, 
30.5, 26.8; IR (film) 1506, 1344, 1249, 1155 cm–1. MS (ESI) 413.1895 (413.1893 calcd for 
C23H28N2O3S, M + H+). 
 
 
(±)-(3S*,4aR*,7S*)-7-Allyl-3-(4-methoxybenzyl)-2-(4-methoxyphenyl)hexahydro-2H-
pyrrolo[1,2-b][1,2,6]thiadiazine-1,1-dioxide (4-9k). General procedure B was employed for the 
coupling of 4-8e (67 mg, 0.2 mmol) and 4-methoxyphenyl triflate (72 µL, 0.4 mmol), using a 
catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). The 
diastereoselectivity of the reaction was judged to be >10:1 dr as determined by 1H NMR analysis 
prior to flash chromatography. This procedure afforded 57 mg (64%) of the title compound as a 
N
O2S N
PMP
Ph
H H
H
N
O2S N
PMP
H H
H
OMe
	   102	  
white solid and as a >20:1 mixture of diastereomers as determined by 1H NMR analysis: mp = 
44–46 ºC.  Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.39 (d, J = 8.6 Hz, 2 
H), 7.00 (d, J = 8.6 Hz, 2 H), 6.88 (d, J = 9.1 Hz, 2 H), 6.81 (d, J = 8.4 Hz, 2 H), 5.82–7.73 (m, 1 
H), 5.10–5.04 (m, 2 H), 4.39–4.35 (m, 1 H), 3.82 (s, 3 H), 3.78 (s, 3 H), 3.77–3.72 (m, 1 H), 
3.46–3.39 (m, 1 H), 2.76 (dd, J = 13.9, 5.3 Hz, 1 H), 2.61 (dd, J = 14.4, 6.0 Hz, 1 H), 2.37 (dt, J 
= 15.0, 7.9 Hz, 1 H), 2.04 (dd, J = 13.9, 10.0 Hz, 1 H), 2.01–1.88 (m, 2 H), 1.78–1.68 (m, 2 H), 
1.62–1.53 (m, 2 H); 13C NMR (175 MHz, CDCl3) δ 159.5, 158.4, 134.4, 131.5, 130.6, 130.0, 
129.3, 117.7, 114.0, 113.9, 62.9, 61.9, 57.9, 55.4, 55.2, 39.8, 39.1, 32.9, 30.5, 26.8; IR (film) 
1507, 1345, 1247, 1156 cm–1. MS (ESI) 443.1993 (443.1999 calcd for C24H30N2O4S, M + H+). 
 
 
(±)-(3S*,4aR*)-3-Benzyl-2-(4-methoxyphenyl)octahydropyrido[1,2-b][1,2,6]thiadiazine-1,1-
dioxide (4-13). General procedure B was employed for the coupling of 4-12 (62 mg, 0.2 mmol) 
and phenyl triflate (65 µL, 0.4 mmol), using a catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 
mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 65 mg (84%) of the title 
compound as a white solid and as a 5:1 mixture of diastereomers as determined by 1H NMR 
analysis: mp = 46–49 ºC. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J 
= 8.5 Hz, 2 H), 7.28–7.20 (m, 3 H), 7.07 (d, J = 7.5 Hz, 2 H), 6.91 (d, J = 9.0 Hz, 2 H), 4.41–
4.37 (m, 1 H), 3.82 (s, 3 H), 3.59–3.43 (m, 2 H), 2.97–2.88 (m, 1 H), 2.79 (dd, J = 13.6, 4.8 Hz, 
1 H), 2.13 (dd, J = 13.7, 10.1 Hz, 1 H), 1.89–1.65 (m, 4 H), 1.58–1.36 (m, 4 H); 13C NMR (175 
MHz, CDCl3) δ 159.4, 137.2, 131.2, 130.0, 129.1, 128.5, 126.7, 114.2, 60.4, 57.1, 55.4, 44.3, 
40.3, 32.1, 31.9, 24.9, 21.9;  IR (film) 1507, 1338, 1250, 1156  cm–1. MS (ESI) 387.1737 
(387.1737 calcd for C21H26N2O3S, M + H+). 
 
Assignment of Stereochemistry 
The relative stereochemistry of compound 4-9a and 4-9j was assigned on the basis of 1D 
NOESY experiments. Significant nOe relationships are shown below. The stereochemistry of all 
other 5-6 bicyclic sulfamide products was assigned based on analogy to 4-9a and 4-9j. 
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The relative stereochemistry of compound 4-13 was assigned on the basis of observed 1D 
NOESY experiments. Significant nOe relationships are shown below. The stereochemistry of all 
other 6-6 bicyclic sulfamide products was assigned based on analogy to 4-13. 
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Chapter 5   
Efforts Towards the Total Synthesis of the Tetraponerine Alkaloids 
5.1 Introduction 
The tetraponerine alkaloids are a group of eight natural products that were first isolated from 
the New Guinean ant Tetraponera sp. in 1987 by Braekman (Figure 5.1).95 Interestingly, these 
compounds are the primary toxic constituents found in the ant’s poisonous venom. Moreover, the 
tetraponerine alkaloids are known to be effective inhibitors of several different nicotinic 
acetylcholine receptors,102 as well as exhibit other biological properties including interesting 
insecticidal and cytotoxic activity.103 
Figure 5.1 Tetraponerine natural products. 
 
We initially became interested in the tetraponerine alkaloids because of the structural and 
stereochemical similarities to the tricyclic guanidine natural products discussed in chapters 1-4. 
For instance, the tetraponerine alkaloids, much like the tricyclic guanidines, can be classified into 
two distinct subgroups based on their stereochemical configuration.104–106 Specifically, four of the 
eight alkaloids (T-1, T-3, T-5 and T-7) feature a cis relationship between the C7 proton and the 
C5 alkyl chain, whereas the other four alkaloids (T-2, T-4, T-6 and T-8) possess a trans 
relationship.  Within each subclass, the molecules differ from one another in terms of C5 chain 
length (propyl or pentyl) and the size of the A ring (5 or 6). 
A number of groups have undertaken the synthetic challenges posed by the structural and 
stereochemical complexity of this family of alkaloids, and developed elegant methods for their 
syntheses.105,107–112 However, general methods that provide access to both sets of stereoisomers 
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are strikingly uncommon. In fact, the only asymmetric synthesis of all eight natural products in 
the tetraponerine family was accomplished by Royer via an iterative sequence of highly 
stereoselective amino nitrile alkylations (Scheme 5.1).113 Thus a synthetic strategy that allows for 
the facile synthesis of both stereoisomeric cores with high levels of stereoselectivity and is 
amenable to the rapid generation of analogs is still a worthwhile pursuit. As such, the research 
described in this chapter details our initial efforts to employ Pd-catalyzed carboamination 
reactions for the asymmetric total synthesis of the tetraponerine family of alkaloids. 
Scheme 5.1 Total synthesis of tetraponerine alkaloids via amino nitrile alkylations. 
 
5.2 Synthetic Strategy 
Overall, we envisioned that all eight of the tetraponerine alkaloids could be synthesized by 
utilizing the Pd-catalyzed carboamination reactions developed in chapters 2-4. As shown in 
Scheme 5.2, we anticipated that we could access the core of the natural products featuring a cis-
configuration (T-1, T-3, T-5 and T-7) by synthesizing bicyclic ureas 5-1 via the syn-
aminopalladation chemistry described in chapter 2.60 Alternatively, the trans-configured 
alkaloids (T-2, T-4, T-6 and T-8) could be prepared from bicyclic sulfamides 5-2 constructed by 
employing the carboamination reactions detailed in chapter 4 that proceed via anti-
aminopalladation. Furthermore, this carboamination strategy was particularly attractive for its 
potential to install different C-5 alkyl chains from a single intermediate (5-3). Specifically, the 
propyl or pentyl side chains could be prepared from a single precursor by simply changing the 
electrophile employed during the carboamination reaction. Similarly, the use of aryl or other 
alkenyl halide coupling partners would facilitate the synthesis of tetraponerine analogs. It should 
be noted that all of the substrates and products in this chapter could be synthesized 
asymmetrically via the enantioselective allylation of N-Boc-pyrrolidine (lit: 95:5 er)100 or N-Boc-
piperidine (lit: 95:5 er).114 However, for purposes of exploratory methodology development we 
N
N RH
H
(prepared in 5 steps) T-1    n = 1, R = C3H7    T-3    n = 2, R = C3H7
T-5    n = 1, R = C5H11    
T-7    n = 2, R = C5H11
Tetraponerines
n
N
N CNH
Hn
H
RMgBr N
N R
H
H
H
n
H
T-2    n = 1, R = C3H7    
T-4    n = 2, R = C3H7
T-6    n = 1, R = C5H11    
T-8    n = 2, R = C5H11
Tetraponerines
1) LDA, RBr
2) Na. NH3
	   106	  
elected to carry out the following optimization studies on inexpensive racemic material; thus, all 
substrates and products in chapter 5 are racemic. 
Scheme 5.2 Synthetic strategy towards the core of the tetraponerines via Pd-catalyzed 
carboamination reactions. 
 
As depicted in Scheme 5.3, we expected that the carboamination products 5-1 and 5-2 could be 
easily transformed into the tetraponerine natural products in a few straightforward steps. 
Cleavage of the urea or sulfamide bridge (X), followed by hydrogenation of the olefin and 
concomitant deprotection of the N-protecting group, would provide diamines 5-4. Based on 
literature precedent, treatment of 5-4 with 4-bromobutanal in the presence of acid is expected to 
afford the tricyclic natural products with high stereocontrol.107 
Scheme 5.3 Proposed synthesis of the tetraponerine alkaloids from bicyclic ureas and 
sulfamides. 
 
5.3 Pd-Catalyzed Carboamination Reactions 
We initially elected to investigate the Pd-catalyzed carboamination reaction of 2-
allylpyrrolidinyl urea substrate 5-3a using the optimized conditions developed in chapter 2 
(Table 5.1). As expected, the coupling of 5-3a with 1-bromobutene afforded bicyclic urea 5-1a 
good yield (67%) and with excellent stereoselectivity (>20:1 dr). Unfortunately, efforts to couple 
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a two-carbon electrophile were met with failure. Vinyl bromide proved to be too volatile and led 
to polymerization side products when employed as the electrophilic coupling partner under the 
reaction conditions. TMS-protected variants of vinyl bromide primarily led to β-hydride 
elimination. Dichloroethane and dibromoethane also proved to be incompatible substrates for the 
desired coupling reactions.  
Table 5.1 Synthesis of 5-6 cis-bicyclic ureas. 
 
Entry PG substrate R-Br Product Yield (%)[b] dr 
1 PMB 5-3a Z-bromobutene 5-1a 67 >20:1 
2 PMB 5-3a Vinyl bromide – – – 
3 PMB 5-3a 1-TMS-vinyl bromide – – – 
4 PMB 5-3a (E)-2-TMS-vinyl 
bromide  
– – – 
5 PMB 5-3a Dibromoethane – – – 
6 PMB 5-3a Dichloroethane – – – 
[a] Reaction Conditions: 1.0 equiv 5-3a, 4.0 equiv R-Br, 5.0 equiv NaOtBu, 3 mol % Pd2dba3, 12 mol % PCy3.HBF4, 
toluene (0.1 M), 110 °C. [b] Isolated yield.  
Application of the syn-aminopalladation chemistry developed in chapter 2 for the synthesis of 
6-6 cis-bicyclic ureas was next examined. The carboamination reaction of 5-3b and 1-
bromobutene using the optimized conditions for the synthesis of 5-6 fused bicyclic ureas 
afforded 6-6 bicyclic urea 5-1b in good yield and with good selectivity (Scheme 5.4). Vinyl 
bromide electrophiles, as was the case with pyrrolidinyl substrate 5-3a, proved to be 
incompatible coupling partners with piperidinyl substrate 5-3b.  
Scheme 5.4 Synthesis of 6-6 cis-bicyclic urea via a Pd-catalyzed carboamination reaction. 
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Following the successful synthesis of both 5-6 and 6-6 cis-bicyclic ureas, Pd-catalyzed 
carboamination reactions for the construction of bicyclic sulfamides featuring a trans-
configuration were explored. To this end, sulfamide substrates 4-8c and 4-12 were subjected to 
the reaction conditions developed in the Wolfe group’s original report on anti-aminopalladation 
for the coupling of aryl and alkenyl bromides (Scheme 5.5).50 The coupling of pyrrolidinyl 
derivative 4-8c with 1-bromobutene generated the desired 5-6 trans-bicyclic sulfamide 5-2a in 
moderate yield and diastereoselectivity. 1-bromobutene proved to be a better substrate for the 
carboamination with piperidinyl sulfamide 4-12, undergoing the desired transformation in much 
better yield and with slightly higher selectivity. Disappointingly, electrophiles possessing two 
carbons, such as vinyl bromide and dibromoethane, led to significant amounts of side products. 
Current studies are focused on improving the yield and selectivity of these reactions by 
employing vinyl triflates, as opposed to vinyl bromides. Additionally, the coupling of 2-
substituted thiophene derivatives would represent another possibility to introducing the four-
carbon subunit as 2-alkyl thiophenes can be reduced to 1-substituted butanes in a single step.115 
Scheme 5.5 Synthesis of trans-bicyclic cyclic sulfamides. 
	  
5.4 Efforts Towards the Total Synthesis of Tetraponerine T-5 
As previously described, we anticipated that carboamination products 5-1 and 5-2 could be 
converted into the tetraponerine natural products in just a few steps (Scheme 5.3). Importantly, 
1-bromobutene proved to be a viable coupling partner for all four sets of substrates (cis-5-6, cis-
6-6, trans-5-6, and trans-6-6), affording bicyclic products that have the potential to serve as key 
intermediates in the synthesis of tetraponerines T-5, T-6, T-7 and T-8.  Admittedly, the current 
inability to couple two-carbon electrophiles is a substantial limitation of this methodology and 
future work is needed in this area in order to develop an efficient synthesis of tetraponerines T-1, 
T-2, T-3 and T-4 using this annulation strategy. The remainder of this chapter describes our 
preliminary efforts to convert bicyclic urea 5-1a into tetraponerine T-5.  
N
O2S NH
PMP
N
O2S N
PMP
H
H
82%, 5:1 dr4-12 5-2b
Br
Et
Et
N
O2S NH
Bn
N
O2S N H
Bn
H
PhCF3, 100 oC
4-8c 5-2a
Pd(OAc)2 (4 mol %)
CPhos (10 mol %)
NaOtBu, LiOTf
Br
Et
Pd(OAc)2 (4 mol %)
CPhos (10 mol %)
NaOtBu, LiOTf
PhCF3, 100 oC
30%, 5:1 dr
Et
	   109	  
Scheme 5.6 Initial synthetic efforts towards tetraponerine T-5. 
 
Conversion of cis-bicyclic urea 5-1a to tetraponerine T-5 commenced with hydrogenation of 
the olefin and concomitant removal of the p-methoxybenzyl protecting group as shown in 
Scheme 5.6. Unfortunately, initial efforts to reduce urea 5-5 with LiAlH4 in refluxing ether or 
THF were unsuccessful.  
Scheme 5.7 Reduction of urea bridge. 
 
Interestingly, by reversing the order of reactions, urea 5-1a could be reduced to diamine 5-6 
via the two-step process depicted in Scheme 5.7. Hydrogenation of the olefin present in 5-6 was 
accomplished with Pd/C under a H2 atmosphere. However, the PMB group was not removed 
under the mild hydrogenolysis conditions (room temperature and H2 balloon). A more thorough 
examination of deprotection conditions, including increasing the temperature and pressure of the 
hydrogenolysis reaction, is needed to test the feasibility of this transformation. Future work in 
this area is warranted, given that completion of the natural product could be accomplished in just 
a single step following the successful removal of the PMB group. It should be noted that a 
similar synthetic strategy should be feasible for the synthesis of tetraponerine alkaloids that 
feature a trans-stereochemical configuration, such as tetraponerines T-6 and T-8, as the reduction 
of bicyclic sulfamide 4-9c with LiAlH4 proceeded with 80% conversion after 16 hours in 
refluxing THF (Scheme 5.8).  
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Scheme 5.8 Removal of sulfamide bridge via LiAlH4. 
 
5.4 Conclusions 
In all, the Pd-catalyzed carboamination reactions developed in chapters 2-4 have been utilized 
to access the core of the tetraponerine alkaloids. One of the bicyclic carboamination products has 
been explored as an intermediate in the total synthesis of tetraponerine T-5, and after preliminary 
studies, only two more steps are required to complete the synthesis of the natural product. 
Importantly, the total synthesis efforts described in this chapter, paired with methodology 
developed in chapters 2-4, has laid the foundation to complete the total synthesis of 
tetraponerines T-6, T-7 and T-8. Overall, the research developed in chapter 5, along with work 
described in chapters 2-4, demonstrates the utility of Pd-catalyzed carboamination reactions for 
the total synthesis of structurally and stereochemically complex natural products and analogs 
thereof. 
 
*Part of the work described in this chapter was carried out by Grace McKenna including the 
synthesis of 4-12, 5-2b, and 5-3b. 
5.5 Experimental 
General: All reactions were carried out under a nitrogen atmosphere unless otherwise noted. 
Tris(dibenzylidene)acetone dipalladium, and palladium acetate were purchased from Strem 
Chemical Co. and used without purification. All phosphine ligands were obtained from 
commercial sources and were used without further purification. All other reagents were obtained 
from commercial sources and were used as obtained unless otherwise noted. (Z)-1-
bromobutene63	   was prepared according to a slight modification of a literature procedure; the 
preparation was conducted at rt instead of using microwave heating as described in chapter 2. 
tert-Butyl 2-allylpyrrolidine-1-carboxylate,100 tert-butyl 2-allylpiperidine-1-carboxylate,100 N-(4-
methoxyphenyl)-2-oxooxazolidine-3-sulfonamide,50 and N-benzyl-2-oxooxazolidine-3-
sulfonamide,50 were prepared according to published procedures. Lithium tert-butoxide, sodium 
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tert-butoxide, and lithium triflate were stored in a glovebox and removed prior to use. Toluene, 
THF, diethyl ether and dichloromethane were purified using a GlassContour solvent purification 
system. Benzotrifluoride was purified by distillation under N2 prior to use. Yields refer to 
isolated yields of compounds estimated to be ≥95% pure as determined by 1H NMR analysis 
unless otherwise noted. The yields reported in the experimental section describe the result of a 
single experiment. Structural and stereochemical assignments were made based on analogy to the 
compounds prepared in chapters 2 and 4, which were determined through 2-D COSY and 
NOESY experiments. Ratios of diastereomers were determined by 1H NMR analysis.  	  
Preparation and Characterization of Substrates 
General Procedure for the Synthesis of Urea Substrates 5-3. A round-bottom flask equipped 
with a stirbar was charged with tert-butyl 2-allylpyrrolidine-1-carboxylate  (1.0 equiv) and 
dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was added to the flask and the mixture 
was stirred until the starting material had been completely consumed as judged by TLC analysis 
(ca. 30 min). The solution was diluted with water, basified with NH4OH to pH > 12, and 
transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3x). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was dissolved in dichloromethane (0.2 M) 
and the appropriate isocyanate (1.1–1.5 equiv) was added. The reaction mixture was stirred at rt 
until starting material had been completely consumed as judged by TLC analysis (ca. 1 h). The 
crude reaction mixture was concentrated in vacuo, and purified by flash chromatography on 
silica gel.  	  
 
(±)-2-Allyl-N-(4-methoxybenzyl)pyrrolidine-1-carboxamide (5-3a). The title compound was 
prepared from 4-methoxybenzyl isocyanate (1.8 mL, 12.6 mmol) and tert-butyl 2-
allylpyrrolidine-1-carboxylate (1.77 g, 8.4 mmol) in two steps via the general procedure 
described above. This procedure afforded 862 mg (37%) of the title compound as a pale yellow 
oil. 1H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.0 Hz, 2 H), 6.90 (d, J = 8.5 Hz, 2 H), 5.78 
N
O NH
PMB
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(dddd, J = 16.9, 10.2, 7.8, 6.6 Hz, 1 H), 5.10–5.00 (m, 2 H), 4.43–4.30 (m, 3 H), 3.97 (m, 1 H), 
3.80 (s, 3 H), 3.34–3.23 (m, 2 H), 2.54–2.49 (m, 1 H), 2.18–2.08 (m, 1 H), 2.02–1.82 (m, 3 H), 
1.78–1.73 (m, 1 H); 13C NMR (175 MHz, CDCl3) δ 158.8, 156.6, 135.3, 131.9, 129.1, 117.1, 
113.9, 56.8, 55.3, 46.0, 44.1, 38.8, 29.4, 23.6; IR (film) 3324, 1626 cm–1. MS (ESI) 275.1747 
(275.1754 calcd for C16H22N2O2, M + H+).  
 
 
(±)-2-Allyl-N-(4-methoxyphenyl)piperidine-1-carboxamide (5-3b). The title compound was 
prepared from 4-methoxyphenyl isocyanate (1.07 g, 7.2 mmol) and tert-butyl 2-allylpiperidine-
1-carboxylate (1.35 g, 6.0 mmol) in two steps via the general procedure described above. This 
procedure afforded 526 mg (35%) of the title compound as a pale brown solid: mp = 53–56 ºC. 
1H NMR (700 MHz, CDCl3) δ 7.21 (d, J = 9.1 Hz, 2 H), 6.81 (d, J = 9.1 Hz, 2 H), 6.28 (s, 1 H), 
5.80 (ddt, J = 17.2, 10.1, 7.2 Hz, 1 H), 5.12 (dd, J = 17.1, 1.5 Hz, 1 H), 5.07 (dd, J = 10.2, 2.0 
Hz, 1 H), 4.25 (m, 1 H), 3.92 (d, br, J = 11.9 Hz, 1 H), 3.76 (s, 3 H), 2.94 (td, J = 13.2, 2.9 Hz, 1 
H), 2.50 (dddt, J = 13.8, 8.2, 6.9, 1.3 Hz, 1 H), 2.33–2.26 (m, 1 H), 1.71–1.58 (m, 5 H), 1.48 (m, 
1 H); 13C NMR (175 MHz, CDCl3) δ 155.6, 135.4, 132.4, 122.1, 117.3, 114.0, 55.5, 51.1, 39.2, 
34.3, 27.8, 25.4, 18.7 (one carbon signal is absent to due incidental equivalence); IR (film) 3306, 
1628 cm–1. MS (ESI) 275.1755 (275.1754 calcd for C16H22N2O2, M + H+). 
 
Preparation and Characterization of Bicyclic Products 
 
General Procedure A: Synthesis of Bicyclic Ureas 5-1. 
A flame-dried Schlenk tube equipped with a stirbar was cooled under vacuum and charged 
with Pd2(dba)3 (0.02 equiv), PCy3.HBF4 (0.08 equiv), NaOtBu (4.0 equiv) and the appropriate 
substrate (1.0 equiv). The flask was evacuated and purged with N2. The appropriate substrate if 
oil (1.0 equiv) in toluene (0.2 M) was added via syringe, followed by the appropriate alkenyl 
bromide (5.0 equiv). The tube was heated to 110 ºC and stirred overnight. The mixture was 
cooled to room temperature and saturated aqueous NH4Cl (5 mL/mmol substrate) and ethyl 
N
O NH
PMP
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acetate (5 mL/mmol substrate) were added. The layers were separated and concentrated in vacuo. 
The crude material was purified by flash chromatography on silica gel. 	  
General Procedure B: Synthesis of Bicyclic Sulfamides 5-2. 
A test tube equipped with a stirbar was charged with Pd(OAc)2 (0.04 equiv), CPhos (0.1 
equiv), NaOtBu (4.0 equiv) and LiOTf (5.0 equiv). The test tube was purged with N2 then the 
appropriate alkenyl bromide (4.0 equiv) was added, followed by the appropriate substrate (1.0 
equiv) in benzotrifluoride (0.2 M). The tube was heated to 100 ºC and stirred overnight. The 
mixture was cooled to room temperature and saturated aqueous NH4Cl (5 mL/mmol substrate) 
and dichloromethane (5 mL/mmol substrate) were added. The layers were separated and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel. 	  
 
(±)-(Z,3R*,4aR*)-2-(4-Methoxybenzyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-
c]pyrimidin-1(2H)-one (5-1a). General procedure A was employed for the coupling of 5-3a 
(274 mg, 1.0 mmol) and (Z)-1-bromobutene (2.0 mL, 4.0 mmol, 2.0 M solution in toluene), 
using NaOtBu (384 mg, 4.0 mmol) and a catalyst composed of Pd2dba3 (18.3 mg, 0.02 mmol), 
and PCy3.HBF4 (29.5 mg, 0.08 mmol). This procedure afforded 219 mg (67%) of the title 
compound as a brown oil and as a >20:1 mixture of diastereomers as determined by 1H NMR 
analysis.  Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.21 (d, J = 8.4 Hz, 2 H), 
6.83 (d, J = 8.4 Hz, 2 H), 5.50–5.44 (m, 1 H), 5.23–5.17 (m, 1 H), 5.13 (d, J = 15.1 Hz, 1 H), 
4.03 (d, J = 15.1 Hz, 1 H), 3.79 (s, 3 H), 3.60 (dt, J = 10.5, 6.0 Hz, 1 H), 3.58–3.54 (m, 1 H), 
3.49 (dt, J = 9.1, 1.8 Hz, 1 H), 3.25–3.21 (m, 1 H),  2.38 (dd, J = 13.5, 6.7 Hz, 1 H), 2.19 (dt, J = 
14.4, 9.4 Hz, 1 H), 2.09–1.94 (m, 5 H), 1.80 (ttd, J = 12.5, 9.6, 6.6 Hz, 1 H), 1.43 (qd, J = 11.9, 
7.1 Hz, 1 H), 1.25 (td, J = 12.3, 5.0 Hz, 1 H), 0.95 (t, J = 7.5 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 158.6, 155.0, 134.5, 131.3, 129.1, 124.5, 113.8, 55.2, 53.4, 52.6, 47.9, 46.1, 33.9, 30.6, 
30.1, 23.5, 20.8, 14.2; IR (film) 1626 cm–1. MS (ESI) 329.2221 (329.2224 calcd for C20H28N2O2, 
M + H+). 
N
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(±)-(Z,3R*,4aR*)-2-(4-Methoxyphenyl)-3-(pent-2-en-1-yl)octahydro-1H-pyrido[1,2-
c]pyrimidin-1-one (5-1b). General procedure A was employed for the coupling of 5-3b (55 mg, 
0.2 mmol) and (Z)-1-bromobutene (500 µL, 1.0 mmol, 2.0 M solution in toluene), using NaOtBu 
(96 mg, 1.0 mmol) and a catalyst composed of Pd2dba3 (5.5 mg, 0.006 mmol), and PCy3.HBF4 
(9.0 mg, 0.024 mmol). This procedure afforded 45 mg (69%) of the title compound as a brown 
oil and as a 10:1 mixture of diastereomers as determined by 1H NMR analysis.  Data are for the 
major isomer. 1H NMR (700 MHz, CDCl3) δ 7.14 (d, J = 9.1 Hz, 2 H), 6.86 (d, J = 8.4 Hz, 2 H), 
5.47–5.41 (m, 1 H), 5.17–5.14 (m, 1 H), 4.58 (d, J = 13.3 Hz, 1 H), 3.79 (s, 3 H), 3.59–3.55 (m, 
1 H), 3.30 (dddd, J = 13.7, 11.0, 6.1, 3.6 Hz, 1 H), 2.57 (td, J = 12.7, 2.9 Hz, 1 H), 2.42–2.39 (m, 
1 H), 2.27 (dt, J = 14.2, 9.4 Hz, 1 H), 2.04–1.93 (m, 3 H), 1.84 (d, J = 12.6 Hz, 1 H), 1.74–1.68 
(m, 2 H), 1.50–1.35 (m, 2 H), 1.31–1.24 (m, 2 H), 0.93 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 157.6, 155.0, 136.4, 134.5, 129.0, 124.1, 114.0, 57.1, 55.4, 50.8, 43.5, 33.6, 32.8, 30.9, 
25.3, 24.0, 20.8, 14.1; IR (film) 1637 cm–1. MS (ESI) 329.2228 (329.2224 calcd for C20H28N2O2, 
M + H+). 	  
	  
(±)-(Z,3S*,4aR*)-2-Benzyl-3-(pent-2-en-1-yl)hexahydro-2H-pyrrolo[1,2-b][1,2,6]thiadiazine-
1,1-dioxide (5-2a). General procedure B was employed for the coupling of 4-8c (56 mg, 0.2 
mmol) and (Z)-1-bromobutene (400 µL, 0.8 mmol, 2.0 M solution in PhCF3), using NaOtBu (96 
mg, 1.0 mmol) and LiOTf (156 mg, 1.0 mmol) a catalyst composed of Pd(OAc)2 (1.8 mg, 0.008 
mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 20 mg (30%) of the title 
compound as a pale yellow brown oil and as a 5:1 mixture of diastereomers as determined by 1H 
NMR analysis. Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 7.44–7.29 (m, 4 H), 
N
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7.24 (t, J = 7.4 Hz, 1 H), 5.41–5.37 (m, 1 H), 5.19–5.13 (m, 1 H), 4.50 (d, J = 16.2 Hz, 1 H), 4.11 
(d, J = 16.2 Hz, 1 H), 3.90–3.85 (m, 1 H), 3.47 (td, J = 9.0, 5.4 Hz, 1 H), 3.40–3.31 (m, 1 H), 
3.24 (td, J = 9.3, 6.1 Hz, 1 H), 2.25–2.08 (m, 3 H), 1.95–1.80 (m, 5 H), 1.59–1.45 (m, 2 H), 0.88 
(t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 138.7, 134.7, 128.4, 127.6, 127.1, 123.9, 
60.9, 60.6, 49.2, 45.9, 31.7, 31.6, 31.3, 21.0, 20.7, 13.9; IR (film) 1334, 1156 cm–1. MS (ESI) 
335.1793 (335.1788 calcd for C18H26N2O2S, M + H+). 
 
 
(±)-(Z,3S*,4aR*)-2-(4-Methoxyphenyl)-3-(pent-2-en-1-yl)octahydropyrido[1,2-
b][1,2,6]thiadiazine-1,1-dioxide (5-2b). General procedure B was employed for the coupling of 
4-12 (62 mg, 0.2 mmol) and (Z)-1-bromobutene (400 µL, 0.8 mmol, 2.0 M solution in PhCF3), 
using NaOtBu (96 mg, 1.0 mmol) and LiOTf (156 mg, 1.0 mmol) a catalyst composed of 
Pd(OAc)2 (1.8 mg, 0.008 mmol), and CPhos (8.7 mg, 0.02 mmol). This procedure afforded 60 
mg (82%) of the title compound as a pale yellow oil and as a 5:1 mixture of diastereomers as 
determined by 1H NMR analysis. Data are for the major isomer. 1H NMR (700 MHz, CDCl3) δ 
7.38 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 9.1 Hz, 2 H), 5.51–5.40 (m, 1 H), 5.25–5.19 (m, 1 H), 
4.13–4.06 (m, 1 H), 3.80 (s, 3 H), 3.67–3.62 (m, 1 H), 3.49 (ddd, J = 10.8, 6.6, 3.7 Hz, 1 H), 2.99 
(ddd, J = 11.7, 8.4, 3.5 Hz, 1 H), 2.04 (dt, J = 13.8, 6.0 Hz, 1 H), 1.92–1.66 (m, 8 H), 1.62–1.45 
(m, 3 H), 0.88 (t, J = 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 159.3, 134.7, 131.1, 130.0, 
123.5, 114.2, 59.5, 56.7, 55.4, 44.1, 32.1, 31.7, 31.4, 24.9, 21.5, 20.7, 13.9; IR (film) 1506, 1339, 
1248, 1159 cm–1. MS (ESI) 365.1905 (365.1893 calcd for C19H28N2O3S, M + H+). 
 
Conversion of 5-1a to Tetraponerine T-5. 
 
N
O2S N H
H
PMP Et
N
N
H Et
H
HO
	   116	  
(±)-(3R,4aR)-3-Pentylhexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (5-5). A flame-dried 
flask was cooled under vacuum and charged with 10% Pd/C (120 mg). The flask was capped 
with a rubber septum, evacuated and backfilled with nitrogen. A solution of 5-1a (66 mg, 0.2 
mmol) in methanol (8 mL) was added to the flask via a syringe, followed by acetic acid (0.2 
mL). The flask was briefly flushed with hydrogen and then a hydrogen-filled balloon attached to 
a needle (via an adaptor) was connected to the flask through the septum. The mixture was placed 
in an oil bath at 50 ºC and the reaction was stirred overnight (ca. 16 h). The crude material was 
then filtered through a plug of celite to remove the Pd/C and washed with methanol (5 mL). The 
crude material was concentrated in vacuo and purified by flash chromatography on silica gel to 
afford 38.5 mg (92%) of the title compound as a pale yellow solid: mp = 63–66 ºC. 1H NMR 
(700 MHz, CDCl3) δ 4.79 (s, br, 1 H), 3.54–3.44 (m, 3 H), 3.39–3.32 (m, 1 H), 2.15–2.08 (m, 1 
H), 1.97–1.92 (m, 2 H), 1.80–1.74 (m, 2 H), 1.54–1.25 (m, 9 H), 0.88 (t, J = 7.0 Hz, 3 H); 13C 
NMR (175 MHz, CDCl3) δ 155.3, 52.3, 50.0, 45.3, 36.8, 33.6, 32.2, 31.6, 25.7, 23.0, 22.6, 14.0; 
IR (film) 3214, 1650 cm–1. MS (ESI) 211.1812 (211.1805 calcd for C12H22N2O, M + H+). 
 
 
(±)-(Z,R,R)-N-(4-Methoxybenzyl)-1-(pyrrolidin-2-yl)hept-4-en-2-amine (5-5). This compound 
was prepared via a modification of a published procedure by Trost.116 A flame-dried flask was 
cooled under vacuum and charged with LAH (190 mg, 5.0 mmol). A reflux condenser was 
attached to the flask and the apparatus was evacuated and backfilled with nitrogen. Diethyl ether 
(4 mL) was added, followed by a solution of 5-1a (66 mg, 0.2 mmol) in diethyl ether (4 mL). 
The flask was placed in an oil bath and allowed to reflux overnight (ca. 16 h). The reaction flask 
was allowed to cool to rt and then the mixture was diluted with ether (10 mL). The reaction flask 
was placed in an ice bath and quenched slowly with water (2 mL). 1M NaOH (2 mL) was added, 
followed by more water (2 mL) and the biphasic mixture was stirred vigorously for 15 min. The 
mixture was decanted, dried with Na2SO4, and concentrated in vacuo. The crude product 
appeared to by clean by 1H NMR and taken unto the next step without further purification. A 
round bottom flask, equipped with a stirbar was charged with the crude product and aqueous 
N
H
HN
PMB Et
H
H
	   117	  
0.01% HCl (10 mL). H2NOH.HCl (69 mg, 1.0 mmol) was added and the reaction mixture was 
heated to 60 ºC in an oil bath and stirred until the starting material had been consumed as judged 
by ESI+ MS analysis (ca. 60 min). The reaction was cooled to rt and aqueous 1M HCl (20 mL) 
was added. The solution was then washed with CHCl3 (2 x 20 mL) and then the aqueous layer 
was carefully basified with Na2CO3 and extracted with CHCl3 (3 x 20 mL). The combined 
organic layers were dried with Na2SO4 and concentrated in vacuo to afford 35 mg (57%) of the 
title compound as a pale yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.22 (d, J = 8.2 Hz, 2 H), 6.85 
(d, J = 8.4 Hz, 2 H), 5.52–5.46 (m, 1 H), 5.33–5.30 (m, 1 H), 3.79 (s, 3 H), 3.75 (d, J = 12.8 Hz, 
1 H), 3.69 (d, J = 12.8 Hz, 1 H), 3.17 (s, br, 1 H), 2.97–2.94 (m, 1 H), 2.85–2.80 (m, 1 H), 2.73 
(m, 1 H), 2.28 (dt, J = 13.9, 6.7 Hz, 1 H), 2.22 (dt, J = 14.1, 6.7 Hz, 1 H), 2.06 (m, 2 H), 1.85 (td, 
J = 12.6, 7.3 Hz, 1 H), 1.63–1.51 (m, 2 H), 1.25 (m, 1 H), 0.95 (t, J = 7.6 Hz, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 158.6, 134.3, 129.3, 125.2, 113.8, 56.3, 55.3, 54.9, 50.5, 46.2, 39.8, 31.9, 
31.8, 25.1, 20.8, 14.3 (one carbon signal is absent due to incidental equivalence); IR (film) 3002, 
1611, 1511, 1246 cm–1. MS (ESI) 303.2427 (303.2431 calcd for C19H30N2O, M + H+). 	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